[go: up one dir, main page]

US20050256525A1 - Dilation introducer for orthopedic surgery - Google Patents

Dilation introducer for orthopedic surgery Download PDF

Info

Publication number
US20050256525A1
US20050256525A1 US11/038,784 US3878405A US2005256525A1 US 20050256525 A1 US20050256525 A1 US 20050256525A1 US 3878405 A US3878405 A US 3878405A US 2005256525 A1 US2005256525 A1 US 2005256525A1
Authority
US
United States
Prior art keywords
dilator tube
dilation introducer
distal
proximal
dilation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/038,784
Inventor
Brad Culbert
Fausto Olmos
Christopher Warren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Interventional Spine Inc
Original Assignee
Triage Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Triage Medical Inc filed Critical Triage Medical Inc
Assigned to TRIAGE MEDICAL INC. reassignment TRIAGE MEDICAL INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CULBERT, BRAD, OLMOS, FAUSTO, WARREN, CHRISTOPHER
Priority to EP16207090.8A priority Critical patent/EP3205371B1/en
Priority to US11/659,025 priority patent/US9387313B2/en
Priority to JP2007524917A priority patent/JP5164571B2/en
Priority to PCT/US2005/027431 priority patent/WO2006017507A2/en
Priority to EP05777628.8A priority patent/EP1773438B1/en
Publication of US20050256525A1 publication Critical patent/US20050256525A1/en
Assigned to INTERVENTIONAL SPINE, INC. reassignment INTERVENTIONAL SPINE, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: TRIAGE MEDICAL, INC.
Priority to US15/186,963 priority patent/US10293147B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Definitions

  • This invention relates to bone fixation devices, and more particularly relates to a dilation introducer for introducing a bone fixation device for orthopedic surgery, such as for vertebral fusion.
  • Fusion of two adjacent vertebrae is a common surgical treatment for back injuries due to damage or defects in a spinal disc between two adjacent vertebrae, such as conditions due to a herniated disc or disc degeneration.
  • the entire disc may be removed by a discectomy procedure, and may be replaced with bone or a bone substitute and/or cage in order to prevent collapse of the disc space between the adjacent vertebrae.
  • Early techniques for stabilizing the adjacent vertebrae included application of a plate or a rod in conjunction with screws across the adjacent vertebrae, after which the adjacent vertebrae would eventually fuse together. However, such techniques commonly required prolonged periods of recovery from the extensive surgery involved, and it would be desirable to provide an improved apparatus and method for providing a minimally invasive procedure that will result in less trauma and improvement in patient recovery.
  • Bone fixation devices are known that are useful for connecting two or more bone segments for the healing of broken bones, typically including an elongate pin with a distal anchor and a proximal anchor movable on the pin to accommodate different bone dimensions, and to permit tensioning of the bone segments together.
  • the surgical procedure of attaching two or more parts of a bone with a pin-like device commonly requires an initial incision into the tissue down to the bone, and the drilling of a hole through the bone parts to be joined.
  • Such bone fixation devices can be useful for fusion of vertebrae together, because such a bone fixation device can be used to join adjacent bone segments through a single percutaneous incision or puncture, without the need to expose any other side of the bone segments to be joined.
  • the invention provides for a telescoping dilation introducer for orthopedic surgery, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's tissue to be treated, and an unlocked, collapsed configuration for dilating the patient's soft surrounding tissue to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's tissue.
  • each individual dilator tube is successively released and advanced to progressively expand the patient's soft tissue down to the tissue to be treated.
  • the tissue to be treated is bone tissue which must be prepared prior to attachment of adjacent bone section in a fusion process.
  • the invention is particularly applicable to fusion of bones in orthopedic surgery using minimally invasive technique, and will be described herein in particular applications of those procedures.
  • the invention also concerns a minimally invasive procedure utilizing the telescoping dilation introducer to insert a bone fixation device into a patient's spine for posterior spine fusion. While posterior spine fusion currently takes up to two hours to complete, and requires a six inch incision, with the apparatus and method of the invention, comparable surgery can be completed in less than thirty minutes, with a dilation port 13 mm or less in diameter, thus lowering the chance of damage to the surrounding soft tissue.
  • a telescoping dilation introducer is typically operated by pressing the introducer against a relatively hard surface, such as bone tissue being treated.
  • the present invention provides for a guide wire assembly when such a telescoping dilation introducer is to used in treatment of soft tissue, such as an organ, to provide a surface against which the telescoping dilation introducer can be pushed during operation of the telescoping dilation introducer.
  • a guide wire or K wire assembly is provided for use with a telescoping dilation introducer according to the invention.
  • the guide wire assembly includes an elongated generally cylindrical first section, and an elongated tubular second section that receives the first section.
  • the elongated generally cylindrical first section includes a proximal enlarged head or stop portion, and an elongated body portion with a proximal section and a relatively narrower diameter main section connected to the proximal section, and a pointed distal tip at the distal end of the narrow main section.
  • the second section of the guide wire assembly includes an elongated tubular body with an internal bore adapted to receive the narrow main section, as is illustrated in FIG. 28 .
  • the tubular second section advantageously includes a frustoconical distal tip with a narrowed portion at the distal end and an enlarged flat shoulder at the proximal end of the frustoconical distal tip.
  • the assembly When the guide wire assembly is assembled, the assembly presents a pointed distal end with a proximal shoulder against which a telescoping dilation introducer can be pushed for operation of the telescoping dilation introducer.
  • the main section thus adds a sharp point to the relatively blunt distal end of the tubular distal section, allowing the guide wire assembly to be inserted through soft tissue for placement in a soft tissue target of interest, such as an organ, and the first section can then be removed to allow a telescoping dilation introducer to be placed over the second section and pressed against the shoulder of the blunt distal end for operation of the telescoping dilation introducer.
  • the first section can be removed from the second section, leaving the blunt distal end in place at the desired location in the soft tissue, and the telescoping dilation introducer can be placed over the second section and pressed against the shoulder of the blunt distal end for operation of the telescoping dilation introducer.
  • the present invention provides for an improvement in a dilation introducer for orthopedic surgery, in which the dilation introducer includes one or more dilator tubes having a distal end and a proximal end, and the distal end of the one or more dilator tubes including a plurality of spikes for engaging bone tissue.
  • the spikes may be formed of radiopaque material, for fluoroscopic imaging of the positioning of the one or more dilator tubes, and the spikes may be formed with a rounded shape so as to deflect soft tissue.
  • the dilation introducer includes a parallel guide insert adapted to be received in the one or more dilator tubes.
  • the parallel guide insert includes a main cylindrical shaft having a proximal end connected to a cylindrical head, and a plurality of longitudinal bores extending the length of the parallel guide insert through the main cylindrical shaft and cylindrical head.
  • the distal tip of the parallel guide insert may be provided with a plurality of spikes for engaging bone tissue.
  • the spikes of the parallel guide insert may be formed of radiopaque material, and may be formed with a rounded shape so as to deflect soft tissue.
  • the present invention concerns a dilation introducer for orthopedic surgery having a locked assembled configuration for initial placement of the dilation introducer against a patient's bone tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the bone tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's bone tissue to be treated.
  • the dilation introducer includes a first dilator tube having a distal end with a tapered tip and a proximal end with a cylindrical head, and a second dilator tube having a distal end with a tapered tip and a proximal end with a cylindrical head, and an inner lumen with a distal opening and a proximal opening.
  • the first dilator tube is removably received in the second dilator tube for slidable telescoping movement within the second dilator tube.
  • Means are provided for removably connecting the first and second dilator tubes together in a locked configuration.
  • the means for removably connecting the first and second dilator tubes includes a first latching member disposed in the cylindrical head of the first dilator tube.
  • the first latching member has a locking button connected transversely to a shaft with a latching end projecting from the cylindrical head of the first dilator tube toward the distal end of the first dilator tube, with the locking button extending transversely from the shaft through a side aperture in the cylindrical head of the first dilator tube.
  • the locking button is biased outwardly from the cylindrical head, such as by a spring, and the first latching member is received in an upper aperture of the cylindrical head of an adjacent second dilator tube.
  • the upper aperture of the cylindrical head of the second dilator tube includes a latching chamber for retaining the latching end of the latching member when the locking button is biased outwardly, to lock the cylindrical heads of the first and second dilator tubes together.
  • the locking button is moveable inwardly to move the latching member inwardly and to move the latching end of the latching member inwardly out of the latching chamber, to unlock the first and second dilator tubes.
  • the dilation introducer may include one or more additional dilator tubes, with the second dilator tube being removably received in the one or more additional dilator tubes for slidable telescoping movement within the one or more additional dilator tubes.
  • the one or more additional dilator tubes likewise have a distal end and a proximal end with a cylindrical head, an inner lumen with a distal opening and a proximal opening, and the distal end having a tapered tip.
  • the second dilator tube and the one or more additional dilator tubes having an unlocked configuration in which the one or more additional dilator tubes may slidably telescope over the second dilator tube to dilate the patient's soft tissue at the distal end of the dilation introducer.
  • Means are provided for removably connecting the second dilator tube and the one or more additional dilator tubes together in a locked configuration.
  • the means for removably connecting the second dilator tube and the one or more additional dilator tubes include a second latching member disposed in the cylindrical head of the second dilator tube.
  • the second latching member has a locking button connected transversely to a shaft with a latching end projecting from the cylindrical head of the second dilator tube toward the distal end of the second dilator tube, and the locking button extends transversely from the shaft through a side aperture in the cylindrical head of the second dilator tube.
  • the locking button is biased outwardly from the cylindrical head, such as by a spring, and the second latching member is received in an upper aperture of the cylindrical head of the additional dilator tube to be connected.
  • the upper aperture of the cylindrical head of the additional dilator tubes include a latching chamber for retaining the latching end of the second latching member when the locking button is biased outwardly, to lock the cylindrical heads of the second and additional dilator tube together, and the locking button is moveable inwardly to move the second latching member inwardly and the latching end of the second latching member inwardly out of the latching chamber.
  • the additional dilator tube comprises a handle connected to the proximal end of the additional dilator tube, and the cylindrical head of the additional dilator tube includes a plurality of the upper apertures, each including a latching chamber for receiving the second latching member.
  • the present invention provides for an improvement in a dilation introducer for orthopedic surgery, in which the dilation introducer includes a dilator tube having a tubular shaft, a distal end and a proximal end, an inner lumen with a distal opening and a proximal opening, and a light emitter disposed in the dilator tube.
  • the light emitter may be a light emitting diode, and the light emitting diode may be embedded in the tubular shaft of the dilator tube.
  • the light emitter may include a fiber optic, and the fiber optic may be embedded in the tubular shaft of the dilator tube.
  • the dilator tube includes a handle and a switch for controlling the light emitter, and at least one battery is disposed in the handle and is connected to the switch to power the light emitter.
  • the light emitter includes one or more fiber optics
  • the light emitter includes a light source providing light conducted to the one or more fiber optics.
  • the light emitter may include one or more elongated energy conducting members disposed on an outer surface of the tubular shaft of the dilator tube, and the one or more elongated energy conducting members may be disposed in a groove on the exterior surface of the tubular shaft.
  • the one or more elongated energy conducting members may be located on the inside of the dilator tube, or may extend through the wall of the dilator tube.
  • the present invention also provides for a telescoping expander sleeve adapted to be slidably disposed over a shaft of a dilator tube for dilating a patient's soft tissue down to a bone tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's bone tissue.
  • the telescoping expander sleeve is moveable between an extended, unexpanded configuration and a collapsed, expanded configuration.
  • the telescoping expander sleeve includes a first generally tubular section having a tubular proximal portion and a distal portion.
  • the tubular proximal portion has an enlarged proximal head, and the distal portion includes two or more active spreader arms each having a proximal end and a distal tip.
  • the tubular proximal portion may optionally be provided with a handle.
  • the two or more active spreader arms are connected at their proximal ends to the tubular proximal portion, and the distal tips of the two or more active spreader arms are moveable radially between an unexpanded configuration and an expanded configuration.
  • the telescoping expander sleeve also includes a second generally tubular section slidably disposed over the first generally tubular section.
  • the second generally tubular section includes a tubular proximal portion and a distal portion including two or more passive spreader flaps each having a narrow proximal end and a wide distal tip.
  • the proximal ends of the two or more passive spreader flaps are hingedly connected to the tubular proximal portion, and the distal tips of the two or more passive spreader flaps are moveable radially between an unexpanded configuration and an expanded configuration.
  • the two or more active spreader arms slidably engage the two or more passive spreader flaps, so that as the telescoping expander sleeve telescopes from the extended, unexpanded configuration to the collapsed, expanded configuration, the two or more active spreader arms slide from the narrow proximal ends of the two or more passive spreader flaps to the wider distal ends of the passive spreader flaps to spread the distal ends of the two or more passive spreader flaps apart, and to spread the distal ends of the two or more active spreader arms apart.
  • the distal tips of the two or more active spreader arms have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve
  • the distal tips of the two or more passive spreader flaps have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve.
  • the purpose of the active spreader arms and passive spreader flaps is to facilitate the creating of a larger working area adjacent to bone or bone tissues being treated.
  • the spreader arms and flaps may optionally be covered by an expandable material, such as latex, for example, to prevent tissues from being pressed into cavities of the telescoping expander sleeve.
  • the present invention is particularly useful for the purposes of orthopedic surgery, those skilled in the art will recognize that the invention can also be used for the treatment of a variety of internal organs or structures when it is desired to minimize the size of an opening in the patient's soft tissue and the resultant damage and trauma to tissue surrounding the operation site.
  • FIG. 1 is a plan view of a first embodiment of a dilation introducer in a locked configuration, according to the present invention.
  • FIG. 2 is a plan view of the dilation introducer of FIG. 1 shown in an unlocked, collapsed configuration.
  • FIG. 3 is a plan view of the first or inner dilator tube of the dilation introducer of FIG. 1 .
  • FIG. 4 is a plan view of the second or intermediate dilator tube of the dilation introducer of FIG. 1 .
  • FIG. 5 is a plan view of the third or outer dilator tube of the dilation introducer of FIG. 1 .
  • FIG. 6A is a top plan view of the first locking clip of the dilation introducer of FIG. 1 .
  • FIG. 6B is an elevational view of the first locking clip of the dilation introducer of FIG. 1 .
  • FIG. 6C is a bottom plan view of the first locking clip of the dilation introducer of FIG. 1 .
  • FIG. 7A is a top plan view of the second locking clip of the dilation introducer of FIG. 1 .
  • FIG. 7B is an elevational view of the second locking clip of the dilation introducer of FIG. 1 .
  • FIG. 8 is a perspective view of a second embodiment of a dilation introducer in a locked configuration, according to the present invention.
  • FIG. 9 is a perspective view of the dilation introducer of FIG. 8 shown in an unlocked, collapsed configuration.
  • FIG. 10 is a perspective view of the first or inner dilator tube of the dilation introducer of FIG. 8 .
  • FIG. 11 is a perspective view of the second or intermediate dilator tube of the dilation introducer of FIG. 8 .
  • FIG. 12 is a plan view of the third or outer dilator tube of the dilation introducer of FIG. 8 .
  • FIG. 13 is a plan view of a third embodiment of a dilation introducer in a locked configuration, according to the present invention.
  • FIG. 14 is a plan view of the dilation introducer of FIG. 13 shown in an unlocked, collapsed configuration.
  • FIG. 15 is a plan view of the first or inner dilator tube of the dilation introducer of FIG. 13 .
  • FIG. 16 is a plan view of the second or intermediate dilator tube of the dilation introducer of FIG. 13 .
  • FIG. 17 is a plan view of the third or outer dilator tube of the dilation introducer of FIG. 13 .
  • FIG. 18 is a plan view of the plastic sleeve of the dilation introducer of FIG. 13 .
  • FIG. 19 is a plan view of a fourth embodiment of a dilation introducer in a locked configuration, according to the present invention.
  • FIG. 20 is a plan view of the dilation introducer of FIG. 19 shown in an unlocked, collapsed configuration.
  • FIG. 21 is a plan view of the first or inner dilator tube of the dilation introducer of FIG. 19 .
  • FIG. 22 is a plan view of the second or intermediate dilator tube of the dilation introducer of FIG. 19 .
  • FIG. 23 is a plan view of the third or outer dilator tube of the dilation introducer of FIG. 19 .
  • FIG. 24 is a schematic diagram illustrating location of a starting point for insertion of a bone fixation device according to the method of the invention.
  • FIG. 25 is a schematic diagram of a lateral view illustrating location of a trajectory for insertion of a bone fixation device according to the method of the invention.
  • FIG. 26 is a schematic diagram of an anterior view illustrating location of a trajectory for insertion of a bone fixation device according to the method of the invention.
  • FIG. 27 is a plan view of a guide wire assembly for use with the various embodiments of the telescoping dilation introducer of the invention, shown disassembled.
  • FIG. 28 is a plan view of the guide wire assembly of FIG. 27 , shown partially assembled.
  • FIG. 29 is a plan view of the guide wire assembly of FIG. 27 , shown fully assembled.
  • FIG. 30 is a perspective view of a variation of the outer dilator tube of the embodiment of FIGS. 8-12 , with a parallel guide.
  • FIG. 31 is a perspective view of the parallel guide from FIG. 30 .
  • FIG. 32 is a perspective view of a variation of the outer dilator tube of the embodiment of FIGS. 8-12 , with an angled tip and with a parallel guide.
  • FIG. 33 is a perspective view of the parallel guide with an angled tip from FIG. 32 .
  • FIG. 34 is a perspective of another variation of the outer dilator tube of the embodiment of FIGS. 8-12 , with an angled tip and spikes.
  • FIG. 35 is a perspective view of the outer dilator tube of FIG. 34 , with a parallel guide with spikes.
  • FIG. 36 is a perspective view of a fifth embodiment of a dilation introducer in an unlocked configuration, according to the present invention.
  • FIG. 37 is a sectional view of a portion of the dilation introducer of FIG. 36 .
  • FIG. 38 is a perspective view of a variation of the dilation introducer of FIG. 36 , shown in a locked configuration, according to the present invention.
  • FIG. 39 is a sectional view of a portion of the dilation introducer of FIG. 36 taken along line 39 - 39 of FIG. 38 .
  • FIG. 40 is a top perspective view of the head end of the handle of the dilation introducer of FIG. 36 , showing multiple locking locations.
  • FIG. 41 is a schematic diagram of a variation of the dilation introducer of FIG. 36 , with a light emitter and switch for the light emitter.
  • FIG. 42 is an enlarged view of the tip of the dilation introducer of FIG. 41 .
  • FIG. 43 is a perspective view of another variation of the dilation introducer of FIG. 41 , with an exterior groove for one or more elongated energy conducting members.
  • FIG. 44 is a side elevational view of a telescoping expander sleeve shown in an extended, unexpanded configuration.
  • FIG. 45 is a side elevational view of the telescoping expander sleeve of FIG. 44 shown in an intermediate partially collapsed, partially expanded configuration.
  • FIG. 46 is a side elevational view of the telescoping expander sleeve of FIG. 44 shown in a fully collapsed, fully expanded configuration.
  • the present invention provides for a telescoping dilation introducer for orthopedic surgery, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's bone tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the bone tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's bone tissue to be treated.
  • a dilation introducer 30 according to a first preferred embodiment is shown in a locked assembled configuration in FIG. 1 , and shown in an unlocked, collapsed configuration in FIG. 2 .
  • the dilation introducer includes a first or inner dilator tube 32 having a distal end 34 with a tapered tip 36 , and a proximal end 38 with a head 40 including a pair of spaced part rings 42 .
  • the first dilator tube has an inner lumen 44 with a distal opening 46 and a proximal opening 48 .
  • the dilation introducer also includes a shorter second or intermediate dilator tube 52 having a distal end 54 with a tapered tip 56 , and a proximal end 58 with a head 60 including a pair of spaced apart rings 62 .
  • the second dilator tube has an inner lumen 64 with a distal opening 66 and a proximal opening 68 .
  • the dilation introducer also includes at least one additional dilator tube, such as a still shorter third or outer dilator tube 72 having a distal end 74 with a tapered tip 76 , and a proximal end 78 with a handle 80 .
  • the third dilator tube has an inner lumen 82 with a distal opening 84 and a proximal opening 86 .
  • the means for removably connecting the first and second dilator tubes together in a locked configuration includes a first locking clip 88 .
  • a means for removably connecting the second and third dilator tubes together in a locked configuration may also be provided, and may include a second locking clip 90 .
  • the first locking clip includes a first portion 92 and a second portion 94 , and a cross-piece or handle 96 having a first end 98 and a second end 100 connected at right angles between the first and second portions.
  • the first portion includes pair of resilient arms 102 each having a proximal narrow neck portion 104 connected to the cross-piece, and a distal gripping portion 106 extending from the narrow neck portion.
  • the resilient arms have an inner rounded surface 108 adapted to snap over the first dilator tube between the spaced apart rings of the first dilator tube.
  • the second portion currently preferably includes a single arm 112 having a proximal narrow neck portion 114 , and a distal gripping portion 116 extending from the narrow neck portion.
  • the gripping portion has an inner rounded surface 118 adapted to fit over the outer surface of the second dilator tube between the spaced apart rings of the second dilator tube, to connect the first and second dilator tubes. Removing the first locking clip allows the second or intermediate dilator tube to slidably telescope over the first inner dilator tube to dilate tissue at the distal end of the dilation introducer.
  • the second locking clip includes a first portion 122 and a second portion 124 , and a cross-piece or handle 126 having a first end 128 and a second end 130 connected between the first portion and the second portion at right angles.
  • the first portion includes a pair of resilient arms 132 each having a proximal narrow neck portion 134 connected to the cross-piece, and a distal gripping portion 136 extending from the narrow neck portion.
  • the pair of resilient arms have an inner rounded surface 138 adapted to snap over the outer surface of the second dilator tube between the spaced apart rings of the second dilator tube.
  • the second portion of the second locking clip includes a pair of resilient arms 142 each having a proximal narrow neck portion (not shown) connected to the cross-piece and a distal gripping portion 146 extending from the narrow neck portion, the pair of resilient arms having an inner rounded surface (not shown) adapted to fit over the outer surface of the third dilator tube to connect the second and third dilator tubes. Removing the second locking clip allows the third or outer dilator tube to slidably telescope over the second inner dilator tube to further dilate tissue at the distal end of the dilation introducer.
  • a tubular bone drill or tap 150 can be inserted through an intermediate or outer dilator tube, and the tubular bone drill or tap can be passed or threaded over a guide wire or K wire 151 to contact the surface of the vertebra or bone to be treated, as will be further described below.
  • the inner dilator tube, the tubular bone drill, and the intermediate dilator tube can be withdrawn and removed to leave the outer dilator tube in place to permit further surgical procedures.
  • the invention provides for a second presently preferred embodiment of a dilation introducer 160 shown in a locked assembled configuration in FIG. 8 , and shown in an unlocked, collapsed configuration in FIG. 9 .
  • the dilation introducer includes a first or inner dilator tube 162 having a distal end 164 with a tapered tip 166 , and a proximal end 168 with a cylindrical head 170 .
  • the means for removably connecting the first and second dilator tubes together in a locked configuration includes a latching member 172 , such as a hook, projecting from the cylindrical head toward the distal end, receiving a locking pin 216 , although other latching members, such as a projection with aperture for receiving a locking pin may also be suitable, as will be apparent from the explanation below.
  • the first dilator tube has an inner lumen 174 with a distal opening 176 and a proximal opening 178 .
  • the dilation introducer includes a shorter second or intermediate dilator tube 182 having a distal end 184 with a tapered tip 186 , and a proximal end 188 having a cylindrical head 190 .
  • the means for removably connecting the second and third dilator tubes together in a locked configuration includes a latching member 192 , such as a hook, projecting from the cylindrical head toward the distal end, receiving a locking pin 218 , although other latching members, such as a projection with aperture for receiving a locking pin may also be suitable, as noted above.
  • the second dilator tube has an inner lumen 194 with a distal opening 196 , and a proximal opening 198 .
  • the cylindrical head includes a first radial aperture 200 for receiving the locking pin 216 , and a second longitudinal aperture 201 for receiving the distally projecting latching member of the cylindrical head of the first or inner dilator tube.
  • the dilation introducer includes at least one additional dilator tube, such as a still shorter third or outer dilator tube 202 having a distal end 204 with a tapered tip 206 , and a proximal end 208 to which a handle 210 is connected at its head end 212 .
  • the head end of the handle includes a radial aperture 214 for receiving the locking pin 218 , and a longitudinal aperture 215 for receiving the distally projecting latching member of the cylindrical head of the second or intermediate dilator tube.
  • the first locking pin 216 is substantially the same as the second locking pin 218 .
  • the third dilator tube has an inner lumen 219 with proximal and distal openings.
  • a tubular bone drill or tap can be inserted through the first or inner dilator tube, and the tubular bone drill or tap can be threaded over a guide wire or K wire to contact the surface of the vertebra or bone to be treated, as described above.
  • the invention provides for a third presently preferred embodiment of a dilation introducer 220 , shown in a locked assembled configuration in FIG. 13 , and shown in an unlocked, collapsed configuration in FIG. 14 .
  • the dilation introducer includes a first or inner dilator tube 222 having a distal end 224 with a tapered, beveled tip 226 , and a proximal end 228 with a cylindrical head 230 .
  • the means for removably connecting the first and second dilator tubes together in a locked configuration includes a pair of opposing bayonet pins 232 extending from the proximal end of the first dilator tube.
  • the first dilator tube has an inner lumen 234 with a distal opening 236 and a proximal opening 238 .
  • the dilation introducer includes a shorter second or intermediate dilator tube 242 having a distal end 244 with a tapered, beveled tip 246 , and a proximal end 248 with a cylindrical head 250 .
  • a means for removably connecting the second and third dilator tubes together in a locked configuration includes a pair of opposing bayonet pins 252 .
  • the second dilator tube has an inner lumen 254 with a distal opening 256 and a proximal opening 258 , and as part of the means for removably connecting the second and third dilator tubes together, interior opposing bayonet slots 260 for receiving the pair of opposing bayonet pins of the first or inner dilator tube.
  • the dilation introducer includes at least one additional dilator tube, such as a still shorter third or outer dilator tube 262 having a distal end 264 with a tapered tip 266 , and a proximal end 268 having a pair of opposing handles 270 .
  • the third dilator tube has an inner lumen 271 , with proximal and distal openings.
  • a plastic sleeve 272 is slidably disposed over the shaft of the third or outer dilator tube, and the plastic sleeve preferably has a distal tapered, beveled end 274 .
  • a proximal sleeve ring 276 may also be slidably disposed over the shaft of the third or outer dilator tube between the plastic sleeve 272 and the opposing handles.
  • the tapered tips of the dilator tubes and plastic sleeve are beveled or angled at a common angle with respect to the longitudinal axis of the dilation introducer, so that the beveled edges of the tapered tips of the dilator tubes and plastic sleeve can be aligned together generally parallel to the surface of the soft tissue to be dilated, so that the bore and dilation passage of the dilation introducer may be aligned at a predetermined desired angle with respect to the soft tissue to be dilated and the bone tissue to be treated.
  • the third dilator tube includes interior opposing bayonet slots 278 for receiving the pair of opposing bayonet pins of the second or intermediate dilator tube.
  • a tubular bone drill or tap can be inserted through the first or inner dilator tube, and the tubular bone drill or tap can be threaded over a guide wire or K wire to contact the surface of the vertebra or bone to be treated, as described above.
  • the invention provides for a fourth embodiment of a dilation introducer 280 shown in a locked assembled configuration in FIG. 19 , and shown in an unlocked, collapsed configuration in FIG. 20 .
  • the dilation introducer includes a first or inner dilator tube 282 having a distal end 284 with a tapered tip 286 , and a proximal end 288 having a generally spherical handle or head 290 .
  • the proximal end of the first dilator tube near the handle includes a bayonet pin 292 .
  • the first dilator tube has an inner lumen 294 with a distal opening 296 , and a proximal opening 298 .
  • the dilation introducer includes a shorter second or intermediate dilator tube 302 having a distal end 304 with a tapered tip 306 , and a proximal end 308 having a generally cylindrical head 310 and a pair of opposing handles 312 .
  • the second dilator tube has an inner lumen 314 with a distal opening 316 and a proximal opening 318 .
  • the proximal end of the second dilator tube includes a bayonet slot 320 formed in the cylindrical head for receiving the bayonet pin of the first or inner dilator tube.
  • the dilation introducer includes at least one additional dilator tube, such as a still shorter third or outer dilator tube 322 , currently preferably formed of plastic, having a distal end 324 with a tapered tip 326 , and a proximal end 328 with a generally cylindrical head end or handle 330 .
  • the third dilator tube has an inner lumen 332 , with proximal and distal openings.
  • a tubular bone drill or tap can be inserted through the first or inner dilator tube, and the tubular bone drill or tap can be threaded over a guide wire or K wire to contact the surface of the vertebra or bone to be treated, as described above.
  • a surgical method for spinal fusion utilizing the dilation introducer apparatus and a bone fixation device such as a bone fixation device available under the trade name BONE-LOK from Triage Medical, Inc. of Irvine, Calif., is described.
  • a bone fixation device available under the trade name BONE-LOK from Triage Medical, Inc. of Irvine, Calif.
  • Other types of bone screws or fixation devices may also be suitable.
  • the method of the invention involves dilating a patient's soft tissue down to bone tissue to be treated in orthopedic surgery, and necessarily entails an incision and fluoroscopy to locate an entry point on the bone tissue to be treated.
  • An entry point is located on the bone tissue to be treated, and the tip of a guide wire or K-wire 151 is placed at the entry point on the bone tissue to be treated shown in FIG. 25 , and driven into the soft tissue of the patient to the target point of the inferior articular facet.
  • a vertical midline incision to a desired depth, such as approximately 17 mm, is made in the skin and fascia of the patient, using the entry point as the middle of the incision.
  • a first dilator tube of the dilation introducer is then passed over the guide wire until the tip of the dilation introducer reaches the target point of the bone.
  • the guide wire is then driven into the facet joint and into the pedicle of the patient, with verification of the trajectory and depth by fluoroscopy.
  • the second dilator tube of the dilation introducer is then released and passed over the first dilator tube to allow it to progress to the bone, allowing removal of the first dilator tube. This is repeated for the remaining, progressively wider telescoping dilator tubes, to progressively expand the patient's soft tissue down to the entry point on the bone tissue to be treated, and leaving an outer dilator tube port in place.
  • a depth gauge is then used to verify that the appropriate depth has been reached.
  • a pre-drill is advanced to the desired location, which is then also verified by fluoroscopy.
  • a cortex drill is advanced until its positive stop engages, and the distal tip of a tap is driven into the bone until it reaches the appropriate depth, which is then also verified by fluoroscopy.
  • the drill can be connected through an AO style quick connect, or a Jacobs chuck, as long as they are fully cannulated, to a ratcheting handle which is also preferably cannulated.
  • a bone fixation device is then driven into the bone until it reaches the appropriate depth, which is then also verified by fluoroscopy.
  • the bone fixation device is compressed to achieve appropriate stabilization, which is then also verified by fluoroscopy. Once compression of the bone fixation device has been achieved, the pull pin is removed, the guide wire is removed, and the remaining outer dilator tube port is removed, and the incision can be closed normally.
  • a guide wire or K wire assembly 340 for use with the telescoping dilation introducer of the invention includes an elongated, generally cylindrical first section 342 and an elongated, tubular second section 344 that is adapted to receive the first section.
  • the first section includes a proximal enlarged head or stop portion 346 , and a relatively narrow elongated body portion 348 .
  • the elongated body portion is preferably formed with a proximal section 350 having a relatively larger diameter to provide relatively greater strength, rigidity and torquability for manipulation of the guide wire, and a relatively narrower diameter main section 352 connected to the proximal section, and a pointed distal tip 354 at the distal end 358 of the main section.
  • the elongated tubular second section has a relatively larger diameter than the main section and an internal bore slightly larger in diameter than the main section for receiving the main section, as is illustrated in FIG. 28 .
  • the tubular second section advantageously also includes a frustoconical distal tip 362 with a narrowed portion 364 at the distal end 366 of the tubular distal section, and presenting an enlarged flat shoulder 368 at the proximal end of the frustoconical distal tip, so that when the guide wire assembly is assembled as shown in FIG.
  • the elongated main section is received in the internal bore of the elongated tubular section, and the proximal section of the elongated body portion of the elongated generally cylindrical section is seated against said proximal end of said elongated tubular section, the pointed distal tip extends out of said frustoconical distal tip of said elongated tubular section so that the assembly presents a pointed distal end, with a proximal shoulder against which a telescoping dilation introducer can be pushed for operation of the telescoping dilation introducer.
  • the elongated generally cylindrical first section thus adds a sharp point to the relatively blunt distal end of the elongated tubular second section, allowing the guide wire assembly to be inserted through soft tissue for placement in a soft tissue target of interest, such as an organ. Since the soft tissue present no hard surface against which the telescoping dilation introducer can be pushed, after the sharp point of the guide wire is placed in the desired location in the soft tissue, the first section can be removed from the second section, leaving the blunt distal end in place at the desired location in the soft tissue, and the telescoping dilation introducer can be placed over the second section and pressed against the shoulder of the blunt distal end for operation of the telescoping dilation introducer.
  • the outer dilator tube 400 includes a parallel guide insert 402 , shown in FIG. 31 .
  • the outer dilator tube has a distal end 404 with a tapered tip 406 , and a proximal portion 408 to which a handle 410 is connected at the extreme proximal or head end 412 of the outer dilator tube.
  • the head end of the outer dilator tube includes a radial aperture 414 for receiving the locking pin 416 , and a longitudinal aperture 418 for receiving a distally projecting latching member 420 of the cylindrical head 422 of the parallel guide insert.
  • the outer dilator tube has an inner bore 424 with proximal and distal openings.
  • the parallel guide insert includes a main cylindrical shaft 425 connected at a proximal end 426 to the cylindrical head of the parallel guide insert.
  • the parallel guide insert includes a plurality of longitudinal bores 428 extending the length of the parallel guide insert from the distal end 430 , with distal openings visible in FIG. 31 , to proximal openings (not shown) in the cylindrical head of the parallel guide insert.
  • a single guide wire or K wire or other device may be passed through one or more of the bores of the parallel guide insert, or multiple guide wires or K wires or other devices may be passed through a plurality of the bores simultaneously, as desired.
  • the parallel guide insert may be provided without a latching member, in order to allow the parallel guide member to be rotated freely to allow alignment of the desired locations of the guide wires through the holes in the parallel guide insert.
  • the outer dilator tube 440 includes a parallel guide insert 442 , shown in FIG. 33 .
  • the outer dilator tube has a distal end 444 with an angled tip 446 , and a proximal end 448 to which a handle 450 is connected at the extreme proximal or head end 452 of the outer dilator tube.
  • the head end of the outer dilator tube includes a radial aperture 454 for receiving the locking pin 456 , and a longitudinal aperture 458 for receiving a distally projecting latching member 460 of the cylindrical head 462 of the parallel guide insert.
  • the outer dilator tube has an inner bore 464 with proximal and distal openings.
  • the parallel guide insert includes a main cylindrical shaft 465 connected at a proximal end 466 to the cylindrical head of the parallel guide insert.
  • the parallel guide insert includes a plurality of longitudinal bores 468 extending the length of the parallel guide insert from the angled distal end 470 , with distal openings visible in FIG. 33 , to proximal openings (not shown) in the cylindrical head of the parallel guide insert.
  • the angled tips of the outer dilator tube and the parallel guide insert are beveled or angled at a common angle with respect to the longitudinal axis of the dilation introducer, so that the angled tips of the outer dilator tube and the parallel guide insert can be aligned together generally parallel to the surface of the soft tissue to be dilated, with the bore and dilation passage of the dilation introducer aligned at a predetermined desired angle with respect to the soft tissue to be dilated and the bone tissue to be treated.
  • a single guide wire or K wire or other device may be passed through one or more of the bores of the parallel guide insert, or multiple guide wires or K wires or other devices may be passed through a plurality of the bores simultaneously, as desired.
  • the distal tip 480 of an outer dilator tube 482 may be angled or beveled, and may include a plurality of spikes 484 to provide for increased traction of the tip of the outer dilator tube on bone tissue.
  • the spikes may be formed of radiopaque material, such as gold, platinum, tantalum or the like, for use with fluoroscopy.
  • a parallel guide 486 disposed in the outer dilator tube has a distal tip 488 that may optionally also be provided with a plurality of embedded spikes 490 for increased traction on bone tissue.
  • the spikes of the outer dilator tube and parallel guide may formed with a rounded shape so as to deflect soft tissue during dilation, and to provide increased traction with bone upon completion of the insertion of the dilator.
  • the invention provides for a fifth presently preferred embodiment of a dilation introducer 500 , which is similar to the embodiment illustrated in FIGS. 8-12 , and which is shown in an unlocked configuration in FIG. 36 .
  • the dilation introducer includes a first or inner dilator tube 502 having distal end (not shown) and a proximal end 504 with a cylindrical head 506 .
  • the means for removably connecting the first and second dilator tubes together in a locked configuration includes a first latching member 508 , having a shaft 510 and a latching end 512 , such as a hook, projecting from the cylindrical head toward the distal end, and connected to a locking button 514 , which extends transversely out through a side aperture 516 in the cylindrical head.
  • the locking button includes a shaft 518 and an enlarged head 520 connected to the shaft, and the locking button is biased outwardly from the cylindrical head by a spring 522 .
  • the latching member is received in an upper aperture 524 of the adjacent cylindrical head of a second or intermediate dilator tube 526 , having a side opening latching chamber 528 for retaining the latching end of the latching member when the locking button is biased outwardly by its spring, to lock the cylindrical heads of the first and second dilator tubes together.
  • the cylindrical heads of the first and second dilator tubes can be unlocked and separated by manually depressing the locking button to move the latching member inwardly and the latching end of the latching member inwardly out of the side opening latching chamber.
  • the first dilator tube is essentially the same as the first dilator tube of the embodiment of FIGS. 8-12 .
  • the second or intermediate dilator tube 526 of the dilation introducer has a distal end (not shown) and a proximal end 530 with a cylindrical head 532 .
  • the means for removably connecting the second and third dilator tubes together in a locked configuration includes a second latching member 534 , having a shaft 536 and a latching end 538 , such as a hook, projecting from the cylindrical head toward the distal end, and connected to a second locking button 540 , which extends transversely out through a side aperture 542 in the cylindrical head.
  • the locking button includes a shaft 544 and an enlarged head 546 connected to the shaft, and the locking button is biased outwardly from the cylindrical head by a spring 548 .
  • the latching member is received in an upper aperture 550 of the adjacent cylindrical head of a third or second intermediate dilator tube 552 , having a side opening latching chamber 554 for retaining the latching end of the latching member when the locking button is biased outwardly by its spring, to lock the cylindrical heads of the second and third dilator tubes together.
  • the cylindrical heads of the second and third dilator tubes can be unlocked and separated by manually depressing the second locking button to move the latching member inwardly and the latching end of the latching member inwardly out of the side opening latching chamber.
  • the second dilator tube is essentially the same as the second dilator tube of the embodiment of FIGS. 8-12 .
  • the third, or second intermediate, dilator tube 552 of the dilation introducer has a distal end (not shown) and a proximal end 556 with a cylindrical head 558 .
  • the means for removably connecting the third dilator tube and the outer dilator tube 560 together in a locked configuration includes a third latching member 562 , having a shaft 564 and a latching end 566 , such as a hook, projecting from the cylindrical head toward the distal end, and connected to a third locking button 568 , which extends transversely out through a side aperture 570 in the cylindrical head.
  • the third locking button includes a shaft 572 and an enlarged head 574 connected to the shaft, and the third locking button is biased outwardly from the cylindrical head by a spring 576 .
  • the latching member is received in an upper aperture 578 of the adjacent cylindrical head 580 of the outer dilator tube, having a side opening latching chamber 582 for retaining the latching end of the latching member when the locking button is biased outwardly by its spring, to lock the cylindrical heads of the third and outer dilator tubes together.
  • the cylindrical heads of the third and outer dilator tubes can be unlocked and separated by manually depressing the third locking button to move the latching member inwardly and the latching end of the latching member inwardly out of the side opening latching chamber.
  • the third dilator tube is essentially the same as the second dilator tube of the embodiment of FIGS. 8-12 .
  • the outer dilator tube includes a distal end (not shown) and a proximal end 584 to which a handle 586 is connected at its cylindrical head end.
  • the head end of the handle preferably includes a plurality of the upper apertures 578 connected to corresponding side opening latching apertures 582 for receiving the latching member of the adjacent dilator tube cylindrical head, as is illustrated in FIG. 40 .
  • the outer dilator tube is essentially the same as the outer dilator tube of the embodiment of FIGS. 8-12 .
  • the side opening latching chambers of the cylindrical heads of the dilator tubes may be closed so as to form covered latching chambers 590 a, b, c for the latching members.
  • the variation shown in FIGS. 38 and 39 is essentially the same as in FIGS. 36 and 37 .
  • an outer dilation tube 600 may be provided with a light emitter 602 , such as one or more light emitting diodes (LEDs) or the end of a fiber optic, connected to or embedded in the tubular shaft 604 of the outer dilation tube, and preferably near the distal end 606 of the tubular shaft.
  • the light emitter may be an LED embedded in the wall 608 of the tubular shaft, with the LED directed to illuminate the interior, exterior, or distal edge of the tubular shaft of the outer dilation tube. As is shown in FIG.
  • one or more elongated energy conducting members 610 may be embedded in the tubular shaft, for conducting electricity or light to the light emitter.
  • the handle 612 of the outer dilator tube preferably contains one or more batteries 614 connected to a switch 616 which is in turn connected to power the light emitter.
  • the handle may be provided with a battery or batteries, which may be disposable, a switch, resistor and other associated electronics, so that the handle is disposable, or alternatively the handle may be provided with a connector for connection to an external power source.
  • the switch is a thumb switch conveniently located on the handle adjacent to the cylindrical head 618 of the outer dilation tube.
  • the handle, cylindrical head, and tubular shaft of the outer dilation tube preferably includes one or more channels 620 for the electrical wires connecting the one or more batteries to the switch and to the light emitter.
  • a light source 622 such as one or more LEDs providing light to be conducted through the one or more fiber optics may be placed adjacent to the switch in the handle, with the one or more fiber optics extending through the wall of the tubular shaft of the outer dilator tube.
  • the one or more elongated energy conducting members such as one or more wires or one or more fiber optics, may be disposed on the outer surface of the tubular shaft of the outer dilation tube.
  • the tubular shaft of the outer dilation tube may be formed with a groove 620 running longitudinally on the exterior surface of the tubular shaft, parallel to the longitudinal axis of the outer dilation tube, to accommodate one or more wires or one or more fiber optics.
  • the one or more elongated energy conducting members may be located on the inside of the dilator tube, or may extend through the wall of the dilator tube.
  • the present invention also provides for a telescoping expander sleeve 630 that is adapted to be slidably disposed over the shaft of an outer dilator tube of any of the foregoing embodiments for expanding the patient's soft tissue down to the entry point on the bone tissue to be treated, while leaving the outer dilator tube in place, or allowing for replacement of the outer dilator tube with other equipment for treatment of the bone tissue.
  • the tubular proximal portion may optionally be provided with a handle.
  • the expander sleeve may be pre-assembled in combination with one or more of the dilation introducers, adapted to be ready for use.
  • the telescoping expander sleeve has a first or inner generally tubular section 632 , having a tubular proximal portion 634 with an enlarged proximal head 636 , and a distal portion 638 with at least two substantially identical opposing active spreader arms 640 (one of which is not visible in FIGS. 44-46 ) connected at one end to the tubular proximal portion and moveable radially at their distal tips 642 .
  • the distal tips of the active spreader arms preferably have beveled edges 644 to deflect soft tissue during insertion of the telescoping expander sleeve.
  • a second or outer generally tubular section 646 is slidably disposed over the first or inner generally tubular section, and includes a tubular proximal portion 648 and a distal portion 650 with at least two substantial identical opposing passive spreader flaps 652 interposed between the active spreader arms, hingedly connected to the tubular proximal portion at proximal ends 654 , and moveable radially at their distal tips 656 .
  • the distal tips of the passive spreader flaps preferably also have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve.
  • the distal tips of the passive spreader flaps when placed together in an unexpanded configuration have a generally circular configuration, so that the distal tips of two passive spreader flaps, for example, have a semi-circular configuration.
  • the passive spreader flaps taper progressively toward their narrowed proximal ends connected to the tubular proximal portion of the outer tubular section.
  • the passive spreader flaps are connected to the tubular proximal portion of the outer generally tubular section by rings 656 passing through apertures 658 and 660 in the adjacent ends of the tubular proximal portion and the passive spreader flaps, respectively.
  • the active spreader arms are slidably interposed between and engage the passive spreader flaps, so that as the telescoping expander sleeve telescopes from an extended, unexpanded configuration to a collapsed, expanded configuration, as shown in FIG. 44 , the active spreader arms slide from the narrow proximal ends of the passive spreader flaps to the wider distal ends of the passive spreader flaps to spread the distal ends of the passive spreader flaps apart, which also forces the distal ends of the active spreader arms apart, as shown in FIG. 46 .
  • the distal ends of the active spreader arms are slidably connected to slots 662 extending along the inner edges 664 of the passive spreader flaps by loops or rings 666 , such as loops of nylon filament or metal rings, for example, which pass through apertures 668 in the distal ends of the active spreader arms.
  • Telescoping of expander sleeve from a collapsed, expanded configuration to an extended, unexpanded configuration thus slides the distal ends of the active spreader arms of the inner tubular section from the wide distal ends of the passive spreader flaps along the inner edges of the passive spreader flaps to the narrowed proximal ends of the passive spreader flaps, to bring the passive spreader flaps together.
  • the purpose of the active spreader arms and passive spreader flaps is to facilitate the creating of a larger working area adjacent to bone or bone tissues being treated.
  • the spreader arms and flaps may optionally be covered by an expandable material, such as latex, for example, with a central through hole permitting operation of the device, to cover the spreader arms and flaps to prevent tissues from being pressed into cavities of the telescoping expander sleeve.
  • the components of the dilation introducer may be formed from plastic, stainless steel, or similar materials or combinations thereof, that can be readily sterilized and packaged ready for use, after which the dilation introducer may be disposed of or resterilized for subsequent use, as desired.
  • the dilator tubes may be radioluscent, with radiopaque markers located on the tips of one or more of the dilator tubes.
  • the tip of the first dilator may also be scored, grooved, or otherwise be provided with a rough surface, to prevent migration.
  • the dilation introducer may also have curved or otherwise non-linear dilator tubes, and the dilation introducer may also have a non-cylindrical shape, such as an oval shape, for example, to allow the dilation introducer to be inserted around objects or a patient's organs.
  • one or more devices can be inserted through the same dilation introducer, and that the dilation introducer can be repositioned within the same incision for fixation of multiple devices.
  • fiber optic devices may be inserted through or integrated with the dilation introducer for visual inspection of the target area. While particular locking features have been described for the different embodiments of the dilation introducer, any combination of locking features or alternate locking features may be utilized.
  • the outer dilator tube may not be locked, and a handle on the outer dilator tube may simply be used as a stop.
  • the dilation introducer of the invention can also be useful in dilation of soft tissue for percutaneous, minimally invasive surgical procedures such as nephrostomy, neurosurgery, heart valve repair or replacement, gastrointestinal surgery such as for gall bladder or gall stone surgery, hernia removal, transjugular intrahepatic portal-systemic shunt (TIPS) procedures for treatment of the liver, and the like.
  • percutaneous, minimally invasive surgical procedures such as nephrostomy, neurosurgery, heart valve repair or replacement
  • gastrointestinal surgery such as for gall bladder or gall stone surgery
  • hernia removal such as for gall bladder or gall stone surgery
  • TIPS transjugular intrahepatic portal-systemic shunt

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Evolutionary Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)

Abstract

The dilation introducer has a locked assembled configuration for placement of the dilation introducer against a patient's tissue to be treated, and an unlocked, collapsed configuration for dilating the patient's soft tissue down to tissue to be treated. Dilator tubes are successively released and advanced to progressively expand the patient's soft tissue down to the bone tissue to be treated. The dilator tubes and a guide insert may include spikes for engaging bone tissue. The dilation introducer may include a light emitter disposed in a dilator tube. A telescoping expander sleeve is also provided.

Description

    CROSS-REFERENCES TO RELATED APPLICATIONS
  • This is a continuation-in-part of Ser. No. 10/911,215, filed Aug. 3, 2004.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • This invention relates to bone fixation devices, and more particularly relates to a dilation introducer for introducing a bone fixation device for orthopedic surgery, such as for vertebral fusion.
  • 2. General Background and State of the Art
  • Fusion of two adjacent vertebrae is a common surgical treatment for back injuries due to damage or defects in a spinal disc between two adjacent vertebrae, such as conditions due to a herniated disc or disc degeneration. The entire disc may be removed by a discectomy procedure, and may be replaced with bone or a bone substitute and/or cage in order to prevent collapse of the disc space between the adjacent vertebrae. Early techniques for stabilizing the adjacent vertebrae included application of a plate or a rod in conjunction with screws across the adjacent vertebrae, after which the adjacent vertebrae would eventually fuse together. However, such techniques commonly required prolonged periods of recovery from the extensive surgery involved, and it would be desirable to provide an improved apparatus and method for providing a minimally invasive procedure that will result in less trauma and improvement in patient recovery.
  • Bone fixation devices are known that are useful for connecting two or more bone segments for the healing of broken bones, typically including an elongate pin with a distal anchor and a proximal anchor movable on the pin to accommodate different bone dimensions, and to permit tensioning of the bone segments together. The surgical procedure of attaching two or more parts of a bone with a pin-like device commonly requires an initial incision into the tissue down to the bone, and the drilling of a hole through the bone parts to be joined. Such bone fixation devices can be useful for fusion of vertebrae together, because such a bone fixation device can be used to join adjacent bone segments through a single percutaneous incision or puncture, without the need to expose any other side of the bone segments to be joined. In either type of procedure, there is substantial trauma to the surrounding tissue if a large incision is required. Thus, it would be desirable to provide a minimally invasive dilation introducer to allow the penetration and spreading of soft tissues down to vertebrae to be fused, for use of such a bone fixation device to join adjacent vertebrae, and to allow for more easily performing the delicate maneuvering of drilling adjacent vertebrae and application of one or more bone fixation devices to join the vertebrae to be fused. The present invention satisfies these and other needs.
    • INVENTION SUMMARY
  • Briefly, and in general terms, the invention provides for a telescoping dilation introducer for orthopedic surgery, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's tissue to be treated, and an unlocked, collapsed configuration for dilating the patient's soft surrounding tissue to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's tissue. As the telescoping dilation introducer is inserted, each individual dilator tube is successively released and advanced to progressively expand the patient's soft tissue down to the tissue to be treated. In a particularly useful aspect of the invention, the tissue to be treated is bone tissue which must be prepared prior to attachment of adjacent bone section in a fusion process. While there are many applications of the dilation introducer of the invention, the invention is particularly applicable to fusion of bones in orthopedic surgery using minimally invasive technique, and will be described herein in particular applications of those procedures. The invention also concerns a minimally invasive procedure utilizing the telescoping dilation introducer to insert a bone fixation device into a patient's spine for posterior spine fusion. While posterior spine fusion currently takes up to two hours to complete, and requires a six inch incision, with the apparatus and method of the invention, comparable surgery can be completed in less than thirty minutes, with a dilation port 13 mm or less in diameter, thus lowering the chance of damage to the surrounding soft tissue.
  • A telescoping dilation introducer is typically operated by pressing the introducer against a relatively hard surface, such as bone tissue being treated. The present invention provides for a guide wire assembly when such a telescoping dilation introducer is to used in treatment of soft tissue, such as an organ, to provide a surface against which the telescoping dilation introducer can be pushed during operation of the telescoping dilation introducer. In a presently preferred embodiment, a guide wire or K wire assembly is provided for use with a telescoping dilation introducer according to the invention. The guide wire assembly includes an elongated generally cylindrical first section, and an elongated tubular second section that receives the first section. The elongated generally cylindrical first section includes a proximal enlarged head or stop portion, and an elongated body portion with a proximal section and a relatively narrower diameter main section connected to the proximal section, and a pointed distal tip at the distal end of the narrow main section. The second section of the guide wire assembly includes an elongated tubular body with an internal bore adapted to receive the narrow main section, as is illustrated in FIG. 28. The tubular second section advantageously includes a frustoconical distal tip with a narrowed portion at the distal end and an enlarged flat shoulder at the proximal end of the frustoconical distal tip. When the guide wire assembly is assembled, the assembly presents a pointed distal end with a proximal shoulder against which a telescoping dilation introducer can be pushed for operation of the telescoping dilation introducer. The main section thus adds a sharp point to the relatively blunt distal end of the tubular distal section, allowing the guide wire assembly to be inserted through soft tissue for placement in a soft tissue target of interest, such as an organ, and the first section can then be removed to allow a telescoping dilation introducer to be placed over the second section and pressed against the shoulder of the blunt distal end for operation of the telescoping dilation introducer. After the sharp point of the guide wire is placed in the desired location in the soft tissue, the first section can be removed from the second section, leaving the blunt distal end in place at the desired location in the soft tissue, and the telescoping dilation introducer can be placed over the second section and pressed against the shoulder of the blunt distal end for operation of the telescoping dilation introducer.
  • In one presently preferred embodiment, the present invention provides for an improvement in a dilation introducer for orthopedic surgery, in which the dilation introducer includes one or more dilator tubes having a distal end and a proximal end, and the distal end of the one or more dilator tubes including a plurality of spikes for engaging bone tissue. In one presently preferred aspect, the spikes may be formed of radiopaque material, for fluoroscopic imaging of the positioning of the one or more dilator tubes, and the spikes may be formed with a rounded shape so as to deflect soft tissue.
  • In another presently preferred aspect, the dilation introducer includes a parallel guide insert adapted to be received in the one or more dilator tubes. The parallel guide insert includes a main cylindrical shaft having a proximal end connected to a cylindrical head, and a plurality of longitudinal bores extending the length of the parallel guide insert through the main cylindrical shaft and cylindrical head. The distal tip of the parallel guide insert may be provided with a plurality of spikes for engaging bone tissue. The spikes of the parallel guide insert may be formed of radiopaque material, and may be formed with a rounded shape so as to deflect soft tissue.
  • In another presently preferred embodiment, the present invention concerns a dilation introducer for orthopedic surgery having a locked assembled configuration for initial placement of the dilation introducer against a patient's bone tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the bone tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's bone tissue to be treated. The dilation introducer includes a first dilator tube having a distal end with a tapered tip and a proximal end with a cylindrical head, and a second dilator tube having a distal end with a tapered tip and a proximal end with a cylindrical head, and an inner lumen with a distal opening and a proximal opening. The first dilator tube is removably received in the second dilator tube for slidable telescoping movement within the second dilator tube. Means are provided for removably connecting the first and second dilator tubes together in a locked configuration. The means for removably connecting the first and second dilator tubes includes a first latching member disposed in the cylindrical head of the first dilator tube. The first latching member has a locking button connected transversely to a shaft with a latching end projecting from the cylindrical head of the first dilator tube toward the distal end of the first dilator tube, with the locking button extending transversely from the shaft through a side aperture in the cylindrical head of the first dilator tube. The locking button is biased outwardly from the cylindrical head, such as by a spring, and the first latching member is received in an upper aperture of the cylindrical head of an adjacent second dilator tube. The upper aperture of the cylindrical head of the second dilator tube includes a latching chamber for retaining the latching end of the latching member when the locking button is biased outwardly, to lock the cylindrical heads of the first and second dilator tubes together. The locking button is moveable inwardly to move the latching member inwardly and to move the latching end of the latching member inwardly out of the latching chamber, to unlock the first and second dilator tubes.
  • The dilation introducer may include one or more additional dilator tubes, with the second dilator tube being removably received in the one or more additional dilator tubes for slidable telescoping movement within the one or more additional dilator tubes. The one or more additional dilator tubes likewise have a distal end and a proximal end with a cylindrical head, an inner lumen with a distal opening and a proximal opening, and the distal end having a tapered tip. The second dilator tube and the one or more additional dilator tubes having an unlocked configuration in which the one or more additional dilator tubes may slidably telescope over the second dilator tube to dilate the patient's soft tissue at the distal end of the dilation introducer. Means are provided for removably connecting the second dilator tube and the one or more additional dilator tubes together in a locked configuration. The means for removably connecting the second dilator tube and the one or more additional dilator tubes include a second latching member disposed in the cylindrical head of the second dilator tube. The second latching member has a locking button connected transversely to a shaft with a latching end projecting from the cylindrical head of the second dilator tube toward the distal end of the second dilator tube, and the locking button extends transversely from the shaft through a side aperture in the cylindrical head of the second dilator tube. The locking button is biased outwardly from the cylindrical head, such as by a spring, and the second latching member is received in an upper aperture of the cylindrical head of the additional dilator tube to be connected. The upper aperture of the cylindrical head of the additional dilator tubes include a latching chamber for retaining the latching end of the second latching member when the locking button is biased outwardly, to lock the cylindrical heads of the second and additional dilator tube together, and the locking button is moveable inwardly to move the second latching member inwardly and the latching end of the second latching member inwardly out of the latching chamber.
  • In a presently preferred aspect, the additional dilator tube comprises a handle connected to the proximal end of the additional dilator tube, and the cylindrical head of the additional dilator tube includes a plurality of the upper apertures, each including a latching chamber for receiving the second latching member.
  • In another presently preferred embodiment, the present invention provides for an improvement in a dilation introducer for orthopedic surgery, in which the dilation introducer includes a dilator tube having a tubular shaft, a distal end and a proximal end, an inner lumen with a distal opening and a proximal opening, and a light emitter disposed in the dilator tube. In one aspect, the light emitter may be a light emitting diode, and the light emitting diode may be embedded in the tubular shaft of the dilator tube. In another aspect, the light emitter may include a fiber optic, and the fiber optic may be embedded in the tubular shaft of the dilator tube.
  • In a presently preferred aspect, the dilator tube includes a handle and a switch for controlling the light emitter, and at least one battery is disposed in the handle and is connected to the switch to power the light emitter. Where the light emitter includes one or more fiber optics, the light emitter includes a light source providing light conducted to the one or more fiber optics. The light emitter may include one or more elongated energy conducting members disposed on an outer surface of the tubular shaft of the dilator tube, and the one or more elongated energy conducting members may be disposed in a groove on the exterior surface of the tubular shaft. Alternatively, the one or more elongated energy conducting members may be located on the inside of the dilator tube, or may extend through the wall of the dilator tube.
  • The present invention also provides for a telescoping expander sleeve adapted to be slidably disposed over a shaft of a dilator tube for dilating a patient's soft tissue down to a bone tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's bone tissue. The telescoping expander sleeve is moveable between an extended, unexpanded configuration and a collapsed, expanded configuration. The telescoping expander sleeve includes a first generally tubular section having a tubular proximal portion and a distal portion. The tubular proximal portion has an enlarged proximal head, and the distal portion includes two or more active spreader arms each having a proximal end and a distal tip. The tubular proximal portion may optionally be provided with a handle. The two or more active spreader arms are connected at their proximal ends to the tubular proximal portion, and the distal tips of the two or more active spreader arms are moveable radially between an unexpanded configuration and an expanded configuration.
  • The telescoping expander sleeve also includes a second generally tubular section slidably disposed over the first generally tubular section. The second generally tubular section includes a tubular proximal portion and a distal portion including two or more passive spreader flaps each having a narrow proximal end and a wide distal tip. The proximal ends of the two or more passive spreader flaps are hingedly connected to the tubular proximal portion, and the distal tips of the two or more passive spreader flaps are moveable radially between an unexpanded configuration and an expanded configuration. The two or more active spreader arms slidably engage the two or more passive spreader flaps, so that as the telescoping expander sleeve telescopes from the extended, unexpanded configuration to the collapsed, expanded configuration, the two or more active spreader arms slide from the narrow proximal ends of the two or more passive spreader flaps to the wider distal ends of the passive spreader flaps to spread the distal ends of the two or more passive spreader flaps apart, and to spread the distal ends of the two or more active spreader arms apart.
  • In a presently preferred aspect, the distal tips of the two or more active spreader arms have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve, and the distal tips of the two or more passive spreader flaps have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve. The purpose of the active spreader arms and passive spreader flaps is to facilitate the creating of a larger working area adjacent to bone or bone tissues being treated. The spreader arms and flaps may optionally be covered by an expandable material, such as latex, for example, to prevent tissues from being pressed into cavities of the telescoping expander sleeve.
  • While the present invention is particularly useful for the purposes of orthopedic surgery, those skilled in the art will recognize that the invention can also be used for the treatment of a variety of internal organs or structures when it is desired to minimize the size of an opening in the patient's soft tissue and the resultant damage and trauma to tissue surrounding the operation site.
  • Other features and advantages of the present invention will become more apparent from the following detailed description of the preferred embodiments in conjunction with the accompanying drawings, which illustrate, by way of example, the operation of the invention.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a plan view of a first embodiment of a dilation introducer in a locked configuration, according to the present invention.
  • FIG. 2 is a plan view of the dilation introducer of FIG. 1 shown in an unlocked, collapsed configuration.
  • FIG. 3 is a plan view of the first or inner dilator tube of the dilation introducer of FIG. 1.
  • FIG. 4 is a plan view of the second or intermediate dilator tube of the dilation introducer of FIG. 1.
  • FIG. 5 is a plan view of the third or outer dilator tube of the dilation introducer of FIG. 1.
  • FIG. 6A is a top plan view of the first locking clip of the dilation introducer of FIG. 1.
  • FIG. 6B is an elevational view of the first locking clip of the dilation introducer of FIG. 1.
  • FIG. 6C is a bottom plan view of the first locking clip of the dilation introducer of FIG. 1.
  • FIG. 7A is a top plan view of the second locking clip of the dilation introducer of FIG. 1.
  • FIG. 7B is an elevational view of the second locking clip of the dilation introducer of FIG. 1.
  • FIG. 8 is a perspective view of a second embodiment of a dilation introducer in a locked configuration, according to the present invention.
  • FIG. 9 is a perspective view of the dilation introducer of FIG. 8 shown in an unlocked, collapsed configuration.
  • FIG. 10 is a perspective view of the first or inner dilator tube of the dilation introducer of FIG. 8.
  • FIG. 11 is a perspective view of the second or intermediate dilator tube of the dilation introducer of FIG. 8.
  • FIG. 12 is a plan view of the third or outer dilator tube of the dilation introducer of FIG. 8.
  • FIG. 13 is a plan view of a third embodiment of a dilation introducer in a locked configuration, according to the present invention.
  • FIG. 14 is a plan view of the dilation introducer of FIG. 13 shown in an unlocked, collapsed configuration.
  • FIG. 15 is a plan view of the first or inner dilator tube of the dilation introducer of FIG. 13.
  • FIG. 16 is a plan view of the second or intermediate dilator tube of the dilation introducer of FIG. 13.
  • FIG. 17 is a plan view of the third or outer dilator tube of the dilation introducer of FIG. 13.
  • FIG. 18 is a plan view of the plastic sleeve of the dilation introducer of FIG. 13.
  • FIG. 19 is a plan view of a fourth embodiment of a dilation introducer in a locked configuration, according to the present invention.
  • FIG. 20 is a plan view of the dilation introducer of FIG. 19 shown in an unlocked, collapsed configuration.
  • FIG. 21 is a plan view of the first or inner dilator tube of the dilation introducer of FIG. 19.
  • FIG. 22 is a plan view of the second or intermediate dilator tube of the dilation introducer of FIG. 19.
  • FIG. 23 is a plan view of the third or outer dilator tube of the dilation introducer of FIG. 19.
  • FIG. 24 is a schematic diagram illustrating location of a starting point for insertion of a bone fixation device according to the method of the invention.
  • FIG. 25 is a schematic diagram of a lateral view illustrating location of a trajectory for insertion of a bone fixation device according to the method of the invention.
  • FIG. 26 is a schematic diagram of an anterior view illustrating location of a trajectory for insertion of a bone fixation device according to the method of the invention.
  • FIG. 27 is a plan view of a guide wire assembly for use with the various embodiments of the telescoping dilation introducer of the invention, shown disassembled.
  • FIG. 28 is a plan view of the guide wire assembly of FIG. 27, shown partially assembled.
  • FIG. 29 is a plan view of the guide wire assembly of FIG. 27, shown fully assembled.
  • FIG. 30 is a perspective view of a variation of the outer dilator tube of the embodiment of FIGS. 8-12, with a parallel guide.
  • FIG. 31 is a perspective view of the parallel guide from FIG. 30.
  • FIG. 32 is a perspective view of a variation of the outer dilator tube of the embodiment of FIGS. 8-12, with an angled tip and with a parallel guide.
  • FIG. 33 is a perspective view of the parallel guide with an angled tip from FIG. 32.
  • FIG. 34 is a perspective of another variation of the outer dilator tube of the embodiment of FIGS. 8-12, with an angled tip and spikes.
  • FIG. 35 is a perspective view of the outer dilator tube of FIG. 34, with a parallel guide with spikes.
  • FIG. 36 is a perspective view of a fifth embodiment of a dilation introducer in an unlocked configuration, according to the present invention.
  • FIG. 37 is a sectional view of a portion of the dilation introducer of FIG. 36.
  • FIG. 38 is a perspective view of a variation of the dilation introducer of FIG. 36, shown in a locked configuration, according to the present invention.
  • FIG. 39 is a sectional view of a portion of the dilation introducer of FIG. 36 taken along line 39-39 of FIG. 38.
  • FIG. 40 is a top perspective view of the head end of the handle of the dilation introducer of FIG. 36, showing multiple locking locations.
  • FIG. 41 is a schematic diagram of a variation of the dilation introducer of FIG. 36, with a light emitter and switch for the light emitter.
  • FIG. 42 is an enlarged view of the tip of the dilation introducer of FIG. 41.
  • FIG. 43 is a perspective view of another variation of the dilation introducer of FIG. 41, with an exterior groove for one or more elongated energy conducting members.
  • FIG. 44 is a side elevational view of a telescoping expander sleeve shown in an extended, unexpanded configuration.
  • FIG. 45 is a side elevational view of the telescoping expander sleeve of FIG. 44 shown in an intermediate partially collapsed, partially expanded configuration.
  • FIG. 46 is a side elevational view of the telescoping expander sleeve of FIG. 44 shown in a fully collapsed, fully expanded configuration.
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Referring to the drawings, which are provided for purposes of illustration and by way of example, the present invention provides for a telescoping dilation introducer for orthopedic surgery, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's bone tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the bone tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's bone tissue to be treated.
  • While the invention will be described with specificity to a spinal fusion procedure, those skilled in the art will recognize that the apparatus and method of the art will recognize that the apparatus and method of the invention can also be advantageously used for procedures in which the dilation introducer can be brought up against other firm or solid structures in the body or introduced into the body to thereby gain the advantages of the invention for other minimally invasive procedures.
  • A dilation introducer 30 according to a first preferred embodiment is shown in a locked assembled configuration in FIG. 1, and shown in an unlocked, collapsed configuration in FIG. 2. Referring to FIG. 3, the dilation introducer includes a first or inner dilator tube 32 having a distal end 34 with a tapered tip 36, and a proximal end 38 with a head 40 including a pair of spaced part rings 42. The first dilator tube has an inner lumen 44 with a distal opening 46 and a proximal opening 48.
  • Referring to FIG. 4, the dilation introducer also includes a shorter second or intermediate dilator tube 52 having a distal end 54 with a tapered tip 56, and a proximal end 58 with a head 60 including a pair of spaced apart rings 62. The second dilator tube has an inner lumen 64 with a distal opening 66 and a proximal opening 68.
  • Referring to FIG. 5, in a presently preferred aspect, the dilation introducer also includes at least one additional dilator tube, such as a still shorter third or outer dilator tube 72 having a distal end 74 with a tapered tip 76, and a proximal end 78 with a handle 80. The third dilator tube has an inner lumen 82 with a distal opening 84 and a proximal opening 86.
  • Referring to FIGS. 6A, 6B and 6C, the means for removably connecting the first and second dilator tubes together in a locked configuration includes a first locking clip 88. As is shown in FIGS. 7A and 7B, a means for removably connecting the second and third dilator tubes together in a locked configuration may also be provided, and may include a second locking clip 90. The first locking clip includes a first portion 92 and a second portion 94, and a cross-piece or handle 96 having a first end 98 and a second end 100 connected at right angles between the first and second portions. The first portion includes pair of resilient arms 102 each having a proximal narrow neck portion 104 connected to the cross-piece, and a distal gripping portion 106 extending from the narrow neck portion. The resilient arms have an inner rounded surface 108 adapted to snap over the first dilator tube between the spaced apart rings of the first dilator tube. The second portion currently preferably includes a single arm 112 having a proximal narrow neck portion 114, and a distal gripping portion 116 extending from the narrow neck portion. The gripping portion has an inner rounded surface 118 adapted to fit over the outer surface of the second dilator tube between the spaced apart rings of the second dilator tube, to connect the first and second dilator tubes. Removing the first locking clip allows the second or intermediate dilator tube to slidably telescope over the first inner dilator tube to dilate tissue at the distal end of the dilation introducer.
  • The second locking clip includes a first portion 122 and a second portion 124, and a cross-piece or handle 126 having a first end 128 and a second end 130 connected between the first portion and the second portion at right angles. The first portion includes a pair of resilient arms 132 each having a proximal narrow neck portion 134 connected to the cross-piece, and a distal gripping portion 136 extending from the narrow neck portion. The pair of resilient arms have an inner rounded surface 138 adapted to snap over the outer surface of the second dilator tube between the spaced apart rings of the second dilator tube. The second portion of the second locking clip includes a pair of resilient arms 142 each having a proximal narrow neck portion (not shown) connected to the cross-piece and a distal gripping portion 146 extending from the narrow neck portion, the pair of resilient arms having an inner rounded surface (not shown) adapted to fit over the outer surface of the third dilator tube to connect the second and third dilator tubes. Removing the second locking clip allows the third or outer dilator tube to slidably telescope over the second inner dilator tube to further dilate tissue at the distal end of the dilation introducer.
  • As is shown in FIG. 1, a tubular bone drill or tap 150 can be inserted through an intermediate or outer dilator tube, and the tubular bone drill or tap can be passed or threaded over a guide wire or K wire 151 to contact the surface of the vertebra or bone to be treated, as will be further described below. Once the outer dilator tube has been moved to the distal end of the dilation introducer into position against the vertebra or bone to be treated to fully dilate the soft tissue, the inner dilator tube, the tubular bone drill, and the intermediate dilator tube can be withdrawn and removed to leave the outer dilator tube in place to permit further surgical procedures.
  • Referring to FIGS. 8-12, the invention provides for a second presently preferred embodiment of a dilation introducer 160 shown in a locked assembled configuration in FIG. 8, and shown in an unlocked, collapsed configuration in FIG. 9. Referring to FIG. 10, the dilation introducer includes a first or inner dilator tube 162 having a distal end 164 with a tapered tip 166, and a proximal end 168 with a cylindrical head 170. The means for removably connecting the first and second dilator tubes together in a locked configuration includes a latching member 172, such as a hook, projecting from the cylindrical head toward the distal end, receiving a locking pin 216, although other latching members, such as a projection with aperture for receiving a locking pin may also be suitable, as will be apparent from the explanation below. The first dilator tube has an inner lumen 174 with a distal opening 176 and a proximal opening 178.
  • Referring to FIG. 11, the dilation introducer includes a shorter second or intermediate dilator tube 182 having a distal end 184 with a tapered tip 186, and a proximal end 188 having a cylindrical head 190. The means for removably connecting the second and third dilator tubes together in a locked configuration includes a latching member 192, such as a hook, projecting from the cylindrical head toward the distal end, receiving a locking pin 218, although other latching members, such as a projection with aperture for receiving a locking pin may also be suitable, as noted above. The second dilator tube has an inner lumen 194 with a distal opening 196, and a proximal opening 198. The cylindrical head includes a first radial aperture 200 for receiving the locking pin 216, and a second longitudinal aperture 201 for receiving the distally projecting latching member of the cylindrical head of the first or inner dilator tube.
  • Referring to FIG. 12, in a preferred aspect, the dilation introducer includes at least one additional dilator tube, such as a still shorter third or outer dilator tube 202 having a distal end 204 with a tapered tip 206, and a proximal end 208 to which a handle 210 is connected at its head end 212. The head end of the handle includes a radial aperture 214 for receiving the locking pin 218, and a longitudinal aperture 215 for receiving the distally projecting latching member of the cylindrical head of the second or intermediate dilator tube. The first locking pin 216 is substantially the same as the second locking pin 218. The third dilator tube has an inner lumen 219 with proximal and distal openings. A tubular bone drill or tap can be inserted through the first or inner dilator tube, and the tubular bone drill or tap can be threaded over a guide wire or K wire to contact the surface of the vertebra or bone to be treated, as described above.
  • With reference to FIGS. 13-18, the invention provides for a third presently preferred embodiment of a dilation introducer 220, shown in a locked assembled configuration in FIG. 13, and shown in an unlocked, collapsed configuration in FIG. 14. As is illustrated in FIG. 15, the dilation introducer includes a first or inner dilator tube 222 having a distal end 224 with a tapered, beveled tip 226, and a proximal end 228 with a cylindrical head 230. The means for removably connecting the first and second dilator tubes together in a locked configuration includes a pair of opposing bayonet pins 232 extending from the proximal end of the first dilator tube. The first dilator tube has an inner lumen 234 with a distal opening 236 and a proximal opening 238.
  • As is shown in FIG. 16, the dilation introducer includes a shorter second or intermediate dilator tube 242 having a distal end 244 with a tapered, beveled tip 246, and a proximal end 248 with a cylindrical head 250. In a preferred aspect, a means for removably connecting the second and third dilator tubes together in a locked configuration includes a pair of opposing bayonet pins 252. The second dilator tube has an inner lumen 254 with a distal opening 256 and a proximal opening 258, and as part of the means for removably connecting the second and third dilator tubes together, interior opposing bayonet slots 260 for receiving the pair of opposing bayonet pins of the first or inner dilator tube.
  • Referring to FIG. 17, in a preferred aspect, the dilation introducer includes at least one additional dilator tube, such as a still shorter third or outer dilator tube 262 having a distal end 264 with a tapered tip 266, and a proximal end 268 having a pair of opposing handles 270. The third dilator tube has an inner lumen 271, with proximal and distal openings. In another presently preferred aspect, a plastic sleeve 272 is slidably disposed over the shaft of the third or outer dilator tube, and the plastic sleeve preferably has a distal tapered, beveled end 274. A proximal sleeve ring 276 may also be slidably disposed over the shaft of the third or outer dilator tube between the plastic sleeve 272 and the opposing handles.
  • As is illustrated in FIGS. 13 and 14, in this embodiment the tapered tips of the dilator tubes and plastic sleeve are beveled or angled at a common angle with respect to the longitudinal axis of the dilation introducer, so that the beveled edges of the tapered tips of the dilator tubes and plastic sleeve can be aligned together generally parallel to the surface of the soft tissue to be dilated, so that the bore and dilation passage of the dilation introducer may be aligned at a predetermined desired angle with respect to the soft tissue to be dilated and the bone tissue to be treated.
  • As part of the means for removably connecting the second and third dilator tubes together, the third dilator tube includes interior opposing bayonet slots 278 for receiving the pair of opposing bayonet pins of the second or intermediate dilator tube. A tubular bone drill or tap can be inserted through the first or inner dilator tube, and the tubular bone drill or tap can be threaded over a guide wire or K wire to contact the surface of the vertebra or bone to be treated, as described above.
  • With reference to FIGS. 19-23, the invention provides for a fourth embodiment of a dilation introducer 280 shown in a locked assembled configuration in FIG. 19, and shown in an unlocked, collapsed configuration in FIG. 20. Referring to FIG. 21, the dilation introducer includes a first or inner dilator tube 282 having a distal end 284 with a tapered tip 286, and a proximal end 288 having a generally spherical handle or head 290. As part of a means for removably connecting first and second dilator tubes together in a locked configuration, the proximal end of the first dilator tube near the handle includes a bayonet pin 292. The first dilator tube has an inner lumen 294 with a distal opening 296, and a proximal opening 298.
  • Referring to FIG. 22, the dilation introducer includes a shorter second or intermediate dilator tube 302 having a distal end 304 with a tapered tip 306, and a proximal end 308 having a generally cylindrical head 310 and a pair of opposing handles 312. The second dilator tube has an inner lumen 314 with a distal opening 316 and a proximal opening 318. As part of the means for removably connecting first and second dilator tubes together in a locked configuration, the proximal end of the second dilator tube includes a bayonet slot 320 formed in the cylindrical head for receiving the bayonet pin of the first or inner dilator tube.
  • Referring to FIG. 23, in a preferred aspect, the dilation introducer includes at least one additional dilator tube, such as a still shorter third or outer dilator tube 322, currently preferably formed of plastic, having a distal end 324 with a tapered tip 326, and a proximal end 328 with a generally cylindrical head end or handle 330. The third dilator tube has an inner lumen 332, with proximal and distal openings. A tubular bone drill or tap can be inserted through the first or inner dilator tube, and the tubular bone drill or tap can be threaded over a guide wire or K wire to contact the surface of the vertebra or bone to be treated, as described above.
  • Facet Screw Surgical Technique:
  • Referring to FIGS. 24-26, a surgical method for spinal fusion utilizing the dilation introducer apparatus and a bone fixation device such as a bone fixation device available under the trade name BONE-LOK from Triage Medical, Inc. of Irvine, Calif., is described. Alternatively, other types of bone screws or fixation devices may also be suitable. The method of the invention involves dilating a patient's soft tissue down to bone tissue to be treated in orthopedic surgery, and necessarily entails an incision and fluoroscopy to locate an entry point on the bone tissue to be treated.
  • An entry point is located on the bone tissue to be treated, and the tip of a guide wire or K-wire 151 is placed at the entry point on the bone tissue to be treated shown in FIG. 25, and driven into the soft tissue of the patient to the target point of the inferior articular facet. A vertical midline incision to a desired depth, such as approximately 17 mm, is made in the skin and fascia of the patient, using the entry point as the middle of the incision. A first dilator tube of the dilation introducer is then passed over the guide wire until the tip of the dilation introducer reaches the target point of the bone. The guide wire is then driven into the facet joint and into the pedicle of the patient, with verification of the trajectory and depth by fluoroscopy. The second dilator tube of the dilation introducer is then released and passed over the first dilator tube to allow it to progress to the bone, allowing removal of the first dilator tube. This is repeated for the remaining, progressively wider telescoping dilator tubes, to progressively expand the patient's soft tissue down to the entry point on the bone tissue to be treated, and leaving an outer dilator tube port in place. A depth gauge is then used to verify that the appropriate depth has been reached. A pre-drill is advanced to the desired location, which is then also verified by fluoroscopy. A cortex drill is advanced until its positive stop engages, and the distal tip of a tap is driven into the bone until it reaches the appropriate depth, which is then also verified by fluoroscopy. The drill can be connected through an AO style quick connect, or a Jacobs chuck, as long as they are fully cannulated, to a ratcheting handle which is also preferably cannulated. A bone fixation device is then driven into the bone until it reaches the appropriate depth, which is then also verified by fluoroscopy. The bone fixation device is compressed to achieve appropriate stabilization, which is then also verified by fluoroscopy. Once compression of the bone fixation device has been achieved, the pull pin is removed, the guide wire is removed, and the remaining outer dilator tube port is removed, and the incision can be closed normally.
  • Referring to FIGS. 27-29, in one presently preferred embodiment, a guide wire or K wire assembly 340 for use with the telescoping dilation introducer of the invention includes an elongated, generally cylindrical first section 342 and an elongated, tubular second section 344 that is adapted to receive the first section. The first section includes a proximal enlarged head or stop portion 346, and a relatively narrow elongated body portion 348. The elongated body portion is preferably formed with a proximal section 350 having a relatively larger diameter to provide relatively greater strength, rigidity and torquability for manipulation of the guide wire, and a relatively narrower diameter main section 352 connected to the proximal section, and a pointed distal tip 354 at the distal end 358 of the main section. The elongated tubular second section has a relatively larger diameter than the main section and an internal bore slightly larger in diameter than the main section for receiving the main section, as is illustrated in FIG. 28. The tubular second section advantageously also includes a frustoconical distal tip 362 with a narrowed portion 364 at the distal end 366 of the tubular distal section, and presenting an enlarged flat shoulder 368 at the proximal end of the frustoconical distal tip, so that when the guide wire assembly is assembled as shown in FIG. 29, and the elongated main section is received in the internal bore of the elongated tubular section, and the proximal section of the elongated body portion of the elongated generally cylindrical section is seated against said proximal end of said elongated tubular section, the pointed distal tip extends out of said frustoconical distal tip of said elongated tubular section so that the assembly presents a pointed distal end, with a proximal shoulder against which a telescoping dilation introducer can be pushed for operation of the telescoping dilation introducer. The elongated generally cylindrical first section thus adds a sharp point to the relatively blunt distal end of the elongated tubular second section, allowing the guide wire assembly to be inserted through soft tissue for placement in a soft tissue target of interest, such as an organ. Since the soft tissue present no hard surface against which the telescoping dilation introducer can be pushed, after the sharp point of the guide wire is placed in the desired location in the soft tissue, the first section can be removed from the second section, leaving the blunt distal end in place at the desired location in the soft tissue, and the telescoping dilation introducer can be placed over the second section and pressed against the shoulder of the blunt distal end for operation of the telescoping dilation introducer.
  • As is shown in FIG. 30, in one presently preferred variation of the at least one additional or outer dilator tube, such as in the embodiment of FIGS. 8-12 for example, the outer dilator tube 400 includes a parallel guide insert 402, shown in FIG. 31. The outer dilator tube has a distal end 404 with a tapered tip 406, and a proximal portion 408 to which a handle 410 is connected at the extreme proximal or head end 412 of the outer dilator tube. The head end of the outer dilator tube includes a radial aperture 414 for receiving the locking pin 416, and a longitudinal aperture 418 for receiving a distally projecting latching member 420 of the cylindrical head 422 of the parallel guide insert. The outer dilator tube has an inner bore 424 with proximal and distal openings.
  • The parallel guide insert includes a main cylindrical shaft 425 connected at a proximal end 426 to the cylindrical head of the parallel guide insert. The parallel guide insert includes a plurality of longitudinal bores 428 extending the length of the parallel guide insert from the distal end 430, with distal openings visible in FIG. 31, to proximal openings (not shown) in the cylindrical head of the parallel guide insert. The insertion of the distally projecting latching member of the cylindrical head of the parallel guide insert in the longitudinal aperture of the head end of the handle of the outer dilator tube insures that the parallel guide insert remains in a fixed position in the outer dilator tube when the parallel guide insert is secured with the locking pin. A single guide wire or K wire or other device may be passed through one or more of the bores of the parallel guide insert, or multiple guide wires or K wires or other devices may be passed through a plurality of the bores simultaneously, as desired. However, the parallel guide insert may be provided without a latching member, in order to allow the parallel guide member to be rotated freely to allow alignment of the desired locations of the guide wires through the holes in the parallel guide insert.
  • Referring to FIG. 32, in another presently preferred variation of the at least one additional or outer dilator tube, such as in the embodiment of FIGS. 13-18 for example, the outer dilator tube 440 includes a parallel guide insert 442, shown in FIG. 33. The outer dilator tube has a distal end 444 with an angled tip 446, and a proximal end 448 to which a handle 450 is connected at the extreme proximal or head end 452 of the outer dilator tube. The head end of the outer dilator tube includes a radial aperture 454 for receiving the locking pin 456, and a longitudinal aperture 458 for receiving a distally projecting latching member 460 of the cylindrical head 462 of the parallel guide insert. The outer dilator tube has an inner bore 464 with proximal and distal openings.
  • The parallel guide insert includes a main cylindrical shaft 465 connected at a proximal end 466 to the cylindrical head of the parallel guide insert. The parallel guide insert includes a plurality of longitudinal bores 468 extending the length of the parallel guide insert from the angled distal end 470, with distal openings visible in FIG. 33, to proximal openings (not shown) in the cylindrical head of the parallel guide insert. The insertion of the distally projecting latching member of the cylindrical head of the parallel guide insert in the longitudinal aperture of the head end of the handle of the outer dilator tube insures that the parallel guide insert remains in a fixed position in the outer dilator tube when the parallel guide insert is secured with the locking pin. The angled tips of the outer dilator tube and the parallel guide insert are beveled or angled at a common angle with respect to the longitudinal axis of the dilation introducer, so that the angled tips of the outer dilator tube and the parallel guide insert can be aligned together generally parallel to the surface of the soft tissue to be dilated, with the bore and dilation passage of the dilation introducer aligned at a predetermined desired angle with respect to the soft tissue to be dilated and the bone tissue to be treated. A single guide wire or K wire or other device may be passed through one or more of the bores of the parallel guide insert, or multiple guide wires or K wires or other devices may be passed through a plurality of the bores simultaneously, as desired.
  • Referring to FIG. 34, in a variation of the outer dilator tube of the embodiment of FIGS. 32-33, the distal tip 480 of an outer dilator tube 482 may be angled or beveled, and may include a plurality of spikes 484 to provide for increased traction of the tip of the outer dilator tube on bone tissue. The spikes may be formed of radiopaque material, such as gold, platinum, tantalum or the like, for use with fluoroscopy. As is illustrated in FIG. 35, a parallel guide 486 disposed in the outer dilator tube has a distal tip 488 that may optionally also be provided with a plurality of embedded spikes 490 for increased traction on bone tissue. The spikes of the outer dilator tube and parallel guide may formed with a rounded shape so as to deflect soft tissue during dilation, and to provide increased traction with bone upon completion of the insertion of the dilator.
  • Referring to FIGS. 36-43, the invention provides for a fifth presently preferred embodiment of a dilation introducer 500, which is similar to the embodiment illustrated in FIGS. 8-12, and which is shown in an unlocked configuration in FIG. 36. Referring to FIGS. 36-37, the dilation introducer includes a first or inner dilator tube 502 having distal end (not shown) and a proximal end 504 with a cylindrical head 506. The means for removably connecting the first and second dilator tubes together in a locked configuration includes a first latching member 508, having a shaft 510 and a latching end 512, such as a hook, projecting from the cylindrical head toward the distal end, and connected to a locking button 514, which extends transversely out through a side aperture 516 in the cylindrical head. The locking button includes a shaft 518 and an enlarged head 520 connected to the shaft, and the locking button is biased outwardly from the cylindrical head by a spring 522. The latching member is received in an upper aperture 524 of the adjacent cylindrical head of a second or intermediate dilator tube 526, having a side opening latching chamber 528 for retaining the latching end of the latching member when the locking button is biased outwardly by its spring, to lock the cylindrical heads of the first and second dilator tubes together. The cylindrical heads of the first and second dilator tubes can be unlocked and separated by manually depressing the locking button to move the latching member inwardly and the latching end of the latching member inwardly out of the side opening latching chamber. In all other aspects, the first dilator tube is essentially the same as the first dilator tube of the embodiment of FIGS. 8-12.
  • The second or intermediate dilator tube 526 of the dilation introducer has a distal end (not shown) and a proximal end 530 with a cylindrical head 532. The means for removably connecting the second and third dilator tubes together in a locked configuration includes a second latching member 534, having a shaft 536 and a latching end 538, such as a hook, projecting from the cylindrical head toward the distal end, and connected to a second locking button 540, which extends transversely out through a side aperture 542 in the cylindrical head. The locking button includes a shaft 544 and an enlarged head 546 connected to the shaft, and the locking button is biased outwardly from the cylindrical head by a spring 548. The latching member is received in an upper aperture 550 of the adjacent cylindrical head of a third or second intermediate dilator tube 552, having a side opening latching chamber 554 for retaining the latching end of the latching member when the locking button is biased outwardly by its spring, to lock the cylindrical heads of the second and third dilator tubes together. The cylindrical heads of the second and third dilator tubes can be unlocked and separated by manually depressing the second locking button to move the latching member inwardly and the latching end of the latching member inwardly out of the side opening latching chamber. In all other aspects, the second dilator tube is essentially the same as the second dilator tube of the embodiment of FIGS. 8-12.
  • The third, or second intermediate, dilator tube 552 of the dilation introducer has a distal end (not shown) and a proximal end 556 with a cylindrical head 558. The means for removably connecting the third dilator tube and the outer dilator tube 560 together in a locked configuration includes a third latching member 562, having a shaft 564 and a latching end 566, such as a hook, projecting from the cylindrical head toward the distal end, and connected to a third locking button 568, which extends transversely out through a side aperture 570 in the cylindrical head. The third locking button includes a shaft 572 and an enlarged head 574 connected to the shaft, and the third locking button is biased outwardly from the cylindrical head by a spring 576. The latching member is received in an upper aperture 578 of the adjacent cylindrical head 580 of the outer dilator tube, having a side opening latching chamber 582 for retaining the latching end of the latching member when the locking button is biased outwardly by its spring, to lock the cylindrical heads of the third and outer dilator tubes together. The cylindrical heads of the third and outer dilator tubes can be unlocked and separated by manually depressing the third locking button to move the latching member inwardly and the latching end of the latching member inwardly out of the side opening latching chamber. In all other aspects, the third dilator tube is essentially the same as the second dilator tube of the embodiment of FIGS. 8-12.
  • Referring to FIG. 36, the outer dilator tube includes a distal end (not shown) and a proximal end 584 to which a handle 586 is connected at its cylindrical head end. The head end of the handle preferably includes a plurality of the upper apertures 578 connected to corresponding side opening latching apertures 582 for receiving the latching member of the adjacent dilator tube cylindrical head, as is illustrated in FIG. 40. Although three locking locations 588 of the upper apertures and corresponding side opening latching apertures in the cylindrical head of the outer dilator tube are shown, more or fewer locking locations may be provided, and the locking locations may be provided at various positions, to aid in user flexibility as to which hand to use during the dilation procedure, as well as varying the position of the inner dilator tubes and optionally a parallel guide member during use or guide pin placement. In all other aspects, the outer dilator tube is essentially the same as the outer dilator tube of the embodiment of FIGS. 8-12.
  • Referring to FIGS. 38 and 39, in a variation of the embodiment shown in FIGS. 36 and 37, the side opening latching chambers of the cylindrical heads of the dilator tubes may be closed so as to form covered latching chambers 590 a, b, c for the latching members. In all other aspects, the variation shown in FIGS. 38 and 39 is essentially the same as in FIGS. 36 and 37.
  • Referring to FIGS. 41-43, in another variation, an outer dilation tube 600 may be provided with a light emitter 602, such as one or more light emitting diodes (LEDs) or the end of a fiber optic, connected to or embedded in the tubular shaft 604 of the outer dilation tube, and preferably near the distal end 606 of the tubular shaft. As is illustrated in FIGS. 41 and 42, the light emitter may be an LED embedded in the wall 608 of the tubular shaft, with the LED directed to illuminate the interior, exterior, or distal edge of the tubular shaft of the outer dilation tube. As is shown in FIG. 42, one or more elongated energy conducting members 610, such as electrically conductive wires or fiber optics, for example, may be embedded in the tubular shaft, for conducting electricity or light to the light emitter. Referring to FIG. 41, the handle 612 of the outer dilator tube preferably contains one or more batteries 614 connected to a switch 616 which is in turn connected to power the light emitter. The handle may be provided with a battery or batteries, which may be disposable, a switch, resistor and other associated electronics, so that the handle is disposable, or alternatively the handle may be provided with a connector for connection to an external power source. In a presently preferred aspect, the switch is a thumb switch conveniently located on the handle adjacent to the cylindrical head 618 of the outer dilation tube. The handle, cylindrical head, and tubular shaft of the outer dilation tube preferably includes one or more channels 620 for the electrical wires connecting the one or more batteries to the switch and to the light emitter. When the light emitter includes one or more fiber optics, a light source 622 such as one or more LEDs providing light to be conducted through the one or more fiber optics may be placed adjacent to the switch in the handle, with the one or more fiber optics extending through the wall of the tubular shaft of the outer dilator tube.
  • Referring to FIG. 43, in another variation of the dilation introducer of FIG. 41, the one or more elongated energy conducting members, such as one or more wires or one or more fiber optics, may be disposed on the outer surface of the tubular shaft of the outer dilation tube. In a presently preferred aspect, the tubular shaft of the outer dilation tube may be formed with a groove 620 running longitudinally on the exterior surface of the tubular shaft, parallel to the longitudinal axis of the outer dilation tube, to accommodate one or more wires or one or more fiber optics. Alternatively, the one or more elongated energy conducting members may be located on the inside of the dilator tube, or may extend through the wall of the dilator tube.
  • Referring to FIGS. 44-46, the present invention also provides for a telescoping expander sleeve 630 that is adapted to be slidably disposed over the shaft of an outer dilator tube of any of the foregoing embodiments for expanding the patient's soft tissue down to the entry point on the bone tissue to be treated, while leaving the outer dilator tube in place, or allowing for replacement of the outer dilator tube with other equipment for treatment of the bone tissue. The tubular proximal portion may optionally be provided with a handle. The expander sleeve may be pre-assembled in combination with one or more of the dilation introducers, adapted to be ready for use. The telescoping expander sleeve has a first or inner generally tubular section 632, having a tubular proximal portion 634 with an enlarged proximal head 636, and a distal portion 638 with at least two substantially identical opposing active spreader arms 640 (one of which is not visible in FIGS. 44-46) connected at one end to the tubular proximal portion and moveable radially at their distal tips 642. The distal tips of the active spreader arms preferably have beveled edges 644 to deflect soft tissue during insertion of the telescoping expander sleeve.
  • A second or outer generally tubular section 646 is slidably disposed over the first or inner generally tubular section, and includes a tubular proximal portion 648 and a distal portion 650 with at least two substantial identical opposing passive spreader flaps 652 interposed between the active spreader arms, hingedly connected to the tubular proximal portion at proximal ends 654, and moveable radially at their distal tips 656. The distal tips of the passive spreader flaps preferably also have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve. The distal tips of the passive spreader flaps when placed together in an unexpanded configuration have a generally circular configuration, so that the distal tips of two passive spreader flaps, for example, have a semi-circular configuration. The passive spreader flaps taper progressively toward their narrowed proximal ends connected to the tubular proximal portion of the outer tubular section. In a presently preferred aspect, the passive spreader flaps are connected to the tubular proximal portion of the outer generally tubular section by rings 656 passing through apertures 658 and 660 in the adjacent ends of the tubular proximal portion and the passive spreader flaps, respectively.
  • The active spreader arms are slidably interposed between and engage the passive spreader flaps, so that as the telescoping expander sleeve telescopes from an extended, unexpanded configuration to a collapsed, expanded configuration, as shown in FIG. 44, the active spreader arms slide from the narrow proximal ends of the passive spreader flaps to the wider distal ends of the passive spreader flaps to spread the distal ends of the passive spreader flaps apart, which also forces the distal ends of the active spreader arms apart, as shown in FIG. 46. In a presently preferred aspect, the distal ends of the active spreader arms are slidably connected to slots 662 extending along the inner edges 664 of the passive spreader flaps by loops or rings 666, such as loops of nylon filament or metal rings, for example, which pass through apertures 668 in the distal ends of the active spreader arms. Telescoping of expander sleeve from a collapsed, expanded configuration to an extended, unexpanded configuration thus slides the distal ends of the active spreader arms of the inner tubular section from the wide distal ends of the passive spreader flaps along the inner edges of the passive spreader flaps to the narrowed proximal ends of the passive spreader flaps, to bring the passive spreader flaps together. The purpose of the active spreader arms and passive spreader flaps is to facilitate the creating of a larger working area adjacent to bone or bone tissues being treated. The spreader arms and flaps may optionally be covered by an expandable material, such as latex, for example, with a central through hole permitting operation of the device, to cover the spreader arms and flaps to prevent tissues from being pressed into cavities of the telescoping expander sleeve.
  • In the foregoing embodiments, the components of the dilation introducer may be formed from plastic, stainless steel, or similar materials or combinations thereof, that can be readily sterilized and packaged ready for use, after which the dilation introducer may be disposed of or resterilized for subsequent use, as desired. The dilator tubes may be radioluscent, with radiopaque markers located on the tips of one or more of the dilator tubes. The tip of the first dilator may also be scored, grooved, or otherwise be provided with a rough surface, to prevent migration. The dilation introducer may also have curved or otherwise non-linear dilator tubes, and the dilation introducer may also have a non-cylindrical shape, such as an oval shape, for example, to allow the dilation introducer to be inserted around objects or a patient's organs.
  • It should also be appreciated that one or more devices can be inserted through the same dilation introducer, and that the dilation introducer can be repositioned within the same incision for fixation of multiple devices. In addition, fiber optic devices may be inserted through or integrated with the dilation introducer for visual inspection of the target area. While particular locking features have been described for the different embodiments of the dilation introducer, any combination of locking features or alternate locking features may be utilized. The outer dilator tube may not be locked, and a handle on the outer dilator tube may simply be used as a stop. It should also be appreciated that while the invention has been described as being used in the context of orthopedic surgery, and more particularly for implantation of bone fixation devices, the dilation introducer of the invention can also be useful in dilation of soft tissue for percutaneous, minimally invasive surgical procedures such as nephrostomy, neurosurgery, heart valve repair or replacement, gastrointestinal surgery such as for gall bladder or gall stone surgery, hernia removal, transjugular intrahepatic portal-systemic shunt (TIPS) procedures for treatment of the liver, and the like.
  • It will be apparent from the foregoing that, while particular forms of the invention have been illustrated and described, various modifications can be made without departing from the spirit and scope of the invention. Accordingly, it is not intended that the invention be limited, except as by the appended claims.

Claims (23)

1. In a dilation introducer for surgery on an internal body structure, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's bone tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's tissue to be treated, the improvement in the dilation introducer comprising:
at least one dilator tube having a distal end and a proximal end, the distal end of the at least one dilator tube including a plurality of spikes.
2. The dilation introducer of claim 1, wherein said spikes are formed of radiopaque material.
3. The dilation introducer of claim 1, wherein said spikes are formed are formed with a rounded shape so as to deflect soft tissue.
4. The dilation introducer of claim 1, further comprising a parallel guide insert adapted to be received in said at least one additional dilator tube, said parallel guide insert including a main cylindrical shaft having a proximal end connected to a cylindrical head, and a plurality of longitudinal bores extending the length of the parallel guide insert through the main cylindrical shaft and cylindrical head, and wherein parallel guide insert has a distal tip with a plurality of spikes.
5. The dilation introducer of claim 4, wherein said spikes are formed of radiopaque material.
6. The dilation introducer of claim 4, wherein said spikes are formed are formed with a rounded shape so as to deflect soft tissue.
7. A dilation introducer for surgery on an internal structure to be treated, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's tissue to be treated, comprising:
a first dilator tube having a distal end with a tapered tip and a proximal end with a cylindrical head;
a second dilator tube, the first dilator tube being removably received in the second dilator tube for slidable telescoping movement within the second dilator tube, the second dilator tube having a distal end with a tapered tip and a proximal end with a cylindrical head, and an inner lumen with a distal opening and a proximal opening; and
means for removably connecting the first and second dilator tubes together in a locked configuration including a first latching member disposed in the cylindrical head of the first dilator tube, the first latching member having locking button connected transversely to a shaft with a latching end projecting from the cylindrical head of the first dilator tube toward the distal end of the first dilator tube, the locking button extending transversely from the shaft through a side aperture in the cylindrical head of the first dilator tube, the locking button being biased outwardly from the cylindrical head, the first latching member being received in an upper aperture of the cylindrical head of the second dilator tube, the upper aperture of the cylindrical head of the second dilator tube having a latching chamber for retaining the latching end of the latching member when the locking button is biased outwardly, to lock the cylindrical heads of the first and second dilator tubes together, the locking button being moveable inwardly to move the latching member inwardly and the latching end of the latching member inwardly out of the latching chamber.
8. The dilation introducer of claim 7, further comprising at least one additional dilator tube, the second dilator tube being removably received in the at least one additional dilator tube for slidable telescoping movement within the at least one additional dilator tube, the at least one additional dilator tube having a distal end and a proximal end with a cylindrical head, an inner lumen with a distal opening and a proximal opening, the distal end having a tapered tip, the second dilator tube and the at least one additional dilator tube having an unlocked configuration in which the at least one additional dilator tube is permitted to slidably telescope over the second dilator tube to dilate the patient's soft tissue at the distal end of the dilation introducer; and
means for removably connecting the second dilator tube and the at least one additional dilator tube together in a locked configuration including a second latching member disposed in the cylindrical head of the second dilator tube, the second latching member having locking button connected transversely to a shaft with a latching end projecting from the cylindrical head of the second dilator tube toward the distal end of the second dilator tube, the locking button extending transversely from the shaft through a side aperture in the cylindrical head of the second dilator tube, the locking button being biased outwardly from the cylindrical head, the second latching member being received in an upper aperture of the cylindrical head of the at least one additional dilator tube, the upper aperture of the cylindrical head of the at least one additional dilator tube having a latching chamber for retaining the latching end of the second latching member when the locking button is biased outwardly, to lock the cylindrical heads of the second and at least one additional dilator tubes together, the locking button being moveable inwardly to move the second latching member inwardly and the latching end of the second latching member inwardly out of the latching chamber.
9. The dilation introducer of claim 8, wherein said at least one additional dilator tube comprises a handle connected to the proximal end of said at least one additional dilator tube, and the cylindrical head of said at least one additional dilator tube including a plurality of said upper apertures each including one said latching chamber for receiving the second latching member.
10. In a dilation introducer for orthopedic surgery, the dilation introducer having a locked assembled configuration for initial placement of the dilation introducer against a patient's tissue to be treated, and an unlocked, collapsed configuration dilating the patient's soft tissue down to the tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's tissue to be treated, the improvement in the dilation introducer comprising:
at least one dilator tube having a tubular shaft, a distal end and a proximal end, an inner lumen with a distal opening and a proximal opening; and
a light emitter disposed in said at least one additional dilator tube.
11. The dilation introducer of claim 10, wherein said light emitter comprises a light emitting diode.
12. The dilation introducer of claim 11, wherein said light emitting diode is embedded in said tubular shaft of said at least one dilator tube.
13. The dilation introducer of claim 10, wherein said light emitter comprises a fiber optic.
14. The dilation introducer of claim 13, wherein said fiber optic is embedded in said tubular shaft of said at least one dilator tube.
15. The dilation introducer of claim 10, wherein said at least one dilator tube comprises a handle and a switch for controlling said light emitter, and at least one battery is disposed in said handle, said at least one battery being connected to said switch to power said light emitter.
16. The dilation introducer of claim 13, wherein said light emitter further comprises a light source providing light conducted to said at least one fiber optic.
17. The dilation introducer of claim 10, wherein said light emitter comprises at least one elongated energy conducting member disposed on an outer surface of the tubular shaft of said at least one dilator tube.
18. The dilation introducer of claim 17, wherein said at least one elongated energy conducting member is disposed in a groove on the exterior surface of the tubular shaft.
19. A telescoping expander sleeve adapted to be slidably disposed over a shaft of a dilator tube for dilating a patient's soft tissue down to tissue to be treated to a desired degree of dilation to permit minimally invasive surgical procedures on the patient's tissue to be treated, the telescoping expander sleeve being moveable between an extended, unexpanded configuration and a collapsed, expanded configuration, the telescoping expander sleeve comprising:
a first generally tubular section having a tubular proximal portion and a distal portion, the tubular proximal portion having an enlarged proximal head, and the distal portion including at least two active spreader arms each having a proximal end and a distal tip, said at least two active spreader arms being connected at the proximal end, respectively, to the tubular proximal portion, said distal tips of said at least two active spreader arms being moveable radially between an unexpanded configuration and an expanded configuration;
a second generally tubular section slidably disposed over the first generally tubular section, said second generally tubular section including a tubular proximal portion and a distal portion including at least two passive spreader flaps each having a narrow proximal end and a wide distal tip, said proximal ends of said at least two passive spreader flaps being hingedly connected to said tubular proximal portion, said distal tips of said at least two passive spreader flaps being moveable radially between an unexpanded configuration and an expanded configuration, said at least two active spreader arms slidably engaging said at least two passive spreader flaps, so that as the telescoping expander sleeve telescopes from the extended, unexpanded configuration to a collapsed, expanded configuration, said at least two active spreader arms slide from the narrow proximal ends of said at least two passive spreader flaps to the wider distal ends of the passive spreader flaps to spread the distal ends of said at least two passive spreader flaps apart and to spread the distal ends of said at least two active spreader arms apart.
20. The telescoping expander sleeve of claim 19, wherein the distal tips of said at least two active spreader arms have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve.
21. The telescoping expander sleeve of claim 19, wherein the distal tips of said at least two passive spreader flaps have beveled edges to deflect soft tissue during insertion of the telescoping expander sleeve.
22. A guide wire assembly for use with a telescoping dilation introducer in treatment of soft tissue, to provide a surface against which the telescoping dilation introducer can be pushed during operation of the telescoping dilation introducer, comprising:
an elongated tubular section having a proximal end, a distal end, an internal bore, and a frustoconical distal tip with a narrowed portion at the distal end and an enlarged flat shoulder at a proximal portion of the frustoconical distal tip; and
an elongated generally cylindrical section removably received in said internal bore of said elongated tubular section, the elongated generally cylindrical section having a proximal enlarged head and an elongated body portion, said elongated body portion having a proximal end and a distal end, said distal end having a pointed distal tip, such that when said elongated generally cylindrical section is received in said elongated tubular section, said pointed distal tip extends out of the distal end of said frustoconical distal tip to present a sharp point that can be positioned in soft tissue, and such that when said elongated generally cylindrical section is thereafter removed, said enlarged flat shoulder of said frustoconical distal tip provides a surface against which a telescoping dilation introducer can be pushed for operation of the telescoping dilation introducer in treatment of soft tissue.
23. The guide wire assembly of claim 22, wherein said elongated body portion of said elongated generally cylindrical section includes a proximal section adjacent to said proximal enlarged head and an elongated main section connected to the proximal section, said proximal section having a diameter larger than an outer diameter of said elongated tubular section, and said elongated main section having a diameter narrower than the diameter of said internal bore of said elongated tubular section so as to be receivable in said internal bore of said elongated tubular section, such that when said elongated main section is received in said internal bore of said elongated tubular section and said proximal section of the elongated body portion of the elongated generally cylindrical section is seated against said proximal end of said elongated tubular section, said pointed distal tip extends out of said frustoconical distal tip of said elongated tubular section so that said guide wire assembly presents a pointed distal end.
US11/038,784 2002-11-14 2005-01-19 Dilation introducer for orthopedic surgery Abandoned US20050256525A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP16207090.8A EP3205371B1 (en) 2004-08-03 2005-08-02 Telescopic percutaneous tissue dilation systems and related methods of producing
US11/659,025 US9387313B2 (en) 2004-08-03 2005-08-02 Telescopic percutaneous tissue dilation systems and related methods
JP2007524917A JP5164571B2 (en) 2004-08-03 2005-08-02 Percutaneous tissue expansion system and related methods
PCT/US2005/027431 WO2006017507A2 (en) 2004-08-03 2005-08-02 Telescopic percutaneous tissue dilation systems and related methods
EP05777628.8A EP1773438B1 (en) 2004-08-03 2005-08-02 Telescopic percutaneous tissue dilation systems
US15/186,963 US10293147B2 (en) 2004-08-03 2016-06-20 Telescopic percutaneous tissue dilation systems and related methods

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42613702P 2002-11-14 2002-11-14
US50205003P 2003-09-10 2003-09-10
US10/714,333 US8090542B2 (en) 2002-11-14 2003-11-14 Functional and hyperfunctional siRNA
US11/083,784 US7820809B2 (en) 2002-11-14 2005-03-18 Functional and hyperfunctional siRNA directed against Bcl-2

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/714,333 Continuation US8090542B2 (en) 2002-11-14 2003-11-14 Functional and hyperfunctional siRNA
US10/911,215 Continuation-In-Part US20060030872A1 (en) 2004-08-03 2004-08-03 Dilation introducer for orthopedic surgery

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/911,215 Continuation-In-Part US20060030872A1 (en) 2004-08-03 2004-08-03 Dilation introducer for orthopedic surgery
US11/659,025 Continuation-In-Part US9387313B2 (en) 2004-08-03 2005-08-02 Telescopic percutaneous tissue dilation systems and related methods

Publications (1)

Publication Number Publication Date
US20050256525A1 true US20050256525A1 (en) 2005-11-17

Family

ID=32329096

Family Applications (52)

Application Number Title Priority Date Filing Date
US10/714,333 Expired - Fee Related US8090542B2 (en) 2002-11-14 2003-11-14 Functional and hyperfunctional siRNA
US10/940,892 Abandoned US20120052487A9 (en) 2002-11-14 2004-09-14 Methods and compositions for selecting sirna of improved functionality
US11/038,784 Abandoned US20050256525A1 (en) 2002-11-14 2005-01-19 Dilation introducer for orthopedic surgery
US11/083,784 Expired - Fee Related US7820809B2 (en) 2002-11-14 2005-03-18 Functional and hyperfunctional siRNA directed against Bcl-2
US11/093,832 Abandoned US20070039072A1 (en) 2002-11-14 2005-03-29 Functional and hyperfunctional siRNA
US11/095,383 Active 2027-05-09 US7834170B2 (en) 2002-11-14 2005-03-30 Functional and hyperfunctional siRNA
US11/101,244 Active 2026-02-28 US7691997B2 (en) 2002-11-14 2005-04-07 Functional and hyperfunctional siRNA
US11/633,404 Abandoned US20070093653A1 (en) 2002-11-14 2006-12-04 siRNA targeting MCL1
US11/633,383 Expired - Lifetime US7645869B2 (en) 2002-11-14 2006-12-04 siRNA targeting spleen tyrosine kinase
US11/633,342 Expired - Fee Related US7608707B2 (en) 2002-11-14 2006-12-04 siRNA targeting survivin
US11/633,306 Expired - Lifetime US7507811B2 (en) 2002-11-14 2006-12-04 siRNA targeting KRAS
US11/635,330 Expired - Lifetime US7696344B2 (en) 2002-11-14 2006-12-07 siRNA targeting complement factor B
US11/635,618 Expired - Fee Related US7579457B2 (en) 2002-11-14 2006-12-07 siRNA targeting carbonic anhydrase II
US11/635,478 Abandoned US20070088155A1 (en) 2002-11-14 2006-12-07 siRNA targeting tumor necrosis factor superfamily member 1A
US11/635,329 Expired - Fee Related US7674896B2 (en) 2002-11-14 2006-12-07 siRNA targeting BCL2L1
US11/880,628 Expired - Fee Related US7595389B2 (en) 2002-11-14 2007-07-23 siRNA targeting casitas B cell lymphoma-B (CBL-B)
US11/880,755 Abandoned US20080293595A1 (en) 2002-11-14 2007-07-24 siRNA targeting protein tyrosine phosphatase-1B (PTP1B)
US11/880,855 Abandoned US20080300395A1 (en) 2002-11-14 2007-07-24 siRNA targeting vascular endothelial growth factor receptor 1 (VEGFR1)
US11/880,775 Expired - Lifetime US7655788B2 (en) 2002-11-14 2007-07-24 siRNA targeting DNA-damage-inducible transcript 4 (DDIT4)
US11/880,777 Abandoned US20080188648A1 (en) 2002-11-14 2007-07-24 siRNA targeting human hairless protein (HR)
US11/881,385 Abandoned US20080306015A1 (en) 2002-11-14 2007-07-25 siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9)
US11/881,386 Abandoned US20080221317A1 (en) 2002-11-14 2007-07-25 siRNA targeting cystic fibrosis transmembrane conductance regulator (CFTR)
US11/903,001 Expired - Lifetime US7514550B2 (en) 2002-11-14 2007-09-20 siRNA targeting myeloid cell leukemia sequence 1
US11/974,610 Abandoned US20080091001A1 (en) 2002-11-14 2007-10-15 Functional and hyperfunctional siRNA directed against Bcl-2
US11/974,885 Expired - Lifetime US7511132B2 (en) 2002-11-14 2007-10-16 Functional and hyperfunctional siRNA directed against Bcl-2
US11/974,865 Abandoned US20080091002A1 (en) 2002-11-14 2007-10-16 Functional and hyperfunctional siRNA directed against Bcl-2
US11/974,878 Abandoned US20080114162A1 (en) 2002-11-14 2007-10-16 Functional and hyperfunctional siRNA directed against Bcl-2
US11/974,880 Abandoned US20080091003A1 (en) 2002-11-14 2007-10-16 Functional and hyperfunctional siRNA directed against Bcl-2
US11/975,152 Expired - Fee Related US7795420B2 (en) 2002-11-14 2007-10-17 Functional and hyperfunctional siRNA directed against Bcl-2
US11/975,331 Abandoned US20080091004A1 (en) 2002-11-14 2007-10-18 Functional and hyperfunctional siRNA directed against Bcl-2
US11/975,661 Abandoned US20080108803A1 (en) 2002-11-14 2007-10-19 Functional and hyperfunctional siRNA directed against Bcl-2
US12/157,137 Expired - Lifetime US7642349B2 (en) 2002-11-14 2008-06-06 siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)
US12/287,757 Expired - Fee Related US7576196B2 (en) 2002-11-14 2008-10-14 siRNA targeting transducin (beta)-like 3 (TBL3)
US12/330,981 Expired - Fee Related US7576197B2 (en) 2002-11-14 2008-12-09 SiRNA targeting KRAS
US12/322,980 Abandoned US20090163701A1 (en) 2002-11-14 2009-02-10 siRNA targeting tumor necrosis factor receptor superfamily member 1A
US12/378,164 Expired - Fee Related US7592444B2 (en) 2002-11-14 2009-02-11 siRNA targeting myeloid cell leukemia sequence 1
US12/384,768 Expired - Lifetime US8030474B2 (en) 2002-11-14 2009-04-08 siRNA targeting cyclin-dependent kinase 4 (CDK4)
US12/459,489 Abandoned US20090291497A1 (en) 2002-11-14 2009-07-01 siRNA targeting transducin (beta)-like 3 (TBL3)
US12/459,670 Expired - Fee Related US7745611B2 (en) 2002-11-14 2009-07-06 siRNA targeting KRAS
US12/463,000 Abandoned US20100004142A1 (en) 2002-11-14 2009-08-12 siRNA targeting myeloid cell Leukemia sequence 1
US12/584,705 Expired - Fee Related US7807819B2 (en) 2002-11-14 2009-09-10 siRNA targeting survivin
US12/590,707 Expired - Lifetime US7803933B2 (en) 2002-11-14 2009-11-12 siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)
US12/592,335 Expired - Lifetime US7893247B2 (en) 2002-11-14 2009-11-23 siRNA targeting spleen tyrosine kinase
US12/657,263 Abandoned US20100152064A1 (en) 2002-11-14 2010-01-15 siRNA targeting BCL2L1
US12/799,844 Expired - Fee Related US8008474B2 (en) 2002-11-14 2010-05-03 siRNA targeting KRAS
US12/802,647 Expired - Lifetime US8000902B2 (en) 2002-11-14 2010-06-11 Methods and compositions for selecting siRNA of improved functionality
US12/806,320 Expired - Lifetime US7985854B2 (en) 2002-11-14 2010-08-10 siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)
US12/806,513 Abandoned US20100331214A1 (en) 2002-11-14 2010-08-13 siRNA Targeting Survivin
US12/928,190 Expired - Fee Related US8093370B2 (en) 2002-11-14 2010-12-06 siRNA targeting spleen tyrosine kinase
US13/199,001 Abandoned US20110319474A1 (en) 2002-11-14 2011-08-17 siRNA targeting cyclin-dependent kinase 4 (CDK4)
US13/373,956 Abandoned US20120135892A1 (en) 2002-11-14 2011-12-06 siRNA targeting spleen tyrosine kinase
US16/292,513 Abandoned US20190345573A1 (en) 2002-11-14 2019-03-05 Methods and Compositions for Selecting siRNA of Improved Functionality

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/714,333 Expired - Fee Related US8090542B2 (en) 2002-11-14 2003-11-14 Functional and hyperfunctional siRNA
US10/940,892 Abandoned US20120052487A9 (en) 2002-11-14 2004-09-14 Methods and compositions for selecting sirna of improved functionality

Family Applications After (49)

Application Number Title Priority Date Filing Date
US11/083,784 Expired - Fee Related US7820809B2 (en) 2002-11-14 2005-03-18 Functional and hyperfunctional siRNA directed against Bcl-2
US11/093,832 Abandoned US20070039072A1 (en) 2002-11-14 2005-03-29 Functional and hyperfunctional siRNA
US11/095,383 Active 2027-05-09 US7834170B2 (en) 2002-11-14 2005-03-30 Functional and hyperfunctional siRNA
US11/101,244 Active 2026-02-28 US7691997B2 (en) 2002-11-14 2005-04-07 Functional and hyperfunctional siRNA
US11/633,404 Abandoned US20070093653A1 (en) 2002-11-14 2006-12-04 siRNA targeting MCL1
US11/633,383 Expired - Lifetime US7645869B2 (en) 2002-11-14 2006-12-04 siRNA targeting spleen tyrosine kinase
US11/633,342 Expired - Fee Related US7608707B2 (en) 2002-11-14 2006-12-04 siRNA targeting survivin
US11/633,306 Expired - Lifetime US7507811B2 (en) 2002-11-14 2006-12-04 siRNA targeting KRAS
US11/635,330 Expired - Lifetime US7696344B2 (en) 2002-11-14 2006-12-07 siRNA targeting complement factor B
US11/635,618 Expired - Fee Related US7579457B2 (en) 2002-11-14 2006-12-07 siRNA targeting carbonic anhydrase II
US11/635,478 Abandoned US20070088155A1 (en) 2002-11-14 2006-12-07 siRNA targeting tumor necrosis factor superfamily member 1A
US11/635,329 Expired - Fee Related US7674896B2 (en) 2002-11-14 2006-12-07 siRNA targeting BCL2L1
US11/880,628 Expired - Fee Related US7595389B2 (en) 2002-11-14 2007-07-23 siRNA targeting casitas B cell lymphoma-B (CBL-B)
US11/880,755 Abandoned US20080293595A1 (en) 2002-11-14 2007-07-24 siRNA targeting protein tyrosine phosphatase-1B (PTP1B)
US11/880,855 Abandoned US20080300395A1 (en) 2002-11-14 2007-07-24 siRNA targeting vascular endothelial growth factor receptor 1 (VEGFR1)
US11/880,775 Expired - Lifetime US7655788B2 (en) 2002-11-14 2007-07-24 siRNA targeting DNA-damage-inducible transcript 4 (DDIT4)
US11/880,777 Abandoned US20080188648A1 (en) 2002-11-14 2007-07-24 siRNA targeting human hairless protein (HR)
US11/881,385 Abandoned US20080306015A1 (en) 2002-11-14 2007-07-25 siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9)
US11/881,386 Abandoned US20080221317A1 (en) 2002-11-14 2007-07-25 siRNA targeting cystic fibrosis transmembrane conductance regulator (CFTR)
US11/903,001 Expired - Lifetime US7514550B2 (en) 2002-11-14 2007-09-20 siRNA targeting myeloid cell leukemia sequence 1
US11/974,610 Abandoned US20080091001A1 (en) 2002-11-14 2007-10-15 Functional and hyperfunctional siRNA directed against Bcl-2
US11/974,885 Expired - Lifetime US7511132B2 (en) 2002-11-14 2007-10-16 Functional and hyperfunctional siRNA directed against Bcl-2
US11/974,865 Abandoned US20080091002A1 (en) 2002-11-14 2007-10-16 Functional and hyperfunctional siRNA directed against Bcl-2
US11/974,878 Abandoned US20080114162A1 (en) 2002-11-14 2007-10-16 Functional and hyperfunctional siRNA directed against Bcl-2
US11/974,880 Abandoned US20080091003A1 (en) 2002-11-14 2007-10-16 Functional and hyperfunctional siRNA directed against Bcl-2
US11/975,152 Expired - Fee Related US7795420B2 (en) 2002-11-14 2007-10-17 Functional and hyperfunctional siRNA directed against Bcl-2
US11/975,331 Abandoned US20080091004A1 (en) 2002-11-14 2007-10-18 Functional and hyperfunctional siRNA directed against Bcl-2
US11/975,661 Abandoned US20080108803A1 (en) 2002-11-14 2007-10-19 Functional and hyperfunctional siRNA directed against Bcl-2
US12/157,137 Expired - Lifetime US7642349B2 (en) 2002-11-14 2008-06-06 siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)
US12/287,757 Expired - Fee Related US7576196B2 (en) 2002-11-14 2008-10-14 siRNA targeting transducin (beta)-like 3 (TBL3)
US12/330,981 Expired - Fee Related US7576197B2 (en) 2002-11-14 2008-12-09 SiRNA targeting KRAS
US12/322,980 Abandoned US20090163701A1 (en) 2002-11-14 2009-02-10 siRNA targeting tumor necrosis factor receptor superfamily member 1A
US12/378,164 Expired - Fee Related US7592444B2 (en) 2002-11-14 2009-02-11 siRNA targeting myeloid cell leukemia sequence 1
US12/384,768 Expired - Lifetime US8030474B2 (en) 2002-11-14 2009-04-08 siRNA targeting cyclin-dependent kinase 4 (CDK4)
US12/459,489 Abandoned US20090291497A1 (en) 2002-11-14 2009-07-01 siRNA targeting transducin (beta)-like 3 (TBL3)
US12/459,670 Expired - Fee Related US7745611B2 (en) 2002-11-14 2009-07-06 siRNA targeting KRAS
US12/463,000 Abandoned US20100004142A1 (en) 2002-11-14 2009-08-12 siRNA targeting myeloid cell Leukemia sequence 1
US12/584,705 Expired - Fee Related US7807819B2 (en) 2002-11-14 2009-09-10 siRNA targeting survivin
US12/590,707 Expired - Lifetime US7803933B2 (en) 2002-11-14 2009-11-12 siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)
US12/592,335 Expired - Lifetime US7893247B2 (en) 2002-11-14 2009-11-23 siRNA targeting spleen tyrosine kinase
US12/657,263 Abandoned US20100152064A1 (en) 2002-11-14 2010-01-15 siRNA targeting BCL2L1
US12/799,844 Expired - Fee Related US8008474B2 (en) 2002-11-14 2010-05-03 siRNA targeting KRAS
US12/802,647 Expired - Lifetime US8000902B2 (en) 2002-11-14 2010-06-11 Methods and compositions for selecting siRNA of improved functionality
US12/806,320 Expired - Lifetime US7985854B2 (en) 2002-11-14 2010-08-10 siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)
US12/806,513 Abandoned US20100331214A1 (en) 2002-11-14 2010-08-13 siRNA Targeting Survivin
US12/928,190 Expired - Fee Related US8093370B2 (en) 2002-11-14 2010-12-06 siRNA targeting spleen tyrosine kinase
US13/199,001 Abandoned US20110319474A1 (en) 2002-11-14 2011-08-17 siRNA targeting cyclin-dependent kinase 4 (CDK4)
US13/373,956 Abandoned US20120135892A1 (en) 2002-11-14 2011-12-06 siRNA targeting spleen tyrosine kinase
US16/292,513 Abandoned US20190345573A1 (en) 2002-11-14 2019-03-05 Methods and Compositions for Selecting siRNA of Improved Functionality

Country Status (9)

Country Link
US (52) US8090542B2 (en)
EP (7) EP1560931B1 (en)
JP (2) JP2006507841A (en)
AT (1) ATE517992T1 (en)
AU (1) AU2003295600A1 (en)
DK (1) DK2284266T3 (en)
ES (1) ES2440284T3 (en)
PT (1) PT2284266E (en)
WO (1) WO2004045543A2 (en)

Cited By (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004398A1 (en) * 2004-07-02 2006-01-05 Binder Lawrence J Jr Sequential dilator system
US20060069384A1 (en) * 2004-09-21 2006-03-30 Daniel Wallaker Instrument for use in a medical simulator
US20070129747A1 (en) * 2005-11-14 2007-06-07 Scapa Flow, Llc Medical dilator system or dilator device
US20080097436A1 (en) * 2006-04-21 2008-04-24 Culbert Brad S Method and apparatus for spinal fixation
US20080294172A1 (en) * 2007-05-23 2008-11-27 Rainer Baumgart Instrument set for minimally invasive preparation for bone nailing
WO2009147527A2 (en) 2008-05-26 2009-12-10 Rudolf Morgernstern Lopez Intervertebral implant and installation tool
US20110004222A1 (en) * 2009-04-07 2011-01-06 Lutz Biedermann Tool for Use with a Bone Anchor, in Particular for Spinal Surgery
USD631962S1 (en) 2006-11-14 2011-02-01 Scapa Flow, Llc Medical dilator
US20110144687A1 (en) * 2009-12-10 2011-06-16 Kleiner Jeffrey Lateral Based Retractor System
US8043343B2 (en) 2007-06-28 2011-10-25 Zimmer Spine, Inc. Stabilization system and method
US8109977B2 (en) 2002-07-19 2012-02-07 Interventional Spine, Inc. Method and apparatus for spinal fixation
US8221396B2 (en) 2009-08-27 2012-07-17 Silver Bullet Therapeutics, Inc. Bone implants for the treatment of infection
WO2012102842A1 (en) * 2011-01-28 2012-08-02 Laser Spine Surgical Center, LLC Foraminoplasty device
USD666292S1 (en) * 2002-06-26 2012-08-28 Nuvasive, Inc. Dilator
US8430813B2 (en) 2006-05-26 2013-04-30 Depuy Spine, Inc. Illuminated surgical access system including a surgical access device and integrated light emitter
US20140171946A1 (en) * 2012-12-14 2014-06-19 Warsaw Orthopedic, Inc. Surgical instrument and method
US8771323B2 (en) 2010-11-12 2014-07-08 Silver Bullet Therapeutics, Inc. Bone implant and systems that controllably releases silver
US8927004B1 (en) 2014-06-11 2015-01-06 Silver Bullet Therapeutics, Inc. Bioabsorbable substrates and systems that controllably release antimicrobial metal ions
US20150094610A1 (en) * 2011-03-10 2015-04-02 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US20150112398A1 (en) * 2011-03-10 2015-04-23 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US9114197B1 (en) 2014-06-11 2015-08-25 Silver Bullett Therapeutics, Inc. Coatings for the controllable release of antimicrobial metal ions
US9277928B2 (en) 2013-03-11 2016-03-08 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US9387009B2 (en) 2007-10-05 2016-07-12 DePuy Synthes Products, Inc. Dilation system and method of using the same
US9452242B2 (en) 2014-06-11 2016-09-27 Silver Bullet Therapeutics, Inc. Enhancement of antimicrobial silver, silver coatings, or silver platings
US9522070B2 (en) 2013-03-07 2016-12-20 Interventional Spine, Inc. Intervertebral implant
US9522028B2 (en) 2013-07-03 2016-12-20 Interventional Spine, Inc. Method and apparatus for sacroiliac joint fixation
US20170000627A1 (en) * 2015-06-30 2017-01-05 Mark M Levy Tool for intervertebral cage
US9821094B2 (en) 2014-06-11 2017-11-21 Silver Bullet Therapeutics, Inc. Coatings for the controllable release of antimicrobial metal ions
US9839530B2 (en) 2007-06-26 2017-12-12 DePuy Synthes Products, Inc. Highly lordosed fusion cage
US9883951B2 (en) 2012-08-30 2018-02-06 Interventional Spine, Inc. Artificial disc
US9895236B2 (en) 2010-06-24 2018-02-20 DePuy Synthes Products, Inc. Enhanced cage insertion assembly
US9913727B2 (en) 2015-07-02 2018-03-13 Medos International Sarl Expandable implant
US9924979B2 (en) 2014-09-09 2018-03-27 Medos International Sarl Proximal-end securement of a minimally invasive working channel
US9931223B2 (en) 2008-04-05 2018-04-03 DePuy Synthes Products, Inc. Expandable intervertebral implant
US9980737B2 (en) 2014-08-04 2018-05-29 Medos International Sarl Flexible transport auger
US9993353B2 (en) 2013-03-14 2018-06-12 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US9993349B2 (en) 2002-06-27 2018-06-12 DePuy Synthes Products, Inc. Intervertebral disc
US10058433B2 (en) 2012-07-26 2018-08-28 DePuy Synthes Products, Inc. Expandable implant
US20180271574A1 (en) * 2017-03-22 2018-09-27 Benvenue Medical, Inc. Minimal Impact Access System To Disc Space
US10111712B2 (en) 2014-09-09 2018-10-30 Medos International Sarl Proximal-end securement of a minimally invasive working channel
US10265435B2 (en) 2009-08-27 2019-04-23 Silver Bullet Therapeutics, Inc. Bone implant and systems and coatings for the controllable release of antimicrobial metal ions
US10264959B2 (en) 2014-09-09 2019-04-23 Medos International Sarl Proximal-end securement of a minimally invasive working channel
US10299838B2 (en) 2016-02-05 2019-05-28 Medos International Sarl Method and instruments for interbody fusion and posterior fixation through a single incision
US10390963B2 (en) 2006-12-07 2019-08-27 DePuy Synthes Products, Inc. Intervertebral implant
US10398563B2 (en) 2017-05-08 2019-09-03 Medos International Sarl Expandable cage
US10433977B2 (en) 2008-01-17 2019-10-08 DePuy Synthes Products, Inc. Expandable intervertebral implant and associated method of manufacturing the same
US10500062B2 (en) 2009-12-10 2019-12-10 DePuy Synthes Products, Inc. Bellows-like expandable interbody fusion cage
US10537436B2 (en) 2016-11-01 2020-01-21 DePuy Synthes Products, Inc. Curved expandable cage
US10548741B2 (en) 2010-06-29 2020-02-04 DePuy Synthes Products, Inc. Distractible intervertebral implant
US10682130B2 (en) 2015-09-04 2020-06-16 Medos International Sarl Surgical access port stabilization
US10786264B2 (en) 2015-03-31 2020-09-29 Medos International Sarl Percutaneous disc clearing device
US10888433B2 (en) 2016-12-14 2021-01-12 DePuy Synthes Products, Inc. Intervertebral implant inserter and related methods
US10940016B2 (en) 2017-07-05 2021-03-09 Medos International Sarl Expandable intervertebral fusion cage
USRE48534E1 (en) 2012-04-16 2021-04-27 DePuy Synthes Products, Inc. Detachable dilator blade
US11013530B2 (en) 2019-03-08 2021-05-25 Medos International Sarl Surface features for device retention
US11045324B2 (en) 2006-12-08 2021-06-29 DePuy Synthes Products, Inc. Method of implanting a curable implant material
US11051862B2 (en) 2001-11-03 2021-07-06 DePuy Synthes Products, Inc. Device for straightening and stabilizing the vertebral column
US11129727B2 (en) 2019-03-29 2021-09-28 Medos International Sari Inflatable non-distracting intervertebral implants and related methods
US11134987B2 (en) 2011-10-27 2021-10-05 DePuy Synthes Products, Inc. Method and devices for a sub-splenius/supra-levator scapulae surgical access technique
US11219439B2 (en) 2012-09-26 2022-01-11 DePuy Synthes Products, Inc. NIR/RED light for lateral neuroprotection
US11224453B2 (en) 2014-07-08 2022-01-18 Spinal Elements, Inc. Apparatus and methods for disrupting intervertebral disc tissue
US11241252B2 (en) 2019-03-22 2022-02-08 Medos International Sarl Skin foundation access portal
US11344424B2 (en) 2017-06-14 2022-05-31 Medos International Sarl Expandable intervertebral implant and related methods
US11426286B2 (en) 2020-03-06 2022-08-30 Eit Emerging Implant Technologies Gmbh Expandable intervertebral implant
US11426290B2 (en) 2015-03-06 2022-08-30 DePuy Synthes Products, Inc. Expandable intervertebral implant, system, kit and method
US11439380B2 (en) 2015-09-04 2022-09-13 Medos International Sarl Surgical instrument connectors and related methods
US11446156B2 (en) 2018-10-25 2022-09-20 Medos International Sarl Expandable intervertebral implant, inserter instrument, and related methods
US11452607B2 (en) 2010-10-11 2022-09-27 DePuy Synthes Products, Inc. Expandable interspinous process spacer implant
US11471145B2 (en) 2018-03-16 2022-10-18 Spinal Elements, Inc. Articulated instrumentation and methods of using the same
US11510788B2 (en) 2016-06-28 2022-11-29 Eit Emerging Implant Technologies Gmbh Expandable, angularly adjustable intervertebral cages
US11559328B2 (en) 2015-09-04 2023-01-24 Medos International Sarl Multi-shield spinal access system
US11564811B2 (en) 2015-02-06 2023-01-31 Spinal Elements, Inc. Graft material injector system and method
US11583327B2 (en) 2018-01-29 2023-02-21 Spinal Elements, Inc. Minimally invasive interbody fusion
US11596523B2 (en) 2016-06-28 2023-03-07 Eit Emerging Implant Technologies Gmbh Expandable and angularly adjustable articulating intervertebral cages
US11612491B2 (en) 2009-03-30 2023-03-28 DePuy Synthes Products, Inc. Zero profile spinal fusion cage
US11660082B2 (en) 2011-11-01 2023-05-30 DePuy Synthes Products, Inc. Dilation system
US11672562B2 (en) 2015-09-04 2023-06-13 Medos International Sarl Multi-shield spinal access system
US11744447B2 (en) 2015-09-04 2023-09-05 Medos International Surgical visualization systems and related methods
US11752009B2 (en) 2021-04-06 2023-09-12 Medos International Sarl Expandable intervertebral fusion cage
US11771517B2 (en) 2021-03-12 2023-10-03 Medos International Sarl Camera position indication systems and methods
US11813026B2 (en) 2019-04-05 2023-11-14 Medos International Sarl Systems, devices, and methods for providing surgical trajectory guidance
US11850160B2 (en) 2021-03-26 2023-12-26 Medos International Sarl Expandable lordotic intervertebral fusion cage
US11911287B2 (en) 2010-06-24 2024-02-27 DePuy Synthes Products, Inc. Lateral spondylolisthesis reduction cage
USRE49973E1 (en) 2013-02-28 2024-05-21 DePuy Synthes Products, Inc. Expandable intervertebral implant, system, kit and method
USRE49994E1 (en) 2013-03-14 2024-06-04 Spinal Elements, Inc. Spinal fusion implants and devices and methods for deploying such implants
US12090064B2 (en) 2022-03-01 2024-09-17 Medos International Sarl Stabilization members for expandable intervertebral implants, and related systems and methods
US12150636B2 (en) 2015-09-04 2024-11-26 Medos International Sárl Surgical instrument connectors and related methods
US12426868B2 (en) 2007-09-28 2025-09-30 DePuy Synthes Products, Inc. Balloon with shape control for spinal procedures

Families Citing this family (1365)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
EP1080226A4 (en) * 1998-05-21 2004-04-21 Isis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF OLIGONUCLEOTIDES
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
ES2569919T3 (en) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of an immunofunctional molecule
US20040157327A1 (en) * 1999-10-22 2004-08-12 Wyeth Pablo, a polypeptide that interacts with BCL-XL, and uses related thereto
DE10100586C1 (en) 2001-01-09 2002-04-11 Ribopharma Ag Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
PT1309726E (en) 2000-03-30 2010-03-08 Whitehead Biomedical Inst RNA INTERFERENCE-SPECIFIC RNA INTERFERENCE MEDIATORS
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DE60130583T3 (en) 2000-12-01 2018-03-22 Europäisches Laboratorium für Molekularbiologie SMALL RNA MOLECULES TRANSFERRING RNA INTERFERENCE
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
EP1390383B1 (en) * 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
US20070173473A1 (en) * 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
WO2008030239A1 (en) * 2006-09-05 2008-03-13 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HISTONE DEACETYLASE (HDAC) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050164968A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20050119212A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
US20030144221A1 (en) * 2001-07-17 2003-07-31 Isis Pharmaceuticals Inc. Antisense modulation of BCL2-associated X protein expression
US7425545B2 (en) * 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US20050043256A1 (en) * 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
AU2002330724A1 (en) * 2001-08-16 2003-03-10 Bar Ilan University Diagnosis, prevention and treatment of cancer
WO2003064621A2 (en) * 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064626A2 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US7405292B2 (en) * 2002-02-19 2008-07-29 The Children's Hospital Of Philadelphia Cellular genes regulated by HIV-1 infection and methods of use thereof
US8067575B2 (en) * 2002-02-20 2011-11-29 Merck, Sharp & Dohme Corp. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US7662952B2 (en) * 2002-02-20 2010-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
WO2003087367A2 (en) * 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US7199107B2 (en) * 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1532248B1 (en) * 2002-07-26 2009-04-01 Novartis Vaccines and Diagnostics, Inc. Modified small interfering rna molecules and methods of use
US20080274989A1 (en) * 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US8729036B2 (en) 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
KR101238701B1 (en) * 2002-08-21 2013-03-05 더 유니버시티 오브 브리티쉬 콜롬비아 RNAi Probes Targeting Cancer-Related Proteins
ES2377318T3 (en) 2002-09-06 2012-03-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for the delivery of covalently bound therapeutic agents to them
WO2004031350A2 (en) 2002-09-26 2004-04-15 Amgen, Inc. Modulation of forkhead box o1a expression
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
US20050259483A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US7892793B2 (en) * 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
US9827263B2 (en) 2002-11-05 2017-11-28 Ionis Pharmaceuticals, Inc. 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US20060009410A1 (en) * 2002-11-13 2006-01-12 Crooke Rosanne M Effects of apolipoprotein B inhibition on gene expression profiles in animals
US7405289B2 (en) * 2002-11-13 2008-07-29 Metabolex, Inc. Pancreatic islet transcription factor and uses thereof
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
EP1560931B1 (en) * 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
US7977471B2 (en) * 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US7612196B2 (en) * 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20090227780A1 (en) * 2002-11-14 2009-09-10 Dharmacon, Inc. siRNA targeting connexin 43
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US20080268457A1 (en) * 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
US7619081B2 (en) * 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US20100113307A1 (en) * 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
US7592442B2 (en) * 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7691998B2 (en) * 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US7635770B2 (en) * 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
CN1742086B (en) * 2002-11-22 2010-05-12 生物智囊团株式会社 Method for searching target base sequence of RNA interference
US7618948B2 (en) * 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20060257851A1 (en) * 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
JP3792655B2 (en) * 2003-01-20 2006-07-05 日本電気株式会社 Novel oncogene, recombinant protein derived from the oncogene, and uses thereof
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
US7732591B2 (en) * 2003-11-25 2010-06-08 Medtronic, Inc. Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
US8084432B2 (en) 2003-02-13 2011-12-27 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
WO2004076664A2 (en) * 2003-02-21 2004-09-10 University Of South Florida Vectors for regulating gene expression
TW200427695A (en) * 2003-03-05 2004-12-16 Senesco Technologies Inc Use of antisense oligonucleotides or sirna to suppress expression of eif-5a1
JP2006521111A (en) * 2003-03-12 2006-09-21 バスジーン セラピューティクス， インコーポレイテッド Polypeptide compounds for inhibiting angiogenesis and tumor growth and applications thereof
US20040185559A1 (en) * 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AU2003225410A1 (en) * 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
US7635673B2 (en) * 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
EP1469070A1 (en) * 2003-04-15 2004-10-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Livin-specific siRNAs for the treatment of therapy-resistant tumors
EP1615943A4 (en) * 2003-04-18 2006-08-16 Univ Pennsylvania COMPOSITIONS AND METHODS FOR INHIBITING ARNIC OF ANGIOPOIETIN 1 AND 2 AND THEIR TIE2 RECEPTOR
KR20060063788A (en) * 2003-05-30 2006-06-12 니뽄 신야쿠 가부시키가이샤 Oligonucleotide Support Complex, Pharmaceutical Composition Containing the Complex
EP1640452A4 (en) * 2003-05-30 2009-12-23 Nippon Shinyaku Co Ltd OLIGO DOUBLE-STRANDED RNA INHIBITING THE EXPRESSION OF Bcl-2 AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
DK1633767T3 (en) * 2003-06-02 2019-03-25 Univ Massachusetts METHODS AND COMPOSITIONS FOR MANAGING THE EFFECT OF RNA SILENCING
US7750144B2 (en) * 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
ES2864206T3 (en) * 2003-06-02 2021-10-13 Univ Massachusetts Methods and compositions to improve the efficacy and specificity of RNAi
US7595306B2 (en) 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
JP4716517B2 (en) * 2003-06-09 2011-07-06 アルナイラム ファーマシューティカルズ， インコーポレイテッド Methods for treating neurodegenerative diseases
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
JP2007528845A (en) * 2003-06-27 2007-10-18 ディアデクサス インコーポレーテッド Pro104 antibody composition and methods of use
FR2857013B1 (en) * 2003-07-02 2005-09-30 Commissariat Energie Atomique SMALL INTERFERING RNA SPECIFIC OF ALPHA, ALPHA PRIME AND BETA SUBUNITS OF PROTEIN KINASE CK2 AND THEIR APPLICATIONS
US20060280725A1 (en) * 2003-07-02 2006-12-14 Barrie Bode Compositions and methods of treating and diagnosing hepatoma
US7173015B2 (en) * 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
US7888497B2 (en) * 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
NZ545544A (en) * 2003-08-13 2009-04-30 Univ Illinois Silencing of TGF-beta receptor type II expression by sirna
CA2539295A1 (en) * 2003-08-18 2005-02-24 Japan Health Sciences Foundation Improved sirna molecule and method of suppressing gene expression with the use of the same
US7825235B2 (en) * 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
JP4664815B2 (en) * 2003-09-11 2011-04-06 ヒュービットジェノミクス株式会社 Method and kit for detecting proliferative disease causing sclerosis, prophylactic and / or therapeutic agent for proliferative disease causing sclerosis, and method and kit for identifying substances effective for prevention and / or treatment of proliferative disease causing sclerosis
US8501705B2 (en) * 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US7947658B2 (en) 2003-09-12 2011-05-24 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
NZ545134A (en) 2003-09-18 2009-06-26 Lilly Co Eli Modulation of eIF4E expression
US8722637B2 (en) * 2003-09-22 2014-05-13 The Board Of Trustees Of The University Of Illinois Methods and compositions of IG20 and DENN-SV splice variants
US20070054849A1 (en) * 2003-09-24 2007-03-08 Oncotherapy Science, Inc. Method for diagnosing hepatocellular carcinomas
AR041407A1 (en) * 2003-09-26 2005-05-18 Nestor Alberto Kerner OLIGONUCLEOTIDOS ANTIANDROGENOS USABLE IN THE TREATMENT OF DERMATOLOGICAL PATHOLOGIES RELATED TO THE ANDROGEN METABOLISM, ITS PHARMACEUTICAL COMPOSITIONS AND THEIR USES AND METHODS OF TREATMENT
US8258105B2 (en) 2003-10-07 2012-09-04 Isis Pharmaceuticals, Inc. Antisense oligonucleotides optimized for kidney targeting
WO2005035004A1 (en) * 2003-10-09 2005-04-21 Takara Bio Inc. COMPOSITION FOR INHIBITING FUNCTION OF HUMAN Flt3
WO2005042719A2 (en) * 2003-10-30 2005-05-12 The Cbr Institute For Biomedical Research, Inc. Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents
US20050191653A1 (en) * 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
WO2005056021A1 (en) 2003-12-04 2005-06-23 University Of South Florida Polynucleotides for reducing respiratory syncytial virus gene expression
SE0303397D0 (en) * 2003-12-17 2003-12-17 Index Pharmaceuticals Ab Compounds and method for RNA interference
US20060134787A1 (en) * 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
AU2005203822A1 (en) * 2004-01-12 2005-07-21 Lorus Therapeutics Inc. Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in combination therapies for the treatment of cancer
WO2005069872A2 (en) * 2004-01-15 2005-08-04 Washington University High throughput pharmaceutical screening using drosophila
JP4767019B2 (en) * 2004-01-16 2011-09-07 武田薬品工業株式会社 Pharmaceuticals for prevention and treatment of arteriosclerosis
EP1711606A2 (en) * 2004-01-20 2006-10-18 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
US7468431B2 (en) * 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US8778900B2 (en) * 2004-01-22 2014-07-15 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP1 expression
WO2005090606A2 (en) * 2004-01-23 2005-09-29 Dharmacon, Inc. Identification of toxic nucleotide sequences
EP1723162A4 (en) 2004-02-13 2010-05-05 Univ Rockefeller ANTI-MICROARN OLIGONUCLEOTIDE MOLECULES
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
GB0404209D0 (en) * 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
JP2007527240A (en) * 2004-03-01 2007-09-27 マサチューセッツ インスティテュート オブ テクノロジー RNAi-based therapy for allergic rhinitis and asthma
DE102004010547A1 (en) * 2004-03-03 2005-11-17 Beiersdorf Ag Oligoribonucleotides for the treatment of irritative and / or inflammatory skin conditions by RNA interference
ES2423060T3 (en) * 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. IRNA agents that target VEGF
US20050277610A1 (en) 2004-03-15 2005-12-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2560269A1 (en) * 2004-03-19 2005-09-29 The Penn State Research Foundation Combinatorial methods and compositions for treatment of melanoma
TW200600785A (en) * 2004-03-23 2006-01-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
JP2005312428A (en) * 2004-03-31 2005-11-10 Keio Gijuku Treatment of cancer using suppression of Skp-2 expression
KR101147147B1 (en) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Modified polynucleotides for reducing off-target effects in rna interference
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
WO2005097817A2 (en) 2004-04-05 2005-10-20 Alnylam Pharmaceuticals, Inc. Process and reagents for oligonucleotide synthesis and purification
US8088902B2 (en) * 2004-04-05 2012-01-03 The Rockefeller University DNA virus microRNA and methods for inhibiting same
US7416842B2 (en) * 2004-04-05 2008-08-26 The Rockefeller University DNA virus microRNA
EP2520652B1 (en) 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
WO2005117938A2 (en) * 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
US20050261233A1 (en) * 2004-04-21 2005-11-24 Sanjay Bhanot Modulation of glucose-6-phosphatase translocase expression
WO2005103254A1 (en) * 2004-04-22 2005-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem UNIVERSAL TARGET SEQUENCES FOR siRNA GENE SILENCING
JP5128273B2 (en) * 2004-04-27 2013-01-23 ガラパゴス・ナムローゼ・フェンノートシャップ Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
WO2006078278A2 (en) 2004-04-27 2006-07-27 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
JP4584987B2 (en) 2004-04-30 2010-11-24 アルニラム ファーマスーティカルズ インコーポレイテッド Oligonucleotides containing C5-modified pyrimidines
US20050287558A1 (en) 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
US7605250B2 (en) * 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
WO2005111211A2 (en) * 2004-05-14 2005-11-24 Rosetta Genomics Ltd. Micronas and uses thereof
JPWO2005111213A1 (en) * 2004-05-18 2008-03-27 学校法人 久留米大学 Myc target gene mimitin
US20100152280A1 (en) * 2004-05-24 2010-06-17 Isis Pharmaceuticals, Inc. Modulation of sid-1 expression
US8101350B1 (en) * 2004-05-24 2012-01-24 Isis Pharmaceuticals, Inc. Modulation of exportin 5 expression
US7563885B1 (en) * 2004-05-24 2009-07-21 Isis Pharmaceuticals, Inc. Modulation of Tudor-SN expression
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
US7575863B2 (en) 2004-05-28 2009-08-18 Applied Biosystems, Llc Methods, compositions, and kits comprising linker probes for quantifying polynucleotides
US20060015264A1 (en) * 2004-06-02 2006-01-19 Mcshea Andrew Interfering stem-loop sequences and method for identifying
CA2568735A1 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US20060156421A1 (en) * 2004-06-18 2006-07-13 Cagan Ross L High throughput screening methods for anti-metastatic compounds
EP1758999B1 (en) * 2004-06-22 2011-03-09 The Board Of Trustees Of The University Of Illinois METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
WO2006012222A2 (en) * 2004-06-25 2006-02-02 The J. David Gladstone Institutes Methods of treating smooth muscle cell disorders
EP3808845A1 (en) 2004-06-28 2021-04-21 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
WO2006088490A2 (en) 2004-06-30 2006-08-24 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a non-phosphate backbone linkage
JP2006031308A (en) * 2004-07-15 2006-02-02 Mitsubishi Space Software Kk Nucleic acid sequence design device, nucleic acid sequence design method, nucleic acid sequence design program, function inhibition effect calculation device, function inhibition effect calculation method, function inhibition effect calculation program, function inhibition influence degree calculation device, function inhibition influence degree calculation method, and function inhibition effect Degree calculation program.
EP1778310A2 (en) * 2004-07-21 2007-05-02 Medtronic, Inc. Medical devices and methods for reducing localized fibrosis
EP1828215A2 (en) 2004-07-21 2007-09-05 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a modified or non-natural nucleobase
US7514548B2 (en) * 2004-08-02 2009-04-07 University Of Iowa Research Foundation Methods of inhibiting COX-2
US7632932B2 (en) 2004-08-04 2009-12-15 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
US7741299B2 (en) 2004-08-16 2010-06-22 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of RTP801
US20080255065A1 (en) * 2004-08-18 2008-10-16 Genesense Technologies, Inc. Small Interfering Rna Molecules Against Ribonucleotide Reductase and Uses Thereof
US20110313024A1 (en) * 2004-08-20 2011-12-22 Leonid Beigelman RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
DK1781787T3 (en) 2004-08-23 2017-07-31 Sylentis Sau TREATMENT OF EYE DISORDERS FEATURED BY AN INCREASED INTRAOCULAR PRESSURE WITH SIRNAS
CN1324136C (en) * 2004-08-24 2007-07-04 暨南大学 siRNA duplex for inhibiting bc1-2 gene expression and its application
CN100395335C (en) * 2004-08-24 2008-06-18 暨南大学 siRNA duplexes inhibiting bcl-2 gene expression
CN100410373C (en) * 2004-08-24 2008-08-13 暨南大学 siRNA duplexes inhibiting bcl-2 gene expression
WO2006024880A2 (en) * 2004-08-31 2006-03-09 Sylentis S.A.U. Methods and compositions to inhibit p2x7 receptor expression
ATE536175T1 (en) 2004-09-17 2011-12-15 Univ Massachusetts COMPOSITIONS AND THEIR USES IN LYSOSOMAL ENZYME DISORDERS
CA2581430A1 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Compositions and methods for detecting and treating tumors
AU2005289588B2 (en) 2004-09-24 2011-12-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of ApoB and uses thereof
CN101291948B (en) * 2004-09-28 2012-05-30 夸克医药公司 Oligoribonucleotides and methods for their use in the treatment of hair loss, kidney failure and other diseases
MX2007003795A (en) 2004-09-28 2007-07-11 Quark Biotech Inc Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases.
CA2580189C (en) * 2004-09-29 2013-05-21 Children's Memorial Hospital Sirna-mediated gene silencing of alpha synuclein
WO2006039656A2 (en) * 2004-10-01 2006-04-13 Novartis Vaccines And Diagnostics Inc. Modified small interfering rna molecules and methods of use
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
US20090186353A1 (en) * 2004-10-04 2009-07-23 Rosetta Genomics Ltd. Cancer-related nucleic acids
US7825229B2 (en) * 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
CA2582464A1 (en) * 2004-10-13 2006-04-27 Sanjay Bhanot Antisense modulation of ptp1b expression
US20060110440A1 (en) * 2004-10-22 2006-05-25 Kiminobu Sugaya Method and system for biasing cellular development
US7790878B2 (en) * 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US8080420B2 (en) 2004-10-22 2011-12-20 University Of Central Florida Research Foundation, Inc. Methods and products for biasing cellular development
US8440610B2 (en) 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
JP2008519861A (en) * 2004-11-12 2008-06-12 マサチューセッツ・インスティテュート・オブ・テクノロジー Methods and compositions for treating cell proliferative disorders
WO2006053430A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
JP4809240B2 (en) * 2004-11-19 2011-11-09 株式会社ジーンケア研究所 Cancer cell-specific cell growth inhibitor
US7935811B2 (en) 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US7923206B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Method of determining a cellular response to a biological agent
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
WO2006073602A2 (en) * 2004-11-24 2006-07-13 Alnylam Pharmaceuticals, Inc. Rnai modulation of the bcr-abl fusion gene and uses thereof
US9944713B2 (en) 2004-11-24 2018-04-17 Medicinal Bioconvergence Research Center Antibody specific to the AIMP2-DX2
US8003780B2 (en) * 2004-11-24 2011-08-23 Neomics Co., Ltd. AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
WO2006062369A1 (en) 2004-12-08 2006-06-15 Bioneer Corporation Method of inhibiting expression of target mrna using sirna consisting of nucleotide sequence complementary to said target mrna
WO2006063164A2 (en) * 2004-12-08 2006-06-15 Wisconsin Alumni Research Foundation Compositions and methods for treating neuroendocrine tumors
EP1819365B1 (en) * 2004-12-09 2014-07-02 Alnylam Pharmaceuticals Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
US20100260675A1 (en) * 2004-12-09 2010-10-14 Chong Huang Oxytocin Receptor Antagonists and Their Use for the Treatment of Pulmonary Related Diseases
WO2006066158A2 (en) * 2004-12-14 2006-06-22 Alnylam Pharmaceuticals, Inc. Rnai modulation of mll-af4 and uses thereof
US7332591B2 (en) * 2004-12-21 2008-02-19 The University Of Iowa Research Foundation Bardet-Biedl susceptibility gene and uses thereof
CA2592099A1 (en) * 2004-12-22 2006-06-29 Nucleonics, Inc. Conserved hbv and hcv sequences useful for gene silencing
TWI401316B (en) * 2004-12-23 2013-07-11 Alcon Inc Rnai inhibition of serum amyloid a for treatment of glaucoma
WO2006071884A2 (en) * 2004-12-27 2006-07-06 The Regents Of The University Of Michigan Oligonucleotide based therapeutics
US7507809B2 (en) 2005-01-07 2009-03-24 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV and therapeutic uses thereof
DE102005003788A1 (en) * 2005-01-19 2006-07-20 Eberhard-Karls-Universität Tübingen Universitätsklinikum siRNA molecules for the treatment of blood vessels
AU2006209192A1 (en) * 2005-01-24 2006-08-03 Alnylam Pharmaceuticals, Inc. RNAi modulation of the Nogo-L or Nogo-R gene and uses thereof
US7879992B2 (en) * 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
EP1859040A2 (en) 2005-02-25 2007-11-28 Isis Pharmaceuticals, Inc. Compositions and their uses directed to il-4r alpha
JP2008531037A (en) * 2005-03-02 2008-08-14 ナショナル インスティテュート オブ イミュノロジー Novel nucleotide sequence
US20070185044A1 (en) * 2005-03-08 2007-08-09 Dobie Kenneth W Modulation of ace2 expression
BRPI0609206A2 (en) * 2005-03-11 2010-03-02 Alcon Inc RNA-mediated inhibition of frizzled-1 related protein for treatment of glaucoma
GB0505081D0 (en) * 2005-03-14 2005-04-20 Genomica Sau Downregulation of interleukin-12 expression by means of rnai technology
ATE524546T1 (en) * 2005-03-25 2011-09-15 Medtronic Inc USE OF ANTI-TNF OR ANTI-IL1 RNAI TO SUPPRESS THE EFFECTS OF PRO-INFLAMMATORY CYTOKINE FOR LOCAL PAIN TREATMENT
JP4131271B2 (en) * 2005-03-30 2008-08-13 ソニー株式会社 Information processing apparatus and method, and program
AU2006230436B2 (en) * 2005-03-31 2011-11-24 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
WO2006110775A2 (en) * 2005-04-08 2006-10-19 Isis Pharmaceuticals, Inc. Compositions and their uses directed to aceytl-coa carboxylases
US20070213293A1 (en) * 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
US20090117539A1 (en) * 2005-04-12 2009-05-07 Larry Gilbertson DNA sequences for gene suppression
CA2604441A1 (en) 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
WO2006112239A1 (en) * 2005-04-15 2006-10-26 National University Corporation Tottori University hTERT GENE EXPRESSION REGULATORY GENE
WO2006113743A2 (en) * 2005-04-18 2006-10-26 Massachusetts Institute Of Technology Compositions and methods for rna interference with sialidase expression and uses thereof
US20060253068A1 (en) * 2005-04-20 2006-11-09 Van Bilsen Paul Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart
EP1714970A1 (en) * 2005-04-22 2006-10-25 Universität des Saarlandes Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity
CN101535331B (en) 2005-04-29 2013-01-30 洛克菲勒大学 Human microRNA and method for inhibiting human microRNA
US7902352B2 (en) * 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
US20060257912A1 (en) * 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
KR20060119412A (en) * 2005-05-20 2006-11-24 아주대학교산학협력단 SiRNA for inhibiting IL-6 expression and composition containing same
CA2609180A1 (en) * 2005-05-24 2006-11-30 Isis Pharmaceuticals, Inc. Modulation of lmw-ptpase expression
EP1728514A1 (en) * 2005-06-03 2006-12-06 Immunotech S.A. Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation
AU2006254891B2 (en) * 2005-06-06 2011-04-14 Gen-Probe Incorporated Compositions, methods and kits for determining the presence of Chlamydophila pneumoniae in a test sample
WO2006131925A2 (en) * 2005-06-10 2006-12-14 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
EP1734118A1 (en) * 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening
FI20050640A0 (en) * 2005-06-16 2005-06-16 Faron Pharmaceuticals Oy Compounds for treating or preventing diseases or disorders related to amine oxidases
PL3308788T3 (en) 2005-06-23 2019-05-31 Biogen Ma Inc Compositions and methods for modulation of smn2 splicing
US7737265B2 (en) * 2005-06-27 2010-06-15 Alnylam Pharmaceuticals, Inc. RNAi modulation of HIF-1 and therapeutic uses thereof
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
US20080280843A1 (en) * 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
US20070044161A1 (en) * 2005-07-21 2007-02-22 Juergen Soutschek RNAi modulation of the Rho-A gene in research models
US20090155241A1 (en) * 2005-07-22 2009-06-18 Japanese Foundation For Cancer Research Prophylactic/therapeutic agent for cancer
WO2007013671A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
AU2006275810A1 (en) * 2005-07-28 2007-02-08 University Of Massachusetts Glucose transport-related genes, polypeptides, and methods of use thereof
WO2007022506A2 (en) * 2005-08-18 2007-02-22 University Of Massachusetts Methods and compositions for treating neurological disease
US20070111226A1 (en) * 2005-08-24 2007-05-17 Applera Corporation Method to Quantify siRNAs, miRNAs and Polymorphic miRNAs
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
EP2281876A3 (en) * 2005-09-16 2012-04-11 deVGen N.V. Methods for controlling pests using RNAi
US20070066557A1 (en) * 2005-09-19 2007-03-22 Monia Brett P Modulation of glucocorticoid receptor expression
CN101341246A (en) * 2005-09-20 2009-01-07 伦敦健康科学中心研究公司 Application of siRNA in organ storage/reperfusion solution
US20120164730A1 (en) * 2005-10-11 2012-06-28 Ben-Gurion University Of The Negev Research And Development Authority Ltd. Compositions for silencing the expression of vdac1 and uses thereof
EP2392646A1 (en) * 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
WO2007047913A2 (en) * 2005-10-20 2007-04-26 Isis Pharmaceuticals, Inc Compositions and methods for modulation of lmna expression
US20090136502A1 (en) * 2005-10-24 2009-05-28 Toshimitsu Arai Preventives/Remedies for Cancer
GB0521716D0 (en) * 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
WO2007051045A2 (en) 2005-10-28 2007-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of huntingtin gene
US7723314B1 (en) * 2005-10-28 2010-05-25 Transderm, Inc. Methods and compositions for treating pachyonychia congenita
EP1948680A4 (en) * 2005-10-28 2010-01-13 Univ California METHODS AND COMPOUNDS FOR DETECTION AND ISOLATION OF LYMPHOMATIC CELLS
US20080090775A1 (en) * 2005-10-31 2008-04-17 Chong Huang Antagonist of TEB4 and Methods of Use
WO2007051303A1 (en) 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. MODIFIED siRNA MOLECULES AND USES THEREOF
CA2626584A1 (en) * 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
EP1945270B1 (en) * 2005-11-09 2011-05-25 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
US7919603B2 (en) * 2005-12-19 2011-04-05 New York University Heat shock RNA
US8067558B2 (en) 2005-12-19 2011-11-29 New York University Constitutively active fragments of eukaryotic heat shock RNA
US20070270366A1 (en) * 2005-12-20 2007-11-22 Karras James G Double stranded nucleic acid molecules targeted to il-4 receptor alpha
US8258287B2 (en) * 2005-12-21 2012-09-04 Centre de Cooperation Internationale en Recherche Agronomique pour le Developpment (CIRAD) Interfering RNAs targeting the morbillivirus nucleoprotein gene
CA2634286A1 (en) * 2005-12-22 2007-08-09 Samuel Jotham Reich Compositions and methods for regulating complement system
AR057252A1 (en) * 2005-12-27 2007-11-21 Alcon Mfg Ltd INHIBITION OF RHO KINASE MEDIATED BY ARNI FOR THE TREATMENT OF EYE DISORDERS
US8673873B1 (en) 2005-12-28 2014-03-18 Alcon Research, Ltd. RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
TW200731980A (en) 2005-12-29 2007-09-01 Alcon Mfg Ltd RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
US7444453B2 (en) * 2006-01-03 2008-10-28 International Business Machines Corporation Address translation device
EP2368912B1 (en) 2006-01-05 2017-05-03 Children's Medical Center Corporation Regulators of NFAT
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
EP1974040B1 (en) * 2006-01-17 2012-10-03 Biolex Therapeutics, Inc. Compositions and methods for humanization and optimization of N-glycans in plants
WO2007084954A2 (en) * 2006-01-19 2007-07-26 The Board Of Trustees Of The University Of Illinois Selective inhibition of ig20 splice variants to treat cancers
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
NL2000439C2 (en) 2006-01-20 2009-03-16 Quark Biotech Therapeutic applications of inhibitors of RTP801.
WO2007089584A2 (en) 2006-01-26 2007-08-09 Isis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
WO2008048342A2 (en) * 2006-02-08 2008-04-24 Dharmacon, Inc. Microarray for detecting and quantifying microrna
US20070259785A1 (en) * 2006-02-13 2007-11-08 Monsanto Technology Llc SELECTING AND STABILIZING dsRNA CONSTRUCTS
JP4961549B2 (en) * 2006-02-16 2012-06-27 国立大学法人愛媛大学 SiRNA specific for androgen receptor gene
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
US7846908B2 (en) * 2006-03-16 2010-12-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of TGF-beta and therapeutic uses thereof
FI20060246A0 (en) 2006-03-16 2006-03-16 Jukka Westermarck A new growth-stimulating protein and its use
WO2007111998A2 (en) * 2006-03-24 2007-10-04 Novartis Ag Dsrna compositions and methods for treating hpv infection
EA014886B1 (en) 2006-03-31 2011-02-28 Элнилэм Фармасьютикалз, Инк. Compositions and methods for inhibiting expression of eg5 gene
EP2016177A2 (en) * 2006-04-12 2009-01-21 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
EP2674493B1 (en) 2006-04-13 2017-12-27 Arrowhead Research Corporation RNAi-mediated inhibition of histamine receptor H1-related conditions
TW200808360A (en) * 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
WO2007123391A1 (en) * 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
WO2007127919A2 (en) * 2006-04-28 2007-11-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the jc virus
ATE513912T1 (en) * 2006-05-05 2011-07-15 Isis Pharmaceuticals Inc COMPOUNDS AND METHODS FOR MODULATING THE EXPRESSION OF SGLT2
US8158598B2 (en) * 2006-05-05 2012-04-17 Isis Pharmaceuticals, Inc. Compositions and their uses directed to PTPR alpha
CN103614375A (en) * 2006-05-11 2014-03-05 阿尔尼拉姆医药品有限公司 Composition and method for inhibiting expression of PCSK9 gene
TWI322690B (en) * 2006-05-11 2010-04-01 Flysun Dev Co Ltd Short interference ribonucleic acids for treating allergic dieases
US8243715B2 (en) * 2006-05-15 2012-08-14 Oracle Israel Ltd. Delivering sip-based call services to circuit-switched terminals
WO2007133758A1 (en) * 2006-05-15 2007-11-22 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
CA2650416A1 (en) * 2006-05-19 2007-11-29 Alcon Research, Ltd. Rnai-mediated inhibition of tumor necrosis factor .alpha.-related conditions
US8198252B2 (en) * 2006-05-19 2012-06-12 Board Of Regents, The University Of Texas System SIRNA inhibition of PI3K P85, P110, and AKT2 and methods of use
US7812150B2 (en) * 2006-05-19 2010-10-12 Alnylam Pharmaceuticals, Inc. RNAi modulation of Aha and therapeutic uses thereof
AU2012201409B2 (en) * 2006-05-19 2014-06-12 Arrowhead Research Corporation RNAi-Mediated inhibition of tumor necrosis factor alpha-related conditions
EP1857548A1 (en) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
WO2007137239A2 (en) * 2006-05-19 2007-11-29 The Scripps Research Institute Treatment of protein misfolding
US7888498B2 (en) * 2006-05-22 2011-02-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of IKK-B gene
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
WO2007143584A2 (en) * 2006-06-02 2007-12-13 Alcon Research, Ltd. RNAi-MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR 1-RELATED TARGETS FOR TREATMENT OF NEOVASCULARIZATION-RELATED CONDITIONS
EP2034017B1 (en) * 2006-06-09 2012-01-25 Kabushiki Kaisha Yakult Honsha Gene involved in immortalization of human cancer cell and use thereof
WO2007141796A2 (en) * 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
US7915399B2 (en) * 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
DK2029746T3 (en) * 2006-06-12 2012-10-08 Exegenics Inc D B A Opko Health Inc Compositions and Methods for siRNA Inhibition of Angiogenesis
KR100794705B1 (en) * 2006-06-13 2008-01-14 (주)바이오니아 Method to Inhibit Expression of Target mRNA Using SiRNA Considering Selective Splicing
GB0612342D0 (en) 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
WO2008005769A2 (en) * 2006-06-30 2008-01-10 Immusol, Incorporated Methods of inhibiting hcv replication
US8124752B2 (en) * 2006-07-10 2012-02-28 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the MYC gene
JP4756271B2 (en) * 2006-07-18 2011-08-24 独立行政法人産業技術総合研究所 Cancer cell aging, apoptosis inducer
EP1884569A1 (en) * 2006-07-31 2008-02-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Sensitization of cancer cells to therapy using siNA targeting genes from the 1p and 19q chromosomal regions
US8138160B2 (en) * 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
US8101585B2 (en) * 2006-08-04 2012-01-24 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
ES2397661T3 (en) 2006-08-04 2013-03-08 Isis Pharmaceuticals, Inc. Compositions and their uses directed to diacylglycerol acyltransferase 1
WO2008017473A2 (en) 2006-08-08 2008-02-14 Gunther Hartmann Structure and use of 5' phosphate oligonucleotides
AU2007282224B2 (en) 2006-08-11 2013-08-29 Vico Therapeutics B.V. Methods and means for treating DNA repeat instability associated genetic disorders
US20080039415A1 (en) * 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
EP2374884A3 (en) * 2006-09-04 2012-01-11 Kyowa Hakko Kirin Co., Ltd. Human miRNAs isolated from mesenchymal stem cells
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
CA2663803A1 (en) * 2006-09-18 2008-03-27 Alnylam Pharmaceuticals, Inc. Rnai modulation of scap and therapeutic uses thereof
WO2008035692A1 (en) * 2006-09-19 2008-03-27 Jcr Pharmaceuticals Co., Ltd. Cancer cell identification marker and cancer cell proliferation inhibitor
AR055648A1 (en) * 2006-09-21 2007-08-29 Gen Med Sa A DOUBLE-CHAIN RNA OLIGONUCLEOTIDE A PHARMACEUTICAL OR COSMETIC COMPOSITION THAT UNDERSTANDS AND USES IT IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES RELATED TO ANDROGEN METABOLISM
AU2007299629C1 (en) 2006-09-21 2012-05-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the HAMP gene
JP5352462B2 (en) 2006-09-22 2013-11-27 ダーマコン， インコーポレイテッド Double-stranded oligonucleotide complex, gene silencing method by RNA interference, and pharmaceutical composition
WO2008063760A2 (en) * 2006-10-18 2008-05-29 The University Of Texas M.D. Anderson Cancer Center Methods for treating cancer targeting transglutaminase
CA2666657A1 (en) * 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof
JP2010507387A (en) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド Novel siRNA and method of using the same
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US8304399B2 (en) * 2006-11-09 2012-11-06 The Board Of Regents Of The University Of Texas System Hedgehog signaling pathway proteins and uses thereof
MX2009004890A (en) * 2006-11-09 2009-05-21 Unibioscreen Sa Targeting of alpha-1 or alpha-3 subunit of na+, k+-atpase in the treatment of proliferative diseases.
CA2669520C (en) * 2006-11-13 2016-07-26 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using sirna molecules directed against cd24
US7819842B2 (en) 2006-11-21 2010-10-26 Medtronic, Inc. Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites
US7988668B2 (en) * 2006-11-21 2011-08-02 Medtronic, Inc. Microsyringe for pre-packaged delivery of pharmaceuticals
US8034921B2 (en) * 2006-11-21 2011-10-11 Alnylam Pharmaceuticals, Inc. IRNA agents targeting CCR5 expressing cells and uses thereof
EP2455471A3 (en) * 2006-11-27 2012-09-12 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
WO2008067373A2 (en) * 2006-11-28 2008-06-05 Alcon Research, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
WO2008084319A2 (en) * 2006-12-18 2008-07-17 Kyowa Hakko Kirin Co., Ltd. Novel nucleic acid
CA2672979A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Selection method
US8476243B2 (en) 2006-12-29 2013-07-02 Transderm, Inc. Methods and compositions for treating keratin hyperproliferative disorders
US7754698B2 (en) * 2007-01-09 2010-07-13 Isis Pharmaceuticals, Inc. Modulation of FR-alpha expression
AU2007344641B2 (en) 2007-01-16 2014-05-22 The University Of Queensland Method of inducing an immune response
JP2010516625A (en) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド Polymer-drug conjugates with tether groups for controlled drug delivery
WO2008094860A2 (en) 2007-01-30 2008-08-07 Allergan, Inc. Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists
EP2111412A2 (en) 2007-02-02 2009-10-28 Amgen, Inc Hepcidin and hepcidin antibodies
US20080188433A1 (en) * 2007-02-07 2008-08-07 Academia Sinica Methods of diagnosis of spinal muscular atrophy and treatments thereof
US20090163431A1 (en) * 2007-02-14 2009-06-25 Ontherex Llc Compositions and methods for modulation of pdx-1
JP2010518880A (en) * 2007-02-26 2010-06-03 クアーク・ファーマスーティカルス、インコーポレイテッド Inhibitors of RTP801 and their use in the treatment of diseases
US20100292301A1 (en) * 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
US20080299659A1 (en) * 2007-03-02 2008-12-04 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting apob gene expression and uses thereof
US20100015706A1 (en) * 2007-03-02 2010-01-21 Mdrna, Inc. Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
US20100105134A1 (en) * 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2009029293A2 (en) * 2007-03-02 2009-03-05 Mdrna, Inc. Nucleic acid compounds for inhibiting myc gene expression and uses thereof
JP2010519905A (en) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド NUCLEIC ACID COMPOUND FOR SUPPRESSING EXPRESSION OF AKT GENE AND USE THEREOF
JP2010519907A (en) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Nucleic acid compound and its use for suppressing the expression of VEGF family gene
CA2679347A1 (en) * 2007-03-02 2008-09-12 Mdrna Inc. Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof
US20100112687A1 (en) * 2007-03-02 2010-05-06 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
ES2397274T3 (en) * 2007-03-02 2013-03-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improvement of protein production
WO2008109518A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
US20080287383A1 (en) * 2007-03-02 2008-11-20 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
US20090018099A1 (en) * 2007-03-02 2009-01-15 Hitto Kaufmann Protein production
WO2008109362A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf gene expression and uses thereof
JP2010519912A (en) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Nucleic acid compound for suppressing expression of RAS gene and use thereof
US20100292302A1 (en) * 2007-03-08 2010-11-18 Mak Tak W Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity
EP2134374B1 (en) * 2007-03-14 2013-11-20 Bionsil S.r.l. Btk inhibitors for use in treating chemotherapeutic drug-resistant epithelial tumours
JP5103621B2 (en) * 2007-03-20 2012-12-19 国立大学法人愛媛大学 SiRNA specific for the ADAT1 gene
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
KR20090128494A (en) 2007-03-24 2009-12-15 겐자임 코포레이션 Antisense Oligonucleotide Administration Complementary to Human Apolipoprotein shock
PE20090064A1 (en) * 2007-03-26 2009-03-02 Novartis Ag DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
EP2905336A1 (en) 2007-03-29 2015-08-12 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of a gene from the ebola
GB0707069D0 (en) * 2007-04-12 2007-05-23 Medical Res Council Methods and uses
WO2008124927A1 (en) * 2007-04-13 2008-10-23 Vincent Research & Consulting Inc. Sirna against thymidylate synthase and uses thereof in cancer treatment regimens
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
ES2399371T3 (en) 2007-05-01 2013-03-27 Santaris Pharma A/S RNA antagonist compounds for beta-catenin modulation
EP2160465B1 (en) * 2007-05-04 2013-01-02 Index Pharmaceuticals AB Tumour growth inhibitory compounds and methods of their use
US20100286238A1 (en) * 2007-05-15 2010-11-11 Rivory Laurent Pierre Suppression of viruses involved in respiratory infection or disease
CA2687336C (en) 2007-05-23 2014-12-23 Dharmacon, Inc. Micro-rna scaffolds and non-naturally occurring micro-rnas
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US20110243904A1 (en) * 2007-05-31 2011-10-06 Xiamen University Rna interference target for treating aids
EP2152897B1 (en) * 2007-06-05 2015-02-18 Melica HB Methods and materials related to hair pigmentation and cancer
AR066984A1 (en) * 2007-06-15 2009-09-23 Novartis Ag INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA)
US20090054366A1 (en) * 2007-06-15 2009-02-26 Reliance Life Sciences Pvt. Ltd. RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY
AU2012203781B2 (en) * 2007-06-15 2012-12-13 Arrowhead Pharmaceuticals, Inc. RNAi inhibition of alpha-ENaC expression
US20100273854A1 (en) * 2007-06-15 2010-10-28 Hagar Kalinski Compositions and methods for inhibiting nadph oxidase expression
HRP20140522T1 (en) * 2007-06-27 2014-08-15 Quark Pharmaceuticals, Inc. PREPARATIONS AND METHODS FOR INHIBITING PROAPOPTOTIC GENE EXPRESSION
CA2691166A1 (en) * 2007-06-27 2008-12-31 Liu Dongxu Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
JP5298014B2 (en) * 2007-07-03 2013-09-25 杏林製薬株式会社 Influenza treatment
AU2008270209B2 (en) 2007-07-05 2012-05-17 Arrowhead Pharmaceuticals, Inc. dsRNA for treating viral infection
CA2942716C (en) * 2007-07-12 2019-07-09 Biomarin Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
EP2167135A2 (en) * 2007-07-12 2010-03-31 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
EP2017340A1 (en) * 2007-07-16 2009-01-21 Qiagen GmbH Positive controls for expression modulating experiments
TW200914052A (en) * 2007-08-03 2009-04-01 Alcon Res Ltd RNAi-related inhibition of TNFα signaling pathway for treatment of glaucoma
WO2009020847A2 (en) * 2007-08-03 2009-02-12 Alcon Research, Ltd. Rnai-related inhibition of tnfa signaling pathway for treatment of ocular angiogenesis
US8435510B2 (en) * 2007-08-08 2013-05-07 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
US8263571B2 (en) * 2007-08-10 2012-09-11 Vendevia Group, Llc Gene silencing of the brother of the regulator of imprinted sites (BORIS)
US20100186102A1 (en) * 2007-08-21 2010-07-22 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Methods and compositions for post-transcriptional gene silencing
EP2190985A4 (en) * 2007-08-24 2010-12-15 Oncotherapy Science Inc Cancer-related genes, cdca5, epha7, stk31 and wdhd1
WO2009029688A2 (en) 2007-08-27 2009-03-05 Boston Biomedical, Inc. Compositions of asymmetric interfering rna and uses thereof
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
JP2010538678A (en) * 2007-09-18 2010-12-16 イントラドイグム コーポレーション K-rassiRNA-containing compositions and methods for their use
DK2548962T3 (en) 2007-09-19 2016-04-11 Applied Biosystems Llc Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof
BRPI0817527A2 (en) * 2007-10-01 2017-05-02 Isis Pharmaceuticals Inc antisense modulation of human fibroblast growth factor receptor expression 4
BRPI0817605A2 (en) * 2007-10-03 2017-05-09 Quark Pharmaceuticals Inc new siren structures
JP2011501662A (en) * 2007-10-12 2011-01-13 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン Method for releasing tight bonds
PT2203173E (en) 2007-10-26 2016-03-15 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
JP2011517279A (en) * 2007-10-29 2011-06-02 ユニバーシティ オブ マサチューセッツ Yeast cell wall particles (YCWP) multi-layered nanoparticles for nucleic acid (siRNA) delivery
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
NZ585250A (en) 2007-11-09 2012-06-29 Isis Pharmaceuticals Inc Antisense modulation of factor 7 expression
WO2009061852A2 (en) * 2007-11-09 2009-05-14 Isis Pharmaceuticals, Inc. Modulation of factor 9 expression
AU2008335202A1 (en) 2007-12-10 2009-06-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Factor VII gene
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
US20110105584A1 (en) * 2007-12-12 2011-05-05 Elena Feinstein Rtp80il sirna compounds and methods of use thereof
CA2709109A1 (en) 2007-12-13 2009-06-18 Alnylam Pharmaceuticals Inc. Methods and compositions for prevention or treatment of rsv infection
JP2011506483A (en) 2007-12-14 2011-03-03 アムジエン・インコーポレーテツド Fracture treatment method using anti-sclerostin antibody
US20090176729A1 (en) * 2007-12-14 2009-07-09 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
KR100949791B1 (en) * 2007-12-18 2010-03-30 이동기 Novel siRNA structure and its use to minimize off-target effect and not saturate the RAN mechanism
RU2010129761A (en) * 2007-12-20 2012-01-27 Ангиочем Инк. (Ca) Nucleic Acid Polypeptides Conjugates and Their Use
EP2077335A1 (en) * 2007-12-22 2009-07-08 Universitätsklinikum Schleswig-Holstein EXO1 promoter polymorphism associated with exceptional life expectancy in humans
KR100942807B1 (en) * 2007-12-26 2010-02-18 재단법인서울대학교산학협력재단 Gene therapy and pharmaceutical composition for the prevention or treatment of lung cancer
AU2008342535B2 (en) * 2007-12-27 2015-02-05 Arbutus Biopharma Corporation Silencing of polo-like kinase expression using interfering RNA
EP2075333A1 (en) * 2007-12-28 2009-07-01 Qiagen GmbH Positive controls for expression modulating experiments
EP2242854A4 (en) * 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc Sirna compounds and methods of use thereof
WO2009093384A1 (en) * 2008-01-24 2009-07-30 National Institute Of Advanced Industrial Science And Technology Polynucleotide or analogue thereof, and gene expression regulation method using the polynucleotide or the analogue thereof
WO2009096612A1 (en) * 2008-01-30 2009-08-06 Korea Institute Of Science And Technology Regulation of neutrotransmittter release through anion channels
JP2011511004A (en) * 2008-01-31 2011-04-07 アルナイラム ファーマシューティカルズ インコーポレイテッド Optimized method for delivering dsRNA targeting the PCSK9 gene
EP2249874A1 (en) * 2008-02-08 2010-11-17 ProSensa Holding BV Methods and means for treating dna repeat instability associated genetic disorders
CN102016036B (en) 2008-02-11 2015-04-08 阿克赛医药公司 Modified RNAi polynucleotides and uses thereof
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
EP2250266A2 (en) * 2008-02-12 2010-11-17 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of cd45 gene
WO2009103067A2 (en) * 2008-02-14 2009-08-20 The Children's Hospital Of Philadelphia Compositions and methods to treat asthma
KR100870314B1 (en) * 2008-02-19 2008-11-25 고려대학교 산학협력단 Pharmaceutical composition containing nucleic acid for treating cancer
DE112009000372A5 (en) * 2008-02-20 2011-01-27 Technische Universität Dresden Use of substances for sensitizing tumor cells to radiation and / or chemotherapy
NZ588280A (en) * 2008-03-05 2012-11-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of eg5 and vegf genes
KR101123130B1 (en) * 2008-03-17 2012-03-30 연세대학교 산학협력단 Inhibitors of cell migration, invasion, or angiogenesis by blocking the function of PTK7 protein
EP2268316A4 (en) * 2008-03-20 2011-05-25 Quark Pharmaceuticals Inc NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801
EP2105145A1 (en) * 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
US20110097335A1 (en) * 2008-03-31 2011-04-28 Yoshikazu Sugimoto Abc transporter protein expression inhibitor
KR20100131509A (en) * 2008-03-31 2010-12-15 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 Two-stranded lipid formula NRNA with high RNA interference effect
US7956044B1 (en) 2008-04-03 2011-06-07 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
TWI348916B (en) * 2008-04-03 2011-09-21 Univ Nat Taiwan A novel treatment tool for cancer: rna interference of bcas2
US8198255B2 (en) * 2008-05-16 2012-06-12 The Board Of Regents Of The University Of Oklahoma SiRNA-mediated inhibition of doublecortin and Ca2+/calmodulin-dependent kinase-like-1
US7902166B2 (en) * 2008-04-03 2011-03-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
US8936941B2 (en) 2008-04-03 2015-01-20 The Board Of Regents Of The University Of Oklahoma Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof
CN102037123A (en) * 2008-04-04 2011-04-27 卡兰多制药股份有限公司 Compositions and use of epas1 inhibitors
CA2720887A1 (en) * 2008-04-09 2009-10-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibitors of stim1 for the treatment of cardiovascular disorders
WO2009144704A2 (en) * 2008-04-15 2009-12-03 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS FOR INHIBITING NRF2
CA2721380A1 (en) * 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
WO2009129465A2 (en) * 2008-04-17 2009-10-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of xbp-1 gene
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
TR201905480T4 (en) * 2008-04-18 2019-05-21 Angiochem Inc Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and their respective preparation and use methods.
US20110038853A1 (en) * 2008-04-22 2011-02-17 Centre National De La Recherche Scientifique Use of Kif13A and AP-1 Inhibitors for Inhibiting Melanogenesis
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
AU2009246134B2 (en) 2008-05-16 2016-03-03 The Children's Hospital Of Philadelphia Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes
US9663585B2 (en) 2008-05-16 2017-05-30 The Board Of Regents Of The University Of Oklahoma Anti-DCLK1 monoclonal antibodies and methods of production and use thereof
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
WO2009143390A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Methods for modulating expression of rbp4
WO2009143391A2 (en) * 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc Methods for modulation expression of creb
JPWO2009148137A1 (en) * 2008-06-04 2011-11-04 協和発酵キリン株式会社 Nucleic acids that control degranulation of mast cells
EP2290063A4 (en) * 2008-06-06 2011-07-27 Gene Techno Science Co Ltd ARNSI OF HUMAN OSTEOPONTINE
EP2297311A1 (en) * 2008-06-06 2011-03-23 Medizinische Universität Graz Compounds reducing or inhibiting the expression of pkd1 for diagnosis and therapy of brain tumors
JP5524189B2 (en) * 2008-06-06 2014-06-18 クォーク ファーマシューティカルズ インコーポレーティッド Compositions and methods for the treatment of otic disorders
EP2235177B1 (en) * 2008-06-13 2012-07-18 RiboxX GmbH Method for enzymatic synthesis of chemically modified rna
CA2643886A1 (en) * 2008-06-13 2009-12-13 Oregon Health & Science University Selection of personalized cancer therapy regimens using interfering rna functional screening
TWI455944B (en) * 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd Double-stranded polynucleotides
WO2010005850A1 (en) * 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
WO2010005310A2 (en) 2008-07-10 2010-01-14 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement antagonists and uses thereof
US20110118337A1 (en) * 2008-07-10 2011-05-19 Merck Sharp & Dohme Corp. Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer
US20110184046A1 (en) 2008-07-11 2011-07-28 Dinah Wen-Yee Sah Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
EP2313506A1 (en) * 2008-07-11 2011-04-27 Medizinische Universität Innsbruck Antagonists of nr2f6 for augmenting the immune response
WO2010008562A2 (en) 2008-07-16 2010-01-21 Recombinetics Methods and materials for producing transgenic animals
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
US8710022B2 (en) 2008-07-18 2014-04-29 National University Corporation Nagoya University Cell proliferation inhibitor
CN101632833B (en) * 2008-07-25 2013-11-06 上海市计划生育科学研究所 Prostatic cancer related gene and application thereof
WO2010014592A1 (en) 2008-07-29 2010-02-04 The Board Of Regents Of The University Of Texas Sytem Selective inhibition of polyglutamine protein expression
EP2323667A4 (en) * 2008-08-07 2012-07-25 Isis Pharmaceuticals Inc MODULATION OF TRANSTHYRETIN EXPRESSION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS
WO2010019270A1 (en) 2008-08-14 2010-02-18 Isis Pharmaceuticals, Inc. Modulation of prion expression
SG196769A1 (en) * 2008-08-25 2014-02-13 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
US20130324478A1 (en) * 2008-09-08 2013-12-05 Laurence Faure Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration
CN102149829A (en) 2008-09-10 2011-08-10 新泽西医科和牙科大学 Method for imaging single mRNA molecules using multiple single-labeled probes
WO2010030963A2 (en) 2008-09-15 2010-03-18 Children's Medical Center Corporation Modulation of bcl11a for treatment of hemoglobinopathies
JP2010068723A (en) * 2008-09-16 2010-04-02 Tokyo Medical & Dental Univ Nucleic acid medicine for treating allergic disease
CA2743981C (en) 2008-09-22 2019-01-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
JP5529142B2 (en) 2008-09-25 2014-06-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド Lipid formulation composition and method for inhibiting expression of serum amyloid A gene
EP2344638A1 (en) 2008-10-06 2011-07-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of an rna from west nile virus
WO2010042636A2 (en) * 2008-10-07 2010-04-15 President And Fellows Of Harvard College Telomerase inhibitors and methods of use thereof
CN102245636A (en) 2008-10-15 2011-11-16 安吉奥开米公司 Etoposide and doxorubicin conjugates for drug delivery
DK2379084T3 (en) 2008-10-15 2018-01-22 Ionis Pharmaceuticals Inc MODULATION OF FACTOR 11 EXPRESSION
BRPI0920209A2 (en) 2008-10-15 2015-12-22 Angiochem Inc conjugates of glp-1 agonists and their uses
US8012948B2 (en) * 2008-10-15 2011-09-06 Promising Future, Llc Fas/FasL or other death receptor targeted methods and compositions for killing tumor cells
AU2015249072C1 (en) * 2008-10-20 2022-10-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
EA020312B1 (en) 2008-10-20 2014-10-30 Элнилэм Фармасьютикалз, Инк. Compositions and methods for inhibiting expression of transthyretin
EP2350277A1 (en) * 2008-10-23 2011-08-03 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
BR122020021379B1 (en) 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. morpholino phosphorodiamidate oligomer, composition comprising the same and use of said oligomer to treat muscular dystrophy
US8962581B2 (en) * 2008-10-30 2015-02-24 The Translational Genomics Research Institute Methods and kits to identify invasive glioblastoma
US9095592B2 (en) * 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US20100267803A1 (en) * 2008-11-07 2010-10-21 The Research Foundation Of State University Of New York Regulators Of Fat Metabolism As Anti-Cancer Targets
MX2011004891A (en) * 2008-11-13 2011-10-06 Modgene Llc Modification of amyloid-beta load in non-brain tissue.
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US8268797B2 (en) 2008-11-21 2012-09-18 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
ES2616051T3 (en) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Method for the synthesis of modified nucleic acids in the phosphorus atom
WO2010064851A2 (en) * 2008-12-02 2010-06-10 울산대학교 산학협력단 Mtor-targeted sirna having an interspecific cross reaction, recombination vector containing same, and pharmaceutical composition containing same
CN107338251A (en) 2008-12-04 2017-11-10 库尔纳公司 It is diseases related that natural antisense transcript by suppressing tumor suppressor gene treats tumor suppressor gene
JP5832293B2 (en) 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー Compositions and methods for selectively inhibiting pro-angiogenic VEGF isoforms
CA2746001C (en) * 2008-12-04 2020-03-31 Joseph Collard Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
AU2009324534B2 (en) 2008-12-10 2015-07-30 Alnylam Pharmaceuticals, Inc. GNAQ targeted dsRNA compositions and methods for inhibiting expression
RU2011129621A (en) * 2008-12-17 2013-01-27 Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн WAYS OF MODULATION OF BIRD FLOOD
US20100249214A1 (en) * 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
JP2012512642A (en) * 2008-12-18 2012-06-07 サントル・ナショナル・ドゥ・ラ・レシェルシュ・サイエンティフィーク−セ・エン・エール・エス− Method for identifying gene related to TRAIL-induced apoptosis and therapeutic application thereof
KR101728655B1 (en) * 2008-12-18 2017-04-19 다이서나 파마수이티컬, 인크. Extended dicer substrate agents and methods for the specific inhibition of gene expression
US11408003B2 (en) 2008-12-18 2022-08-09 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
JPWO2010079819A1 (en) * 2009-01-08 2012-06-28 塩野義製薬株式会社 Pharmaceutical composition for the treatment of obesity or diabetes
WO2010083162A2 (en) * 2009-01-13 2010-07-22 The Board Of Regents Of The University Of Texas System Unc-45a splice variants based cancer diagnostics and therapeutics
KR20110100316A (en) * 2009-02-03 2011-09-09 에프. 호프만-라 로슈 아게 Compositions and methods for inhibiting the expression of PTP1 gene
WO2010093263A1 (en) * 2009-02-03 2010-08-19 Solilrna Biosciences Limited Compositions and methods for the treatment and prevention of neoplastic disorders
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2010091396A2 (en) * 2009-02-09 2010-08-12 Archemix Corp. Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics
PL2396038T3 (en) * 2009-02-12 2016-05-31 Curna Inc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2010091878A2 (en) * 2009-02-13 2010-08-19 Silence Therapeutics Ag Means for inhibiting the expression of opa1
DE10704945T8 (en) * 2009-02-24 2013-04-25 Riboxx Gmbh IMPROVED CONSTRUCTION OF SMALL INTERFERING RNA
GB2468477A (en) * 2009-03-02 2010-09-15 Mina Therapeutics Ltd Double stranded RNA molecule comprising siRNA and miRNA precursors
ES2845644T3 (en) * 2009-03-04 2021-07-27 Curna Inc Treatment of sirtuin1-related diseases (SIRT1) by inhibition of the natural antisense transcript to sirtuin 1
JPWO2010101249A1 (en) 2009-03-06 2012-09-10 国立大学法人三重大学 Method for enhancing T cell function
US20100267806A1 (en) * 2009-03-12 2010-10-21 David Bumcrot LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
EP2408796B1 (en) 2009-03-16 2020-04-22 Ionis Pharmaceuticals, Inc. Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
ES2656290T3 (en) * 2009-03-16 2018-02-26 Curna, Inc. Treatment of diseases related to nuclear factor (derived from erythroid 2) similar to 2 (NRF2) by inhibition of natural antisense transcript to NRF2
US20120035247A1 (en) * 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
MX2011009724A (en) * 2009-03-19 2011-10-14 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING.
WO2010111198A1 (en) 2009-03-23 2010-09-30 Quark Pharmaceuticals, Inc. Compounds compositions and methods of treating cancer and fibrotic diseases
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
WO2010111490A2 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521760A (en) * 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of apoptosis signal-regulated kinase 1 (ASK1) gene expression using small interfering nucleic acids (siNA)
EP2411018A2 (en) * 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
CN107090454A (en) * 2009-03-31 2017-08-25 德尔塔菲制药股份有限公司 Target RNAi molecule and its application of thymidylate synthase
WO2010120511A2 (en) 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Method of treating respiratory disorders
WO2010115202A2 (en) * 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
EP3199165B1 (en) 2009-04-03 2022-06-08 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
JP2012524540A (en) 2009-04-24 2012-10-18 プロセンサ テクノロジーズ ビー．ブイ． Oligonucleotides containing inosine for treating DMD
TW201105793A (en) 2009-05-05 2011-02-16 Boehringer Ingelheim Int CHO/CERT cell lines
US8349808B2 (en) * 2009-05-05 2013-01-08 Medical Diagnostic Laboratories, Llc Identification of a novel repressor on IFN-lambda promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-lambda gene activity
KR101835889B1 (en) * 2009-05-06 2018-03-08 큐알엔에이, 인크. Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
KR101224828B1 (en) 2009-05-14 2013-01-22 (주)바이오니아 SiRNA conjugate and preparing method thereof
GB0908467D0 (en) * 2009-05-15 2009-06-24 Univ Gent Use of the gtpase rab27b as biomarker to stratify patients with estrogen-receptor-positive breast cancer and to monitor their disease progression
CA2762524A1 (en) * 2009-05-18 2011-01-13 Ensysce Biosciences, Inc. Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
CA2762987A1 (en) * 2009-05-22 2010-11-25 Joseph Collard Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
DK2435583T3 (en) * 2009-05-25 2014-09-29 Universit Degli Studi Di Roma La Sapienza miR-31 IN TREATMENT OF THE MUSCLE DROPS OF THE DUCHENNES
US8848602B2 (en) * 2009-05-27 2014-09-30 Oracle Israel Ltd. Providing session-based services to event-based networks in multi-leg calls
GB2471065A (en) * 2009-06-10 2010-12-22 Univ Sheffield Modulator of claspin for treatment of cell proliferative disorder
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
MX2011013421A (en) * 2009-06-15 2012-03-16 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene.
PT3449926T (en) 2009-06-17 2019-11-12 Cold Spring Harbor Laboratory COMPOSITIONS AND METHODS OF MODULATION OF SMN2 EXCISIONS IN A SUBJECT
KR101807324B1 (en) * 2009-06-26 2017-12-08 큐알엔에이, 인크. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
ES2613498T3 (en) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. New lipid formulations for the delivery of therapeutic agents to solid tumors
IN2012DN00248A (en) 2009-07-02 2015-05-01 Angiochem Inc
KR101885383B1 (en) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 Novel nucleic acid prodrugs and methods of use thereof
US8603814B2 (en) * 2009-07-20 2013-12-10 Rutgers The State University Of New Jersey Method of inhibiting nonsense-mediated mRNA decay
US9849146B2 (en) 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
CN102712925B (en) * 2009-07-24 2017-10-27 库尔纳公司 Treatment of SIRTUIN (SIRT)-associated diseases by inhibiting the natural antisense transcript of SIRTUIN (SIRT)
WO2011019763A2 (en) * 2009-08-10 2011-02-17 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
JP6189594B2 (en) * 2009-08-11 2017-08-30 クルナ・インコーポレーテッド Treatment of adiponectin (ADIPOQ) -related diseases by suppression of natural antisense transcripts against adiponectin (ADIPOQ)
US8840889B2 (en) 2009-08-13 2014-09-23 The Johns Hopkins University Methods of modulating immune function
WO2011020023A2 (en) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US8598327B2 (en) * 2009-08-18 2013-12-03 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
CN102482670B (en) * 2009-08-21 2018-06-15 库尔纳公司 Treatment of CHIP-associated diseases by inhibiting the natural antisense transcript of 'C-terminus of HSP70-interacting protein' (CHIP)
WO2011030329A1 (en) * 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
CN111705058A (en) 2009-09-11 2020-09-25 Ionis制药公司 Modulation of huntingtin expression
US8859516B2 (en) 2009-09-15 2014-10-14 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
WO2011038031A1 (en) 2009-09-22 2011-03-31 Alnylam Pharmaceuticals, Inc. Dual targeting sirna agents
US9222086B2 (en) * 2009-09-23 2015-12-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
CN102028947B (en) * 2009-09-29 2014-02-05 苏州瑞博生物技术有限公司 Inhibitor, inhibitor composition and inhibiting method of FAM3B gene, fatty liver treatment method and pharmaceutical application of inhibitor
BR112012007160A2 (en) 2009-09-30 2018-03-13 Harvard College methods for modulating autophagy by modulating autophagy inhibitor gene products
US8394778B1 (en) 2009-10-08 2013-03-12 Immune Disease Institute, Inc. Regulators of NFAT and/or store-operated calcium entry
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
WO2011053774A1 (en) 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
WO2011056883A1 (en) 2009-11-03 2011-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
JP2013509874A (en) * 2009-11-04 2013-03-21 エラスムス ユニバーシティ メディカル センター ロッテルダム Novel compounds for modulating angiogenesis and methods of treatment using these compounds
CN101708328A (en) * 2009-11-06 2010-05-19 上海市免疫学研究所 Pharmaceutical application of CYR61 protein
US9799416B2 (en) * 2009-11-06 2017-10-24 Terrapower, Llc Methods and systems for migrating fuel assemblies in a nuclear fission reactor
US8901097B2 (en) 2009-11-08 2014-12-02 Quark Pharmaceuticals, Inc. Methods for delivery of siRNA to the spinal cord and therapies arising therefrom
DK2499249T3 (en) 2009-11-12 2018-12-03 Univ Western Australia ANTISENCE MOLECULES AND PROCEDURES FOR TREATING PATHOLOGIES
EP2322927A1 (en) * 2009-11-16 2011-05-18 Deutsches Krebsforschungszentrum Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer
WO2011066475A1 (en) 2009-11-26 2011-06-03 Quark Pharmaceuticals, Inc. Sirna compounds comprising terminal substitutions
KR101168726B1 (en) 2009-11-30 2012-07-30 한국생명공학연구원 Pharmaceutical composition for treating cancer
EP3012324A3 (en) * 2009-12-09 2016-07-06 Nitto Denko Corporation Modulation of hsp47 expression
AU2014280918B2 (en) * 2009-12-18 2016-11-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat HSF1-related diseases
JP5819848B2 (en) * 2009-12-18 2015-11-24 アローヘッド リサーチ コーポレイション Organic composition for treating HSF1-related diseases
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
DK2516648T3 (en) * 2009-12-23 2018-02-12 Curna Inc TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF
WO2011079263A2 (en) * 2009-12-23 2011-06-30 Curna, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
JP6141018B2 (en) 2009-12-24 2017-06-07 バイオマリン テクノロジーズ ベー．フェー． Molecules for treating inflammatory disorders
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
AU2011203986C1 (en) 2010-01-08 2015-03-05 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
CA2786535C (en) * 2010-01-11 2019-03-26 Curna, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
US20110172296A1 (en) * 2010-01-12 2011-07-14 Bennett C Frank Modulation of transforming growth factor-beta 1 expression
WO2011091396A1 (en) * 2010-01-25 2011-07-28 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mylip/idol gene
WO2011097643A1 (en) 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
EP2534262B1 (en) 2010-02-08 2016-12-14 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
US20110213011A1 (en) * 2010-02-26 2011-09-01 Dean Nicholas M Modulation of smad3 expression
ES2641642T3 (en) 2010-03-08 2017-11-10 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
KR20180044433A (en) 2010-03-24 2018-05-02 알엑스아이 파마슈티칼스 코포레이션 Rna interference in dermal and fibrotic indications
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
WO2011118778A1 (en) 2010-03-26 2011-09-29 国立大学法人東京大学 Cell proliferation suppression agent and method for screening same
US8853182B2 (en) * 2010-03-26 2014-10-07 The University Of Tokyo Cell growth inhibitor and screening method thereof
CA2792291A1 (en) 2010-03-29 2011-10-06 Kumamoto University Sirna therapy for transthyretin (ttr) related ocular amyloidosis
AU2015268740B2 (en) * 2010-04-06 2017-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
US8507663B2 (en) 2010-04-06 2013-08-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of CD274/PD-L1 gene
KR20180033606A (en) 2010-04-23 2018-04-03 애로우헤드 파마슈티컬스 인코포레이티드 ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
SI2563920T1 (en) 2010-04-29 2017-05-31 Ionis Pharmaceuticals, Inc. Modulation of transthyretin expression
RU2018110642A (en) * 2010-05-03 2019-02-27 Курна, Инк. TREATMENT OF DISEASES ASSOCIATED WITH SIRTUIN (SIRT) BY INHIBITING A NATURAL ANTISENSE TRANSCRIPT TO SIRTUIN (SIRT)
WO2011140365A1 (en) * 2010-05-05 2011-11-10 Auburn University Targeted particles comprising landscape phage fusion proteins and heterologous nucleic acid
JP6033218B2 (en) * 2010-05-21 2016-11-30 ペプティメド， インコーポレイテッド Reagents and methods for treating cancer
JP6081910B2 (en) 2010-06-02 2017-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Composition for treating liver fibrosis and method for treating liver fibrosis
CN103025873B (en) * 2010-06-23 2018-05-08 库尔纳公司 Treatment of SCNA-associated diseases by inhibiting natural antisense transcripts of voltage-gated sodium channel alpha subunit (SCNA)
FR2962041B1 (en) * 2010-07-01 2012-07-27 Genethon INHIBITORS OF CALPAIN 3 FOR THE TREATMENT OF MUSCULAR DYSTROPHIES AND CARDIOMYOPATHIES
CA2804210A1 (en) * 2010-07-06 2012-01-12 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
KR101900770B1 (en) 2010-07-19 2018-09-20 아이오니스 파마수티컬즈, 인코포레이티드 Modulation of dystrophia myotonica-protein kinase (dmpk) expression
JP2013539456A (en) 2010-07-28 2013-10-24 アルコン リサーチ，リミテッド SiRNA Targeting VEGFA and Methods for In Vivo Treatment
US8455304B2 (en) 2010-07-30 2013-06-04 Atmel Corporation Routable array metal integrated circuit package fabricated using partial etching process
WO2012023288A1 (en) * 2010-08-20 2012-02-23 Oncotherapy Science, Inc. Fam161a as a target gene for cancer therapy and diagnosis
WO2012027467A1 (en) * 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP3118316A1 (en) 2010-09-02 2017-01-18 Université de Mons Agents useful in treating facioscapulohumeral muscular dystrophy
JP6105470B2 (en) 2010-09-09 2017-03-29 ファイザー・インク 4-1BB binding molecule
US8946186B2 (en) * 2010-09-20 2015-02-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University QSOX1 as an anti-neoplastic drug target
US20140141015A1 (en) 2010-09-20 2014-05-22 Douglas Lake QSOX1 as an Anti-Neoplastic Drug Target
US8217163B2 (en) * 2010-09-20 2012-07-10 Biomics Biotechnologies Co., Ltd. Application of highly conserved domain sequences from viral genome as template to design therapeutic slirnas
JP5860038B2 (en) * 2010-09-22 2016-02-16 国立大学法人北海道大学 Nucleic acid with anti-metabolic syndrome effect
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
US20130030034A9 (en) * 2010-09-30 2013-01-31 Quark Pharmaceuticals, Inc. Modulation of timp1 and timp2 expression
JP5996431B2 (en) * 2010-09-30 2016-09-21 Ｌｓｉｐファンド運営合同会社 Dominant mutant gene expression inhibitor
US20120083035A1 (en) 2010-09-30 2012-04-05 Dharmacon, Inc. Modified Cell Lines for Increasing Lentiviral Titers
US9567580B2 (en) 2010-10-08 2017-02-14 Anjana Rao Regulators of NFAT and/or store-operated calcium entry
US9637742B2 (en) 2010-10-22 2017-05-02 Sungkyunkwan University Foundation For Corporate Collaboration Nucleic acid molecules inducing RNA interference, and uses thereof
WO2012055982A2 (en) 2010-10-27 2012-05-03 Devgen Nv Down-regulating gene expression in insect pests
WO2012056441A1 (en) * 2010-10-28 2012-05-03 Nanodoc Ltd. Compositions and methods for specific cleavage of exogenous rna in a cell
WO2012058693A2 (en) * 2010-10-29 2012-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of pcsk9 genes
WO2012064758A2 (en) 2010-11-08 2012-05-18 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
ES2633565T3 (en) 2010-11-12 2017-09-22 The General Hospital Corporation Non-coding RNAs associated with polycomb
WO2012068405A2 (en) 2010-11-17 2012-05-24 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
EP2643463B1 (en) * 2010-11-23 2017-09-27 CuRNA, Inc. Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
CA2818024C (en) * 2010-12-06 2019-09-24 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
EP2648763A4 (en) * 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
US9193973B2 (en) * 2010-12-10 2015-11-24 Alynylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (EPO) production
WO2012091965A1 (en) 2010-12-17 2012-07-05 Carnegie Mellon University Electrochemically mediated atom transfer radical polymerization
EP2652135A1 (en) * 2010-12-17 2013-10-23 Université Pierre et Marie Curie (Paris 6) The abcg1 gene as a marker and a target gene for treating obesity
ES2710109T3 (en) * 2010-12-17 2019-04-23 Inst Nat Sante Rech Med Nucleic acids that target TCTP for use in the treatment of chemoresistant or hormone-resistant cancers
WO2012094115A1 (en) * 2010-12-17 2012-07-12 Arrowhead Research Corporation Compositions and methods for inhibiting expression of flt3 genes
WO2012083363A1 (en) 2010-12-22 2012-06-28 Murdoch Childrens Research Institute A method of treatment
WO2012091496A2 (en) * 2010-12-30 2012-07-05 Samyang Biopharmaceuticals Corporation siRNA FOR INHIBITION OF Hif1α EXPRESSION AND ANTICANCER COMPOSITION CONTAINING THE SAME
US10196691B2 (en) * 2011-01-25 2019-02-05 Almac Diagnostics Limited Colon cancer gene expression signatures and methods of use
KR101697396B1 (en) 2011-02-02 2017-01-17 엑스칼리아드 파마슈티컬즈, 인코포레이티드 Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
WO2012106175A1 (en) * 2011-02-02 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma
CA2865468C (en) * 2011-03-11 2021-05-04 Sarissa Inc. Methods of treating cancer by inhibition of dna repair proteins
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
MX343008B (en) * 2011-03-29 2016-10-21 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of tmprss6 gene.
RS58489B1 (en) 2011-04-01 2019-04-30 Ionis Pharmaceuticals Inc Modulation of signal transducer and activator of transcription 3 (stat3) expression
EP2697244B1 (en) 2011-04-13 2017-05-17 Ionis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
WO2012142480A1 (en) * 2011-04-14 2012-10-18 Beth Israel Deaconess Medical Center, Inc. Chimeric rna oligonucleotides and uses thereof
CN103582648B (en) 2011-04-21 2016-08-31 Isis制药公司 Regulation of Hepatitis B Virus (HBV) Expression
TW201243330A (en) * 2011-04-22 2012-11-01 Univ Nat Cheng Kung Method for analyzing sectretome, biomarker for lung cancer metastasis, and siRNA compound for inhibiting lung cancer metastasis
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
PL2717883T3 (en) 2011-05-02 2017-07-31 Stichting Vumc Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg)
JP2014522242A (en) * 2011-06-06 2014-09-04 メルク・シャープ・アンド・ドーム・コーポレーション RNA interference-mediated suppression of isocitrate dehydrogenase (IDH1) gene expression
ES2653247T3 (en) * 2011-06-09 2018-02-06 Curna, Inc. Treatment of frataxin-related diseases (FXN) by inhibiting the natural antisense transcript to the FXN gene
EP2717923B1 (en) 2011-06-10 2017-09-27 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US9187749B2 (en) 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
EP2721156B1 (en) 2011-06-16 2016-12-21 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
US9068184B2 (en) 2011-06-21 2015-06-30 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of protein C (PROC) genes
US9315813B2 (en) 2011-06-21 2016-04-19 Alnylam Pharmaceuticals, Inc Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
JP5993002B2 (en) 2011-06-21 2016-09-14 ミナ セラピューティクス リミテッド Albumin production and cell proliferation
SG10201800715PA (en) 2011-06-21 2018-02-27 Alnylam Pharmaceuticals Inc Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
US9228188B2 (en) * 2011-06-21 2016-01-05 Alnylam Pharmaceuticals, Inc. Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
FI20115640A0 (en) * 2011-06-22 2011-06-22 Turun Yliopisto combination therapy
EP3597750B1 (en) * 2011-06-23 2022-05-04 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
EP2726153B1 (en) 2011-06-29 2018-03-28 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
CN103889461B (en) * 2011-07-18 2016-11-09 肯塔基大学研究基金会 Protection of cells from ALU-RNA-induced degeneration and inhibitors for cell protection
CN107365339A (en) 2011-07-19 2017-11-21 波涛生命科学有限公司 Methods of Synthesizing Functionalized Nucleic Acids
JP2014526887A (en) * 2011-08-01 2014-10-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド How to improve the success rate of hematopoietic stem cell transplantation
ES2635866T5 (en) 2011-08-11 2021-04-05 Ionis Pharmaceuticals Inc Modified bonding of oligomeric compounds and their uses
WO2013028756A1 (en) 2011-08-22 2013-02-28 Carnegie Mellon University Atom transfer radical polymerization under biologically compatible conditions
KR101275264B1 (en) * 2011-08-24 2013-06-17 포항공과대학교 산학협력단 Method of screening for chaperonin modulator
DK2751270T3 (en) 2011-08-29 2018-10-29 Ionis Pharmaceuticals Inc OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
US9617538B2 (en) * 2011-08-29 2017-04-11 Niigata University Of Pharmacy And Applied Life Science Heptamer-type small guide nucleic acids inducing apoptosis of human leukemia cells
KR20140057374A (en) * 2011-09-02 2014-05-12 노파르티스 아게 Organic compositions to treat hsf1-related diseases
FI20115876A0 (en) 2011-09-06 2011-09-06 Turun Yliopisto combination therapy
US20130064881A1 (en) * 2011-09-08 2013-03-14 Gradalis, Inc. Compositions and methods for treating prostate cancer
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
AR087862A1 (en) * 2011-09-13 2014-04-23 Monsanto Technology Llc METHODS AND COMPOSITIONS FOR WEED CONTROL
BR112014005958A2 (en) 2011-09-13 2020-10-13 Monsanto Technology Llc agricultural chemical methods and compositions for plant control, method of reducing expression of an accase gene in a plant, microbial expression cassette, method for making a polynucleotide, method of identifying polynucleotides useful in modulating expression of the accase gene and herbicidal composition
UY34328A (en) 2011-09-13 2013-04-30 Monsanto Technology Llc ? COMPOSITIONS AND METHODS TO CONTROL MALEZAS UNDERSTANDING A POLINUCLEOTIDE AND TRANSFER AGENT, AND THAT MODULATE PROTOPORPHYRINOGEN IX OXIDASE.
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
WO2013040057A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
CN107739737A (en) 2011-09-13 2018-02-27 孟山都技术公司 Method and composition for Weeds distribution
MX2014002600A (en) * 2011-09-14 2014-08-29 Nippon Kayaku Kk Method for inhibiting cell growth, nucleic acid molecule having rna interference effect on nek10 variant gene, and anticancer agent.
US11058708B2 (en) * 2011-09-19 2021-07-13 Sweyshen Chen RNA interference of galectin-3 expression and methods of use thereof
US8865674B2 (en) 2011-09-20 2014-10-21 Isis Pharmaceuticals, Inc. Antisense modulation of GCGR expression
US9453261B2 (en) * 2011-09-20 2016-09-27 The George Washington University Alternative splicing variants of genes associated with prostate cancer risk and survival
EP2758531B1 (en) 2011-09-23 2017-04-12 GE Healthcare Dharmacon, Inc. The introduction of modular vector elements during production of a lentivirus
EP2760457A4 (en) * 2011-09-28 2015-07-08 Agency Science Tech & Res METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER
JP2013079210A (en) * 2011-10-04 2013-05-02 Nagoya City Univ Therapeutic agent, gene therapy agent, and method for preventing invasion of eosinophil
EP2764123B1 (en) 2011-10-05 2019-01-16 Dharmacon, Inc. Optimization of vectors for effective delivery and expression of genetic content
BR112014009790A2 (en) 2011-10-25 2018-05-15 Isis Pharmaceuticals Inc compound for antisense modulation of gccr expression, its use and composition
CN102373206B (en) * 2011-10-31 2013-02-27 暨南大学 PPP2R5C-siRNA799 targeted to inhibit PPP2R5C gene expression and tumor T cell proliferation and its application
EP3514798A1 (en) * 2011-10-31 2019-07-24 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
US9773091B2 (en) 2011-10-31 2017-09-26 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
WO2013070786A1 (en) 2011-11-07 2013-05-16 Isis Pharmaceuticals, Inc. Modulation of tmprss6 expression
EP2776450B1 (en) 2011-11-10 2018-04-04 Shire Human Genetic Therapies, Inc. Antisense oligonucleotide modulators of serotonin receptor 2c and uses thereof
EP2725103A3 (en) * 2011-11-14 2016-01-06 Silenseed Ltd Methods and compositions for treating prostate cancer
CA2856117A1 (en) * 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Auto-recognizing therapeutic rna/dna chimeric nanoparticles (np)
PT3301177T (en) 2011-11-18 2020-06-29 Alnylam Pharmaceuticals Inc Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
WO2013075233A1 (en) * 2011-11-21 2013-05-30 The Royal Institution For The Advancement Of Learning / Mcgill University Method for treating brain cancer
US9546367B2 (en) * 2011-12-07 2017-01-17 Jenny Chee Ning Chang siRNA compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer
EP2802658A2 (en) 2012-01-09 2014-11-19 Novartis AG Rnai agents to treat beta-catenin related diseases
US9707235B1 (en) 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
CN112251436A (en) 2012-01-27 2021-01-22 比奥马林技术公司 RNA-regulated oligonucleotides with improved properties for the treatment of duchenne muscular dystrophy and becker muscular dystrophy
EA201400911A1 (en) 2012-02-13 2014-11-28 Юнилевер Н.В. LIGHTENING LEATHER COMPOSITION
NZ700075A (en) 2012-02-24 2016-05-27 Protiva Biotherapeutics Inc Trialkyl cationic lipids and methods of use thereof
US9139829B2 (en) * 2012-02-28 2015-09-22 Medical Diagnostic Laboratories, Llc SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment
US9708605B2 (en) 2012-03-16 2017-07-18 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of MCL1 by double-stranded RNA
US9340784B2 (en) 2012-03-19 2016-05-17 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
US9410156B2 (en) 2012-03-28 2016-08-09 Somalogic, Inc. Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions
WO2013149191A1 (en) * 2012-03-29 2013-10-03 The Trustees Of Columbia University In The City Of New York Methods for regulating hair growth disorders
KR20140139512A (en) * 2012-03-29 2014-12-05 고쿠리쓰다이가쿠호진 규슈다이가쿠 Nucleic acid molecule capable of inhibiting expression of periostin gene, method for inhibiting expression of periostin gene, and use of said nucleic acid molecule
EP2831232A4 (en) 2012-03-30 2015-11-04 Univ Washington METHODS OF MODULATING THE EXPRESSION OF TAU TO REDUCE THE STROKE AND MODIFY A NEURODEGENERATIVE SYMPTOM
EP2835424B1 (en) * 2012-04-03 2019-02-20 National Center For Child Health And Development DNA CONTROLLING miR-140 EXPRESSION, AND SCREENING METHOD OF DRUGS USING SAID DNA
US9133461B2 (en) * 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
SG11201406787TA (en) * 2012-04-20 2014-12-30 Agency Science Tech & Res Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
US10407677B2 (en) * 2012-04-26 2019-09-10 Intana Bioscience Gmbh High complexity siRNA pools
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
TWI480043B (en) * 2012-05-01 2015-04-11 Univ Kaohsiung Medical A medication for phthalates-induced estrogen receptor-negative breast cancer
CA3173610A1 (en) * 2012-05-02 2013-11-07 Arrowhead Research Corporation Organic compositions to treat kras-related diseases
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
BR112014028644A2 (en) 2012-05-16 2017-08-15 Rana Therapeutics Inc COMPOSITIONS AND METHODS FOR MODULATION OF ATP2A2 EXPRESSION
EA201492121A1 (en) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF THE FAMILY OF HEMOGLOBIN GENES
US20150152410A1 (en) 2012-05-16 2015-06-04 Rana Therapeutics, Inc. Compositions and methods for modulating mecp2 expression
KR20150030205A (en) 2012-05-16 2015-03-19 라나 테라퓨틱스, 인크. Compositions and methods for modulating smn gene family expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
JP2015518713A (en) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド Compositions and methods for modulating UTRN expression
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9518261B2 (en) 2012-05-22 2016-12-13 Ionis Pharmaceuticals, Inc. Modulation of enhancer RNA mediated gene expression
WO2013176477A1 (en) 2012-05-22 2013-11-28 비엠티 주식회사 Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
IN2014MN02404A (en) 2012-05-24 2015-08-21 Seeds Ltd Ab
US9487780B2 (en) 2012-06-01 2016-11-08 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
US9828602B2 (en) * 2012-06-01 2017-11-28 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
US9201916B2 (en) * 2012-06-13 2015-12-01 Infosys Limited Method, system, and computer-readable medium for providing a scalable bio-informatics sequence search on cloud
CN102703451B (en) * 2012-06-21 2013-04-17 浙江省医学科学院 Expression box for inhibiting expression of Bcl12 gene and vector containing expression box
CN102703452B (en) * 2012-06-21 2013-06-05 浙江省医学科学院 siRNA double-strand for inhibiting Bcl2 gene expression and application thereof
CA2890235A1 (en) * 2012-06-22 2013-12-27 Syngenta Participations Ag Biological control of coleopteran pests
ES2987225T3 (en) 2012-06-25 2024-11-14 Ionis Pharmaceuticals Inc Modulation of UBE3A-ATS expression
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
ES2627500T3 (en) 2012-07-13 2017-07-28 Turun Yliopisto Combination therapy
RU2693381C2 (en) 2012-07-13 2019-07-02 Уэйв Лайф Сайенсес Лтд. Asymmetric auxiliary group
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
CN103540655A (en) * 2012-07-16 2014-01-29 复旦大学 Application of MK5 gene for screening anti-liver cancer drug
JP6327713B2 (en) * 2012-07-27 2018-05-23 国立研究開発法人理化学研究所 Acute myeloid leukemia treatment or recurrence inhibitor
WO2014022655A1 (en) * 2012-08-01 2014-02-06 The Trustees Of Columbia University In The City Of New York Methods for regulating hair growth disorders
KR101520383B1 (en) 2012-08-02 2015-05-15 에이비온 주식회사 Composition for Treating HPV-related Cancers
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN104755936B (en) * 2012-08-30 2018-04-27 图尔库大学 The method of the personalized cancer of the brain therapy of selection
WO2014036427A1 (en) * 2012-08-31 2014-03-06 The General Hospital Corporation Biotin complexes for treatment and diagnosis of alzheimer's disease
US20140066595A1 (en) * 2012-09-04 2014-03-06 Thermo Fisher Scientific Biosciences Inc. Modulators of Protein Production in a Human Cell Line and Cell-free Extracts Produced Therefrom
IN2015DN02699A (en) 2012-09-05 2015-09-04 Sylentis Sau
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
ES2872349T3 (en) 2012-09-12 2021-11-02 Quark Pharmaceuticals Inc Double-stranded oligonucleotide molecules for DDIT4 and methods of using them
NZ615098A (en) * 2012-09-13 2015-05-29 Seminis Vegetable Seeds Inc Genetic markers for myb28
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9175291B2 (en) * 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
EP4052709A1 (en) 2012-10-11 2022-09-07 Ionis Pharmaceuticals, Inc. Methods of treating kennedy's disease
US9963699B2 (en) 2012-10-15 2018-05-08 Ionis Pharmaceuticals, Inc. Methods for modulating C9ORF72 expression
AU2013331434B2 (en) 2012-10-15 2019-08-08 Ionis Pharmaceuticals, Inc. Compositions for modulating C90RF72 expression
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
WO2014060392A1 (en) * 2012-10-16 2014-04-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Caspase-6 inhibitors for treating t cell activation and/or proliferation disorders
EP2912194B1 (en) 2012-10-26 2019-05-08 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
WO2014076703A1 (en) * 2012-11-14 2014-05-22 Silenseed Ltd. Methods and compositions for treating cancer
WO2014077693A1 (en) * 2012-11-16 2014-05-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for reducing an effect of aging in a mammalian cell
SG11201504038XA (en) 2012-11-27 2015-06-29 Childrens Medical Center Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction
CA2892160C (en) 2012-12-05 2021-03-23 Anna Borodovsky Pcsk9 irna compositions and methods of use thereof
US9850486B2 (en) * 2012-12-14 2017-12-26 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of CKAP5 by double-stranded RNA
EA032406B1 (en) 2013-01-01 2019-05-31 Эй.Би. СИДЗ ЛТД. METHODS OF INTRODUCING dsRNA TO PLANT SEEDS FOR MODULATING GENE EXPRESSION
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
WO2014113431A2 (en) * 2013-01-15 2014-07-24 Tufts Medical Center Methods and compositions for targeting immunoglobulins
KR101409445B1 (en) * 2013-01-17 2014-06-24 한국과학기술연구원 siRNA for Inhibition of OTUB1 Expression and Pharmaceutical Composition Containing the same
KR101480523B1 (en) * 2013-02-07 2015-01-08 고려대학교 산학협력단 siRNA for Inhibiting Endogenous rpS3 Expression
CA2901119C (en) 2013-02-14 2022-10-18 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
DE102013003869B4 (en) * 2013-02-27 2016-11-24 Friedrich-Schiller-Universität Jena A method for the targeted killing of cells by mRNA binding aligned nucleotide molecules and nucleotide molecules and application kit for such use
HK1214301A1 (en) 2013-02-28 2016-07-22 箭头研究公司 Organic compositions to treat epas1-related diseases
US9265789B2 (en) * 2013-03-12 2016-02-23 The Medical College Of Wisconsin, Inc. Targeting CLPTM1L by RNA interference for treatment and prevention of cancer
CA2905104A1 (en) 2013-03-13 2014-10-09 Monsanto Technology Llc Control of lolium species by topical application of herbicidal composition comprising dsrna
WO2014164761A1 (en) 2013-03-13 2014-10-09 Monsanto Technology Llc Methods and compositions for weed control
HK1213019A1 (en) 2013-03-13 2016-06-24 Meso Scale Technologies, Llc Improved assay methods
KR20150130430A (en) 2013-03-14 2015-11-23 아이시스 파마수티컬즈 인코포레이티드 Compositions and methods for modulating tau expression
MX418589B (en) 2013-03-14 2024-12-09 Alnylam Pharmaceuticals Inc Complement component c5 irna compositions and methods of use thereof
WO2014153118A1 (en) * 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
AU2014236140B2 (en) 2013-03-14 2019-10-03 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
US9418203B2 (en) 2013-03-15 2016-08-16 Cypher Genomics, Inc. Systems and methods for genomic variant annotation
WO2014144799A2 (en) 2013-03-15 2014-09-18 New York University siRNA TARGETING HSR1
US11342048B2 (en) 2013-03-15 2022-05-24 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US10235496B2 (en) 2013-03-15 2019-03-19 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
US20140288149A1 (en) 2013-03-15 2014-09-25 Graham Lord Mir-142 and antagonists thereof for treating disease
WO2014144978A2 (en) 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy
CA2906663A1 (en) * 2013-03-15 2014-09-18 Techulon Inc. Antisense molecules for treatment of staphylococcus aureus infection
US9132174B2 (en) 2013-03-15 2015-09-15 Anchored Rsk3 Inhibitors, Llc Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)
WO2014148529A1 (en) * 2013-03-21 2014-09-25 学校法人埼玉医科大学 Double-stranded nucleic acid molecule, dna, vector, cancer cell proliferation inhibitor, and pharmaceutical product
WO2014153394A1 (en) 2013-03-21 2014-09-25 Genisphere, Llc Cellular delivery of dna intercalating agents
CN103205400B (en) * 2013-04-19 2014-09-17 青岛大学医学院附属医院 Recombinant lentiviral vector containing ubiquitin-specific protease gene USP39-shRNA (short hairpin ribonucleic acid) and application thereof
US9264644B2 (en) * 2013-04-25 2016-02-16 Forza Silicon Corporation Analog-to-digital conversion for image sensor with non-destructive read pixel
RS60796B1 (en) 2013-05-01 2020-10-30 Ionis Pharmaceuticals Inc Compositions and methods for modulating apolipoprotein (a) expression
WO2014179807A2 (en) * 2013-05-03 2014-11-06 President And Fellows Of Harvard Colllege Foreign dna surveillance protein
TWI727917B (en) 2013-05-22 2021-05-21 美商阿尼拉製藥公司 TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
BR112015029139B1 (en) 2013-05-22 2022-07-12 Alnylam Pharmaceuticals, Inc DOUBLE-STRAND RNAI AGENT FOR INHIBITING SERPINA1 EXPRESSION IN A CELL, ITS USES, AS WELL AS PHARMACEUTICAL COMPOSITION AND IN VITRO METHOD OF INHIBITING SERPINA1 EXPRESSION IN A CELL
US20160083733A1 (en) * 2013-05-23 2016-03-24 University Of Bremen Novel treatment of metabolic diseases
WO2014189996A1 (en) * 2013-05-24 2014-11-27 Nikolai Khodarev Anti-tumor therapy
ES2885823T3 (en) 2013-06-03 2021-12-15 Univ Bar Ilan Liposomes for Wiskott-Aldrich syndrome protein modulation
US10961531B2 (en) * 2013-06-05 2021-03-30 Agex Therapeutics, Inc. Compositions and methods for induced tissue regeneration in mammalian species
KR102306656B1 (en) * 2013-07-03 2021-09-29 삼성전자주식회사 Combination therapy for the treatment of cancer using an anti-c-Met antibody
EP3017047A4 (en) 2013-07-03 2017-06-14 Dicerna Pharmaceuticals Inc. Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna
US9512430B2 (en) 2013-07-03 2016-12-06 Wisconsin Alumni Research Foundation Compositions and methods to promote erythropoiesis
KR20150006742A (en) * 2013-07-09 2015-01-19 (주)바이오니아 Liver cancer related genes-specific siRNA, double-stranded oligo RNA molecules comprising the siRNA, and composition for the prevention or treatment of cancer comprising the same
KR20150006743A (en) * 2013-07-09 2015-01-19 (주)바이오니아 Liver cancer related genes-specific siRNA, double-stranded oligo RNA molecules comprising the siRNA, and composition for the prevention or treatment of cancer comprising the same
TW202246503A (en) 2013-07-19 2022-12-01 美商百健Ｍａ公司 Compositions for modulating tau expression
PL3030663T3 (en) 2013-07-19 2020-04-30 Monsanto Technology Llc Compositions and methods for controlling leptinotarsa
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
TW201536329A (en) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc Compound and method for regulating the manifestation of dystrophic myotonic protein kinase (DMPK)
WO2015023975A1 (en) * 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Compositions and methods for modulating rna
US10144928B2 (en) 2013-08-23 2018-12-04 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
AU2014312196C1 (en) 2013-08-28 2019-12-19 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (PKK) expression
US10385114B2 (en) * 2013-09-05 2019-08-20 Inis Biotech Llc SPARC (secreted protein, acidic and rich in cysteine), a new target for the treatment and prevention of acute liver failure
CN105793422B (en) * 2013-09-05 2020-03-03 萨罗塔治疗公司(美国) Antisense-induced exon 2 inclusion in acid α -glucosidase
CA3221709A1 (en) * 2013-09-09 2015-03-12 Somalogic Operating Co., Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
SG11201601445XA (en) * 2013-09-13 2016-03-30 Ionis Pharmaceuticals Inc Modulators of complement factor b
EP2853596A1 (en) * 2013-09-30 2015-04-01 IKBT (Institut für Klinische Biomedizinische Forschung Thurgau) Protein phosphatase inhibitor
MX385871B (en) * 2013-10-02 2025-03-18 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE LECT2 GENE.
US9994845B2 (en) * 2013-10-02 2018-06-12 Albert Einstein College Of Medicine, Inc. Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing
UA124961C2 (en) * 2013-10-04 2021-12-22 Елнілем Фармасьютикалз, Інк. Compositions and methods for inhibiting expression of the alas1 gene
KR20160062069A (en) 2013-10-11 2016-06-01 아이오니스 파마수티컬즈, 인코포레이티드 Compositions for modulating c9orf72 expression
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
EP2865757A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
UY35817A (en) 2013-11-04 2015-05-29 Us Agriculture ? COMPOSITIONS AND METHODS TO CONTROL INFESTATIONS OF PESTS AND PARASITES OF ARTHROPODES ?.
WO2015070158A1 (en) 2013-11-11 2015-05-14 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety
CN107075515B (en) 2013-11-22 2020-10-30 米纳治疗有限公司 C/EBPa composition and method of use
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
US10150965B2 (en) 2013-12-06 2018-12-11 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
UA119253C2 (en) 2013-12-10 2019-05-27 Біолоджикс, Інк. METHOD FOR VARROA TREATMENT AND VEGETABLES
IL314045A (en) * 2013-12-12 2024-09-01 Alnylam Pharmaceuticals Inc Complementary component iRNA compositions and methods for using them
CA2931510A1 (en) 2013-12-24 2015-07-02 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
WO2015100436A1 (en) 2013-12-27 2015-07-02 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
AR099092A1 (en) 2014-01-15 2016-06-29 Monsanto Technology Llc METHODS AND COMPOSITIONS FOR WEED CONTROL USING EPSPS POLYUCLEOTIDES
WO2015108048A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
PT3094728T (en) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Chiral design
CN104805085A (en) * 2014-01-29 2015-07-29 江苏命码生物科技有限公司 Tandem expressed siRNA and use of tandem expressed siRNA in treatment on chronic lymphocytic leukemia
CN106103718B (en) 2014-02-11 2021-04-02 阿尔尼拉姆医药品有限公司 Hexokinase (KHK) iRNA compositions and methods of use
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
KR101425140B1 (en) * 2014-02-19 2014-08-13 한국과학기술원 Inhibitors of methylation of LIN28A for controlling differentiation of pluripotent stem cells, its screening method and Compositions of the same
CN106132436B (en) 2014-02-21 2021-06-15 Ibc药品公司 Disease therapy by inducing an immune response to TROP-2 expressing cells
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US10011837B2 (en) 2014-03-04 2018-07-03 Sylentis Sau SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN104894223B (en) * 2014-03-07 2019-03-26 上海吉凯基因化学技术有限公司 The purposes and its related drugs of people's COPB2 gene
EP3118315A4 (en) * 2014-03-13 2017-11-15 Kyowa Hakko Kirin Co., Ltd. Nucleic acid that inhibits expression of irf5
EP3119797B1 (en) * 2014-03-18 2020-12-23 University of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
US10006027B2 (en) 2014-03-19 2018-06-26 Ionis Pharmaceuticals, Inc. Methods for modulating Ataxin 2 expression
CA2942340A1 (en) 2014-03-19 2015-09-24 Ionis Pharmaceuticals, Inc. Compositions for modulating ataxin 2 expression
ES2727078T3 (en) * 2014-03-20 2019-10-14 Oommen Varghese Improved interference small ribonucleic acid molecules
KR20230085222A (en) 2014-04-01 2023-06-13 바이오젠 엠에이 인코포레이티드 Compositions for modulating sod-1 expression
EP3420809A1 (en) 2014-04-01 2019-01-02 Monsanto Technology LLC Compositions and methods for controlling insect pests
WO2015152693A2 (en) * 2014-04-04 2015-10-08 (주)바이오니아 Novel double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases
WO2015161170A2 (en) 2014-04-17 2015-10-22 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
KR102390629B1 (en) 2014-04-25 2022-04-26 칠드런'즈 메디컬 센터 코포레이션 Compositions and methods to treating hemoglobinopathies
EP3137119B1 (en) 2014-04-28 2020-07-01 Phio Pharmaceuticals Corp. Methods for treating cancer using a nucleic acid targeting mdm2
DK3137604T3 (en) 2014-05-01 2020-08-03 Ionis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION
SI3137596T1 (en) * 2014-05-01 2019-08-30 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor b expression
EP3137091B1 (en) 2014-05-01 2020-12-02 Ionis Pharmaceuticals, Inc. Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
JP2017521045A (en) 2014-05-01 2017-08-03 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Compositions and methods for modulating angiopoietin-like factor 3 expression
US10408823B2 (en) 2014-05-15 2019-09-10 Meso Scale Technologies, Llc. Assay methods
US10450571B2 (en) * 2014-05-23 2019-10-22 Università Degli Studi Dell'aquila Small interfering RNA (siRNA) for the therapy of type 2 (ADO2) autosomal dominant osteopetrosis caused by CLCN7 (ADO2 CLCN7-dependent) gene mutation
KR20150137473A (en) * 2014-05-29 2015-12-09 한국과학기술연구원 siRNA for Inhibition of USP15 Expression and Pharmaceutical Composition Containing the same
US20170101639A1 (en) * 2014-06-04 2017-04-13 Kyowa Hakko Kirin Co., Ltd. RNAi PHARMACEUTICAL COMPOSITION FOR SUPPRESSING EXPRESSION OF CKAP5 GENE
TW201620526A (en) 2014-06-17 2016-06-16 愛羅海德研究公司 Composition and method for inhibiting α-1 antitrypsin gene expression
US10988764B2 (en) 2014-06-23 2021-04-27 Monsanto Technology Llc Compositions and methods for regulating gene expression via RNA interference
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
CN114009454A (en) 2014-07-29 2022-02-08 孟山都技术公司 Compositions and methods for controlling insect pests
AR101449A1 (en) * 2014-08-04 2016-12-21 Miragen Therapeutics Inc MYH7B INHIBITORS AND USES OF THE SAME
US20170137820A1 (en) * 2014-08-06 2017-05-18 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (tlr) 13
US11198874B2 (en) * 2014-08-20 2021-12-14 Lifesplice Pharma Llc SCN8A splice modulating oligonucleotides and methods of use thereof
ES2928500T3 (en) 2014-08-29 2022-11-18 Alnylam Pharmaceuticals Inc Patisiran for use in the treatment of transthyretin-mediated amyloidosis
CN120591279A (en) * 2014-08-29 2025-09-05 儿童医疗中心有限公司 Methods and compositions for treating cancer
WO2016034611A1 (en) * 2014-09-02 2016-03-10 Max-Delbrück-Centrum für Molekulare Medizin Antisense oligonucleotides targeting 3'utr region of a20
CN107073294A (en) 2014-09-05 2017-08-18 阿克赛医药公司 Methods of treating aging and skin disorders using nucleic acids targeting TYR or MMP1
WO2016040167A1 (en) * 2014-09-08 2016-03-17 Brandon Higgs Compositions and methods for detecting and treating small cell lung cancer
WO2016040589A1 (en) * 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016040748A1 (en) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
EP3194597B1 (en) * 2014-09-18 2021-06-30 The University Of British Columbia Allele-specific therapy for huntington disease haplotypes
US9777279B2 (en) 2014-09-24 2017-10-03 University Of Cincinnati Methods and compositions for treating autoimmune disorders by targeting Kv1.3 ion channels with functionalized lipid-derived nanovesicles
JOP20200115A1 (en) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
WO2016061487A1 (en) * 2014-10-17 2016-04-21 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
KR101646609B1 (en) * 2014-10-24 2016-08-08 한국원자력의학원 Composition for diagnosing laryngeal cancer or radio resistance of laryngeal cancer and diagnosing method
EP3904519A1 (en) 2014-10-30 2021-11-03 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
US10858650B2 (en) 2014-10-30 2020-12-08 The General Hospital Corporation Methods for modulating ATRX-dependent gene repression
WO2016073184A1 (en) * 2014-11-04 2016-05-12 Dana Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2016077566A1 (en) * 2014-11-12 2016-05-19 Research Institute At Nationwide Children's Hospital Modulation of alternative mdm2 splicing
WO2016077540A1 (en) * 2014-11-12 2016-05-19 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of comp
US10364433B2 (en) 2014-11-14 2019-07-30 The Regents Of The University Of California Modulation of AGPAT5 expression
SG11201703281RA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN107250362B (en) 2014-11-17 2021-10-22 阿尔尼拉姆医药品有限公司 Apolipoprotein C3 (APOC3) iRNA compositions and methods of use
WO2016085852A1 (en) 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
WO2016086104A1 (en) 2014-11-25 2016-06-02 Ionis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
CN104450710B (en) * 2014-11-28 2018-06-05 广州市锐博生物科技有限公司 Inhibit nucleic acid oligomer and its application of MYD88 genes
US9714424B1 (en) * 2014-12-16 2017-07-25 Icahn School Of Medicine At Mount Sinai RNAi inhibition of USP10 to treat ocular disorders
BR112017013528A2 (en) * 2014-12-23 2018-03-06 Syngenta Participations Ag biological control of beetle pests
US10774326B2 (en) * 2014-12-24 2020-09-15 Massachusetts Institute Of Technology Compositions and methods for manipulation of adipocyte energy consumption regulatory pathway
WO2016103042A1 (en) * 2014-12-25 2016-06-30 Guangzhou Ribobio Co., Ltd. Compositions and methods for inhibiting expression of adamts-5 and adam17
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US10793855B2 (en) * 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
US9982070B2 (en) 2015-01-12 2018-05-29 Carnegie Mellon University Aqueous ATRP in the presence of an activator regenerator
WO2016115490A1 (en) 2015-01-16 2016-07-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of dux4
US9434947B2 (en) * 2015-01-20 2016-09-06 Oregon Health & Science University Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
CN108064288B (en) 2015-01-22 2021-11-26 孟山都技术公司 Compositions and methods for controlling phyllometaca
CA2976445A1 (en) * 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP3256591A4 (en) 2015-02-13 2018-08-08 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
US10036017B2 (en) 2015-02-17 2018-07-31 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
WO2016134021A1 (en) 2015-02-20 2016-08-25 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting genes associated with cystic fibrosis
US10525076B2 (en) 2015-02-20 2020-01-07 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting genes associated with cystic fibrosis
US10174322B2 (en) * 2015-02-24 2019-01-08 National Cheng Kung University Short interfering RNA for treating cancer
EP3261643B1 (en) 2015-02-26 2020-11-25 Ionis Pharmaceuticals, Inc. Allele specific modulators of p23h rhodopsin
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
MX367563B (en) 2015-03-20 2019-08-27 Unilever Nv Antiperspirant composition.
EP3072969A1 (en) * 2015-03-23 2016-09-28 DKFZ Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
US10376535B2 (en) 2015-03-26 2019-08-13 University Of Rochester Therapy for malignant disease
WO2016159789A1 (en) * 2015-04-01 2016-10-06 Institute Of Environmental Science And Research Limited Methods and materials for detecting rna sequences
JP6833705B2 (en) 2015-04-03 2021-02-24 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Compounds and methods for regulating TMPRSS6 expression
CA2980339A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
SI3277814T1 (en) * 2015-04-03 2020-12-31 University Of Massachusetts Oligonucleotide compounds for targeting huntingtin mrna
US20160319278A1 (en) 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
MX2017012610A (en) 2015-04-08 2018-03-16 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the lect2 gene.
JP6975641B2 (en) 2015-04-13 2021-12-01 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Angiopoetin-like 3 (ANGPTL3) iRNA compositions and their use
AU2016249002B2 (en) 2015-04-16 2019-07-18 Ionis Pharmaceuticals, Inc. Compositions for modulating C90RF72 expression
CN107530439B (en) * 2015-04-17 2021-06-18 詹尼斯费尔公司 siRNA inhibition of human antigen R expression for the treatment of cancer
WO2016170348A2 (en) * 2015-04-22 2016-10-27 Mina Therapeutics Limited Sarna compositions and methods of use
ES2835861T5 (en) 2015-05-08 2025-02-18 Childrens Medical Ct Corp Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
AU2016271147B2 (en) 2015-05-29 2022-09-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
AU2016270870A1 (en) 2015-06-02 2018-01-04 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
WO2016196782A1 (en) 2015-06-03 2016-12-08 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
ES2826827T3 (en) 2015-06-15 2021-05-19 Angiochem Inc Methods for the treatment of leptomeningeal carcinomatosis
WO2016209862A1 (en) * 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
US10874622B2 (en) 2015-06-24 2020-12-29 Board Of Regents, The University Of Texas System Dual assembly nanoparticles
EP3112466A1 (en) 2015-07-01 2017-01-04 Samsung Electronics Co., Ltd. Composition for reducing cellular senescence level including activity inhibitor inhibiting dcun1d3 activity or expression inhibitor inhibiting expression of dcun1d3-encoding gene and use thereof
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
KR20180026739A (en) 2015-07-06 2018-03-13 알엑스아이 파마슈티칼스 코포레이션 A nucleic acid molecule targeting superoxide dismutase 1 (SOD1)
EP4092119A3 (en) 2015-07-10 2023-03-22 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (dgat2)
WO2017011286A1 (en) * 2015-07-10 2017-01-19 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
EP3323892A4 (en) * 2015-07-13 2019-07-17 Kyowa Hakko Kirin Co., Ltd. Antisense oligonucleotide inhibiting 2gpi expression
US20170051282A1 (en) * 2015-07-23 2017-02-23 Cold Spring Harbor Laboratory Extracellular vesicle methods and compositions
WO2017019660A1 (en) * 2015-07-27 2017-02-02 Alnylam Pharmaceuticals, Inc. Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
RU2018106970A (en) * 2015-07-30 2019-08-28 Байер Кропсайенс Акциенгезельшафт METHODS AND COMPOSITIONS FOR THE FIGHT AGAINST RUST MUSHROOMS BY INHIBITING EXPRESSION OF THE NXT1 GENE
BR112018000542B1 (en) 2015-07-31 2023-01-24 Alnylam Pharmaceuticals, Inc DOUBLE-STRANDED RIBONUCLEIC ACID AGENT FOR INHIBITING TRANSTHYRTIN EXPRESSION IN A CELL, PHARMACEUTICAL COMPOSITION, USE OF THE FOREGOING, AND IN VITRO METHOD FOR INHIBITING TRANSTHYRTIN EXPRESSION IN A CELL
CN105063048A (en) * 2015-08-13 2015-11-18 吉林大学 SiRNA (small interfering ribonucleic acid) capable of inhibiting expression of Survivin genes and application of siRNA
AU2016309948B2 (en) * 2015-08-14 2021-05-20 The University Of Sydney Connexin 45 inhibition for therapy
EP3334499A4 (en) 2015-08-14 2019-04-17 University of Massachusetts BIOACTIVE CONJUGATES FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
CN106467914A (en) * 2015-08-18 2017-03-01 华东理工大学 The siRNA of targeting people's TSPAN8 gene and its application
WO2017029391A1 (en) * 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
MX2018002158A (en) 2015-08-25 2018-07-06 Alnylam Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING A DISORDER ASSOCIATED WITH PROPROTEIN CONVERTASE SUBTILISIN KEXIN GENE (PCSK9).
WO2017040078A1 (en) 2015-09-02 2017-03-09 Alnylam Pharmaceuticals, Inc. PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
MA44908A (en) * 2015-09-08 2018-07-18 Sylentis Sau ARNSI MOLECULES AND THEIR USE IN PROCESSES AND COMPOSITIONS TO INHIBIT NRARP GENE EXPRESSION
WO2017042239A1 (en) * 2015-09-08 2017-03-16 Sylentis Sau siRNA and their use in methods and compositions for inhibiting the expression of the CHI3L1 gene
GB201516685D0 (en) * 2015-09-21 2015-11-04 Varghese Oommen P And Oommen Oommen P Nucleic acid molecules with enhanced activity
WO2017053681A1 (en) 2015-09-24 2017-03-30 Wisconsin Alumni Research Foundation Methods of expanding hematopoietic stem cells, compositions, and methods of use thereof
EP3353303B1 (en) 2015-09-25 2023-08-02 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating ataxin 3 expression
CN106554962B (en) * 2015-09-30 2021-06-04 中国科学院上海药物研究所 Prevention, diagnosis and treatment of cancers overexpressing GPR160
WO2017062422A1 (en) 2015-10-07 2017-04-13 The Research Foundation For The State University Of New York METHODS FOR INCREASING PLATELET COUNT BY INHIBITING BILIVERDIN IXβ REDUCTASE
EP3359164A4 (en) 2015-10-08 2019-06-12 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
HK1258370A1 (en) 2015-10-14 2019-11-08 拜奥-帕斯控股股份有限公司 P-ethoxy nucleic acids for liposomal formulation
WO2017066697A1 (en) * 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
WO2017066657A1 (en) * 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Nucleic acid based tia-1 inhibitors
KR101842679B1 (en) * 2015-10-15 2018-03-28 한국과학기술원 Rna oligonucleotide and enhancer of immune system comprising the same
WO2017065369A1 (en) * 2015-10-15 2017-04-20 한국과학기술원 Rna oligonucleotide and immune activator comprising same
CN109563509B (en) 2015-10-19 2022-08-09 菲奥医药公司 Reduced size self-delivering nucleic acid compounds targeting long non-coding RNAs
EP3366774A4 (en) * 2015-10-23 2019-03-27 Rena Therapeutics Inc. NUCLEIC ACID COMPLEX HAVING AT LEAST ONE REFINED STRUCTURE
WO2017075038A1 (en) 2015-10-26 2017-05-04 Rana Therapeutics, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
US20180320177A1 (en) 2015-11-05 2018-11-08 University Of Connecticut Compositions and methods for the treatment of liver fibrosis
CN108348478A (en) 2015-11-06 2018-07-31 Ionis 制药公司 Regulates apolipoprotein(a) expression
HK1258902A1 (en) * 2015-11-10 2019-11-22 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
US10059949B2 (en) 2015-11-16 2018-08-28 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using RNA complexes that target MYD88 or TLR3
JP6198201B1 (en) * 2015-11-19 2017-09-20 公立大学法人名古屋市立大学 Antitumor drug delivery formulation
EP3378492A4 (en) * 2015-11-20 2019-11-13 Kyushu University National University Corporation IMMUNOREGULATOR
AU2016363683B2 (en) * 2015-11-30 2023-04-27 The University Of British Columbia Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer
US11058709B1 (en) 2015-12-04 2021-07-13 Ionis Pharmaceuticals, Inc. Methods of treating breast cancer
KR20230119027A (en) 2015-12-07 2023-08-14 젠자임 코포레이션 Methods and compositions for treating a serpinc1-associated disorder
EP3387112A4 (en) 2015-12-07 2019-08-21 BioTime, Inc. METHODS FOR RETRANSTIGATION OF VARIOUS CELLS OF ADIPOSE BROWN TISSUE DERIVED FROM PLURIPOTENT STEM CELLS
WO2017100193A1 (en) 2015-12-10 2017-06-15 Fibrogen, Inc. Methods for treatment of motor neuron diseases
EP3387129A1 (en) * 2015-12-10 2018-10-17 Alnylam Pharmaceuticals, Inc. STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP3816287A1 (en) 2015-12-13 2021-05-05 Nitto Denko Corporation Sirna structures for high activity and reduced off target
EP3181698A1 (en) 2015-12-16 2017-06-21 European Molecular Biology Laboratory (EMBL) Microrna mir-142 as stem cell marker
US20190002887A1 (en) 2015-12-31 2019-01-03 Ionis Pharmaceuticals, Inc. Methods for reducing ataxin-2 expression
WO2017120365A1 (en) 2016-01-05 2017-07-13 Ionis Pharmaceuticals, Inc. Methods for reducing lrrk2 expression
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
CA3022874A1 (en) * 2016-02-02 2017-08-10 Olix Pharmaceuticals, Inc. Treatment of atopic dermatitis and asthma using rna complexes that target il4ra, trpa1, or f2rl1
CA3022877A1 (en) 2016-02-02 2017-08-10 Olix Pharmaceuticals, Inc. Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb
US10519442B2 (en) 2016-02-11 2019-12-31 City Of Hope Twist signaling inhibitor compositions and methods of using the same
WO2017143156A1 (en) 2016-02-19 2017-08-24 Genisphere Llc Nucleic acid carriers and therapeutic methods of use
EP3416660A4 (en) * 2016-02-19 2019-11-06 The Regents of the University of California SHORT NARROW RNA (SHRNA734) AND USE THEREOF FOR POSITIVE SELECTION AND ELIMINATION OF GENETICALLY MODIFIED CELLS
AU2017229778A1 (en) 2016-03-09 2018-08-16 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting PMP22 expression
WO2017161168A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Modulation of dyrk1b expression
AU2017234678A1 (en) 2016-03-16 2018-08-16 Ionis Pharmaceuticals, Inc. Methods of modulating KEAP1
CN105925576B (en) * 2016-03-24 2018-04-20 嘉兴市第一医院 SiRNA, ShorthairpinRNA and carrier and application for mammal R Spondin3 gene targets
MA45328A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
MA45340A (en) * 2016-04-01 2019-02-06 Avidity Biosciences Llc ANDROGEN RECEPTOR NUCLEIC ACIDS AND THEIR USES
ES2640524B1 (en) * 2016-04-01 2018-09-24 Universidad Autónoma de Madrid USE OF TCFL5 / CHA AS A NEW MARKER FOR THE PROGNOSIS AND / OR DIFFERENTIAL DIAGNOSIS OF ACUTE LYMPHOBLASTIC LEUKEMIES
WO2017178883A2 (en) 2016-04-11 2017-10-19 Olix Pharmaceuticals, Inc. Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
WO2017177277A1 (en) * 2016-04-14 2017-10-19 Benitec Biopharma Limited Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
EP3445405A4 (en) 2016-04-18 2019-12-18 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMERS AND METHODS OF USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE
CN107345230A (en) * 2016-05-05 2017-11-14 江苏命码生物科技有限公司 A kind of siRNA of suppression K-RAS gene expressions and its precursor and application
CN105969771A (en) * 2016-05-30 2016-09-28 东北师范大学 shRNA targeted to silent FOXG1
WO2017211999A1 (en) * 2016-06-08 2017-12-14 Aalborg Universitet Antisense oligonucleotides for modulation of long noncoding rnas
PT109454A (en) * 2016-06-14 2017-12-14 Phyzat Biopharmaceuticals Lda NUCLEIC ACIDS OF INTERFERENCE AND COMPOSITIONS THAT UNDERSTAND THEM
WO2017218884A1 (en) 2016-06-16 2017-12-21 Ionis Pharmaceuticals, Inc. Combinations for the modulation of smn expression
CA3023514A1 (en) 2016-06-17 2017-12-21 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
MA45496A (en) 2016-06-17 2019-04-24 Hoffmann La Roche NUCLEIC ACID MOLECULES FOR PADD5 OR PAD7 MRNA REDUCTION FOR TREATMENT OF HEPATITIS B INFECTION
KR101916652B1 (en) 2016-06-29 2018-11-08 올릭스 주식회사 Compounds improving RNA interference of small interfering RNA and use thereof
CN107557363B (en) * 2016-06-30 2021-03-12 中国科学院分子细胞科学卓越创新中心 Inducible siRNA expression vector and its preparation and application
EP3481432A4 (en) * 2016-07-05 2020-05-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services DIAGNOSIS OF COL6-RELATED DISEASES AND METHOD FOR TREATING THEM
EP3484280A4 (en) 2016-07-13 2020-08-12 Indiana University Research & Technology Corporation RNAI INSECTICIDE MATERIALS AND PROCEDURES
AR109207A1 (en) * 2016-08-05 2018-11-07 Syngenta Participations Ag PATHOPE CONTROL OF COLEOPTERS USING RNA MOLECULES
EP3496758A4 (en) 2016-08-12 2020-11-11 University of Massachusetts CONJUGATED OLIGONUCLEOTIDS
UY37376A (en) 2016-08-26 2018-03-23 Amgen Inc ARNI CONSTRUCTIONS TO INHIBIT EXPRESSION OF ASGR1 AND METHODS FOR USE
WO2018052891A2 (en) * 2016-09-15 2018-03-22 The Brigham And Women's Hospital, Inc. Modulation of pcsk9 and ldlr through drp1 inhibition
BR112019005166A2 (en) 2016-09-16 2019-07-02 Bio-Path Holding, Inc. combination therapy with liposomal antisense oligonucleotides
WO2018057575A1 (en) 2016-09-21 2018-03-29 Alnylam Pharmaceuticals, Inc Myostatin irna compositions and methods of use thereof
JOP20190065A1 (en) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc Compounds and Methods for Reducing the Expression of TAU
EP3522898A4 (en) 2016-10-06 2020-05-27 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
US11896615B2 (en) 2016-10-13 2024-02-13 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
US10806715B2 (en) * 2016-10-25 2020-10-20 Council Of Scientific & Industrial Research Gold nanoparticle based formulation for use in cancer therapy
JOP20190104A1 (en) * 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc Compounds and methods for reducing atxn3 expression
US10646540B2 (en) 2016-11-18 2020-05-12 City Of Hope Peptide inhibitors of twist
TW202313978A (en) 2016-11-23 2023-04-01 美商阿尼拉製藥公司 Serpina1 irna compositions and methods of use thereof
CN106421790B (en) * 2016-11-25 2018-12-25 复旦大学附属金山医院 Application of the inhibitor of CMPK in the drug of preparation treatment oophoroma
US11033570B2 (en) 2016-12-02 2021-06-15 Cold Spring Harbor Laboratory Modulation of Lnc05 expression
JP2019536461A (en) 2016-12-05 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Production of engineered cells for adoptive cell therapy
WO2018117253A1 (en) * 2016-12-23 2018-06-28 協和発酵キリン株式会社 Nucleic acid inhibiting expression of complement factor b
CN110381980A (en) 2017-01-06 2019-10-25 艾维迪提生物科学有限责任公司 The method that nucleic acid-peptide composition and inducing exon are skipped
IL267959B2 (en) 2017-01-10 2024-07-01 Arrowhead Pharmaceuticals Inc Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use
US11174325B2 (en) 2017-01-12 2021-11-16 Carnegie Mellon University Surfactant assisted formation of a catalyst complex for emulsion atom transfer radical polymerization processes
WO2018130584A1 (en) * 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb2 expression
JP7424728B2 (en) 2017-02-10 2024-01-30 オリック パルマセゥティカルズ インコーポレイテッド Long double-stranded RNA for RNA interference
CN106668863B (en) * 2017-02-21 2019-04-23 南方医科大学 Drug targeting KTN1 for cutaneous squamous cell carcinoma
WO2018164186A1 (en) * 2017-03-09 2018-09-13 協和発酵キリン株式会社 Nucleic acid capable of inhibiting expression of masp2
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
FI3607068T3 (en) * 2017-04-05 2023-02-19 Rna interference mediated inhibition of tmprss6
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
AU2018255352B2 (en) * 2017-04-19 2023-11-16 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for STAT3 inhibition
AU2018254468B2 (en) 2017-04-19 2023-11-16 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for BCL2 inhibition
NO344051B1 (en) * 2017-05-04 2019-08-26 Patogen As Novel virus in Fish and Method for detection
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2018208972A1 (en) 2017-05-09 2018-11-15 University Of Massachusetts Methods of treating amyotrophic lateral sclerosis (als)
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery
CA3065149A1 (en) * 2017-05-31 2018-12-06 Kyowa Kirin Co., Ltd. Nucleic acid suppressing expression of apcs
KR101940061B1 (en) * 2017-06-02 2019-01-21 김준 Composition for Inhibition of Metastasis in Cancer Cells Including Ribosomal Protein S3 siRNAs
CN107177594B (en) * 2017-06-07 2020-03-03 浙江大学 siRNA that specifically inhibits CA7 gene expression and its recombinant vector and application
FR3067933B1 (en) * 2017-06-21 2020-07-17 L'oreal MODULATORS OF OPSIN 3 IN THE MODULATION OF PIGMENTATION OF THE SKIN
US10844377B2 (en) 2017-06-23 2020-11-24 University Of Massachusetts Two-tailed self-delivering siRNA
EP3645748A4 (en) * 2017-06-30 2021-03-17 The Trustees of Princeton University GENETIC VARIANTS ASSOCIATED WITH A HYPER-SOCIAL HUMAN-DIRECTED BEHAVIOR IN DOMESTIC DOGS
AU2018297274B2 (en) * 2017-07-06 2023-05-18 Michael S. Kapiloff Treatment of heart disease by inhibition of the action of muscle A-kinase anchoring protein (mAKAP)
JP2020526192A (en) 2017-07-06 2020-08-31 アローヘッド ファーマシューティカルズ インコーポレイテッド RNAi agents for inhibiting the expression of alpha-ENaC and how to use them
US11261447B2 (en) 2017-07-13 2022-03-01 Alnylam Pharmaceuticals, Inc. Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
WO2019018383A1 (en) 2017-07-18 2019-01-24 Calimmune, Inc. Compositions and methods for treating beta-hemoglobinopathies
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
JP2020532955A (en) * 2017-08-07 2020-11-19 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． Chemically modified oligonucleotide
CN110020273B (en) * 2017-08-16 2021-06-29 北京京东尚科信息技术有限公司 Method, apparatus, and system for generating heatmaps
WO2019036613A1 (en) 2017-08-18 2019-02-21 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
EP3678674B1 (en) * 2017-09-06 2025-02-12 Baylor College of Medicine Park2 nucleic acid and/or park2 polypeptide and salvador shrna for use in the treatment of cardiac conditions
WO2019047914A1 (en) * 2017-09-07 2019-03-14 北京泰德制药股份有限公司 Double-stranded rna molecule targeting ckip-1 and use thereof
EP4233880A3 (en) * 2017-09-08 2023-09-20 MiNA Therapeutics Limited Hnf4a sarna compositions and methods of use
WO2019051173A1 (en) 2017-09-08 2019-03-14 Ionis Pharmaceuticals, Inc. Modulators of smad7 expression
US10597657B2 (en) 2017-09-11 2020-03-24 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
CN111343994B (en) 2017-09-14 2023-11-21 箭头药业股份有限公司 RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3) and methods of use
MA50267A (en) 2017-09-19 2020-07-29 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS OF TREATMENT OF TRANSTHYRETIN-MEDIA AMYLOSIS (TTR)
CN111448321A (en) 2017-09-22 2020-07-24 马萨诸塞大学 SOD1 dual expression vector and its use
WO2019063792A2 (en) * 2017-09-28 2019-04-04 Secarna Pharmaceuticals Gmbh & Co. Kg Oligonucleotide inhibiting the expression of chop
WO2019074884A2 (en) * 2017-10-10 2019-04-18 University Of Virginia Patent Foundation Compositions and methods for treating age-related macular degeneration and geographic atrophy
TW202413649A (en) 2017-10-16 2024-04-01 美商航海家醫療公司 Treatment of amyotrophic lateral sclerosis (als)
JP2021500013A (en) 2017-10-16 2021-01-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Nucleic acid molecule for reducing PAPD5 and PAPD7 mRNA for the treatment of hepatitis B infection
WO2019079781A2 (en) 2017-10-20 2019-04-25 Dicerna Pharmaceuticals, Inc Methods for treating hepatitis b infection
CA3078971A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
BR112020008478A2 (en) * 2017-11-01 2020-10-20 Editas Medicine, Inc. methods, compositions and components for editing crispr-cas9 of tgfbr2 in t cells for immunota-rapy
US20230201357A1 (en) * 2017-11-08 2023-06-29 Aptamer Diagnostic, Inc. D-dimer-specific aptamers and methods of use in diagnostics, therapeutic and theranostic purposes
TWI809004B (en) 2017-11-09 2023-07-21 美商Ionis製藥公司 Compounds and methods for reducing snca expression
GB201718701D0 (en) * 2017-11-13 2017-12-27 Syngenta Participations Ag Improvements in or relating to gene silencing
CN109777800A (en) * 2017-11-15 2019-05-21 信雅生物科技（苏州）有限公司 It is a kind of be capable of specificity inhibit ZBED1 gene siRNA construction method and its application
WO2019100039A1 (en) * 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
GB201719680D0 (en) * 2017-11-27 2018-01-10 Devgen Nv Improvements in or relating to gene silencing
EP4455285A3 (en) 2017-12-01 2025-02-26 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
WO2019105418A1 (en) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof
WO2019105414A1 (en) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
CN110944675B9 (en) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 Nucleic acid, composition and conjugate containing the nucleic acid, preparation method and use thereof
US11660347B2 (en) 2017-12-01 2023-05-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
SG11202005022YA (en) 2017-12-06 2020-06-29 Avidity Biosciences Inc Compositions and methods of treating muscle atrophy and myotonic dystrophy
JP2021505175A (en) * 2017-12-11 2021-02-18 ロシュ イノベーション センター コペンハーゲン エーエス Oligonucleotides for regulating the expression of FNDC3B
WO2019126641A2 (en) 2017-12-21 2019-06-27 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
JP7436030B2 (en) 2017-12-29 2024-02-21 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド Complexes and their preparation and use
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136456A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
CN108387621B (en) * 2018-01-10 2019-11-26 暨南大学 Cadmium ion aptamer and screen printing electrode electrochemica biological sensor
GB201800370D0 (en) * 2018-01-10 2018-02-21 Ucl Business Plc Anionic nanocomplexes for nucleic acid delivery
EP3740575A1 (en) 2018-01-15 2020-11-25 Ionis Pharmaceuticals, Inc. Modulators of dnm2 expression
CN111601891A (en) * 2018-01-16 2020-08-28 迪克纳制药公司 Compositions and methods for inhibiting ALDH2 expression
US20210363587A1 (en) * 2018-02-07 2021-11-25 St. Jude Children's Research Hospital EPIGENETIC HISTONE REGULATION MEDIATED BY CXorf67
KR20200108315A (en) 2018-02-09 2020-09-17 제넨테크, 인크. Oligonucleotide to regulate the expression of TMEM106B
WO2019169243A1 (en) 2018-03-02 2019-09-06 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-beta precursor protein
MX2020009072A (en) * 2018-03-02 2020-10-08 Dicerna Pharmaceuticals Inc Compositions and methods for inhibiting gys2 expression.
TWI840345B (en) 2018-03-02 2024-05-01 美商Ionis製藥公司 Modulators of irf4 expression
EP3765094A4 (en) * 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
AU2019239971B2 (en) * 2018-03-21 2025-09-11 Regeneron Pharmaceuticals, Inc. 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof
WO2019183440A1 (en) 2018-03-22 2019-09-26 Ionis Pharmaceuticals, Inc. Methods for modulating fmr1 expression
US11648260B2 (en) * 2018-03-29 2023-05-16 Technion Research And Development Foundation Limitted Vesicles comprising a PTEN inhibitor and uses of same
US11365416B2 (en) 2018-04-11 2022-06-21 Ionis Pharmaceuticals, Inc. Modulators of EZH2 expression
EP3788144B1 (en) 2018-05-01 2025-09-24 The Children's Medical Center Corporation Enhanced bcl11a rnp / crispr delivery & editing using a 3xnls-cas9
US12350284B2 (en) 2018-05-02 2025-07-08 The Children's Medical Center Corporation BCL11A microRNAs for treating hemoglobinopathies
CA3098136A1 (en) 2018-05-09 2019-11-14 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing fxi expression
SG11202010215TA (en) 2018-05-09 2020-11-27 Ionis Pharmaceuticals Inc Compounds and methods for reducing atxn3 expression
JP7557378B2 (en) * 2018-06-14 2024-09-27 アイオーニス ファーマシューティカルズ， インコーポレーテッド Compounds and methods for increasing STMN2 expression
NO344698B1 (en) * 2018-06-15 2020-03-09 Patogen As Novel fish virus
AU2019291050A1 (en) 2018-06-22 2020-12-24 F. Hoffmann-La Roche Ag Oligonucleotides for modulating SCN9A expression
TWI833770B (en) 2018-06-27 2024-03-01 美商Ionis製藥公司 Compounds and methods for reducing lrrk2 expression
CN112567033A (en) 2018-07-03 2021-03-26 豪夫迈·罗氏有限公司 Oligonucleotides for modulating Tau expression
WO2020011653A1 (en) * 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting kynu
WO2020011744A2 (en) * 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers5
EP3823725A4 (en) 2018-07-17 2023-05-10 Aronora, Inc. METHODS OF SAFELY REDUCING THROMBOPOIETIN
JOP20210018A1 (en) 2018-07-25 2021-01-21 Ionis Pharmaceuticals Inc Compounds and Methods to Reduce Genetic Expression of ATXN2
EP3598995A1 (en) * 2018-07-26 2020-01-29 Silence Therapeutics GmbH Products and compositions
KR20210081324A (en) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. Muscle targeting complexes and their use for treating facioscapulohumeral muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP3833763A4 (en) 2018-08-10 2023-07-19 University of Massachusetts MODIFIED OLIGONUCLEOTIDES TARGETING SNPs
TW202023574A (en) 2018-08-13 2020-07-01 美商阿尼拉製藥公司 Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
WO2020037076A1 (en) * 2018-08-14 2020-02-20 Emory University Inducing proliferation of cardiomyocytes and therapeutic uses related thereto
CN111655849B (en) 2018-08-21 2024-05-10 苏州瑞博生物技术股份有限公司 Nucleic acid, pharmaceutical composition and conjugate containing the nucleic acid and use thereof
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN109085365B (en) * 2018-08-27 2020-06-23 山东农业大学 Blocking agent for inhibiting highly pathogenic porcine reproductive and respiratory syndrome virus infection
EP3844278A4 (en) * 2018-08-27 2022-05-25 North Carolina State University TARGETING KIT BY SPLICING SWITCHING OLIGONUCLEOTIDES TO INDUCE MASTOCYTE APOPTOSIS
EP3843791A4 (en) * 2018-08-31 2023-08-02 University of Florida Research Foundation, Incorporated ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF BEST DISEASE
WO2020055917A1 (en) * 2018-09-10 2020-03-19 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating cln3 expression
CN111655297A (en) 2018-09-30 2020-09-11 苏州瑞博生物技术有限公司 siRNA conjugate and preparation method and application thereof
WO2020071392A1 (en) * 2018-10-02 2020-04-09 小胞体ストレス研究所株式会社 Proliferation inhibitor of poor-prognosis cancer cells
SG11202103938UA (en) * 2018-11-02 2021-05-28 Biomarin Tech Bv Bispecific antisense oligonucleotides for dystrophin exon skipping
TW202028222A (en) 2018-11-14 2020-08-01 美商Ionis製藥公司 Modulators of foxp3 expression
EA202191342A1 (en) 2018-11-15 2021-08-10 Айонис Фармасьютикалз, Инк. IRF5 EXPRESSION MODULATORS
MY205095A (en) 2018-11-21 2024-10-01 Ionis Pharmaceuticals Inc Compounds and methods for reducing prion expression
EP3884051A2 (en) * 2018-11-23 2021-09-29 Sanofi Novel rna compositions and methods for inhibiting angptl8
CN111228289A (en) * 2018-11-28 2020-06-05 中国科学院大连化学物理研究所 Application of PLIN2 inhibitor and medicine mixture for treating tumor
ES2766950A1 (en) * 2018-12-14 2020-06-15 Consejo Superior Investigacion ARHGEF6 as a pharmaceutical target for neurological disorders (Machine-translation by Google Translate, not legally binding)
ES2766855A1 (en) * 2018-12-14 2020-06-15 Consejo Superior Investigacion Rhoq as a pharmaceutical target for neurological disorders (Machine-translation by Google Translate, not legally binding)
KR102875569B1 (en) 2018-12-20 2025-10-23 암젠 인크 KIF18A inhibitor
IL312067B2 (en) 2018-12-21 2025-08-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
CN112423794A (en) 2018-12-28 2021-02-26 苏州瑞博生物技术股份有限公司 Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application
US11452738B2 (en) * 2019-01-04 2022-09-27 Empirico Inc. Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
CN113613661B (en) 2019-01-09 2025-11-14 箭头药业股份有限公司 RNAi reagents for inhibiting HIF-2α (EPAS1) expression, their compositions and methods of use
EP3908328A1 (en) 2019-01-10 2021-11-17 BioNTech RNA Pharmaceuticals GmbH Localized administration of rna molecules for therapy
CN113454223B (en) * 2019-01-15 2024-09-13 柏业公司 DKK1 gene-targeted double-stranded oligonucleotide, construct comprising same, and hair loss prevention or hair growth composition comprising same
JP2022523467A (en) 2019-01-18 2022-04-25 ユニバーシティ・オブ・マサチューセッツ Anchors that modify dynamic pharmacokinetics
MX2021008918A (en) 2019-01-31 2021-08-24 Ionis Pharmaceuticals Inc Modulators of yap1 expression.
CA3131700A1 (en) * 2019-02-27 2020-09-03 Ionis Pharmaceuticals, Inc. Modulators of malat1 expression
WO2020180645A1 (en) * 2019-03-01 2020-09-10 Meso Scale Technologies, Llc. Electrochemiluminescent labeled probes for use in immunoassay methods, methods using such and kits comprising same
CA3129782A1 (en) * 2019-03-15 2020-09-24 Charles E. Murry Improved survival of human cells differentiated <i>in vitro</i> by prpf31 gene expression knockdown
CA3133241A1 (en) * 2019-03-15 2020-09-24 University Of Massachusetts Oligonucleotides for tissue specific apoe modulation
PL3947684T3 (en) 2019-03-29 2025-07-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating ube3a-ats
CN114007654A (en) 2019-04-17 2022-02-01 阿迪根有限公司 Peptides and nanoparticles for intracellular delivery of molecules
WO2020214820A2 (en) * 2019-04-18 2020-10-22 University Of Massachusetts Aim2 inhibitors and uses thereof
AU2020263487A1 (en) 2019-04-25 2021-12-16 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
CN111849968A (en) * 2019-04-30 2020-10-30 中美瑞康核酸技术(南通)研究院有限公司 Oligonucleotide molecule and application thereof in acute intermittent porphyria treatment
WO2020225813A1 (en) 2019-05-05 2020-11-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Restoration of the cftr function by splicing modulation
EP3969032A1 (en) 2019-05-15 2022-03-23 University Of Miami Treatment of heart disease by disruption of the anchoring of pp2a
TW202517786A (en) 2019-05-22 2025-05-01 大陸商蘇州瑞博生物技術股份有限公司 Nucleic acid, pharmaceutical composition and conjugate containing the same and use thereof
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
CN113891939B (en) * 2019-05-24 2024-04-02 苏州瑞博生物技术股份有限公司 Nucleic acid, pharmaceutical composition and conjugate, and preparation method and application thereof
EP3978609A4 (en) * 2019-05-24 2024-02-07 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
EP3976059A4 (en) * 2019-05-24 2024-09-11 Empirico Inc. TREATMENT OF DISEASES ASSOCIATED WITH ANGIOPOIETIN 7 (ANGPTL7)
US20220251567A1 (en) * 2019-07-10 2022-08-11 Inserm (Institut National De La Santè Et De La Recherche Médicale) Methods for the treatment of epilepsy
HRP20251033T1 (en) 2019-07-26 2025-10-24 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gfap
EP4005602A4 (en) 2019-07-30 2024-06-12 Shionogi & Co., Ltd Nucleic acid drug targeting murf1
BR112022002307A2 (en) 2019-08-09 2022-06-28 Univ Massachusetts CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING SNPS
AU2020329191B2 (en) 2019-08-12 2025-12-04 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
JP2022550670A (en) * 2019-08-23 2022-12-05 ユニバーシティ オブ バージニア パテント ファウンデーション DDX17 and NLRC4 targeting for inflammatory diseases
EP4022065A4 (en) * 2019-08-30 2024-02-14 Baylor College Of Medicine METHOD FOR REGULATING GENE EXPRESSION
WO2021041846A1 (en) * 2019-08-30 2021-03-04 Inari Agriculture, Inc. Rna-guided nucleases and dna binding proteins
WO2021040627A1 (en) * 2019-08-30 2021-03-04 Agency For Science, Technology And Research A method of promoting survival and/or function of a motor neuron and related agents, uses and methods
EP3791930A1 (en) * 2019-09-13 2021-03-17 Secarna Pharmaceuticals GmbH & Co. KG Inhibitor of metadherin expression
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
KR102100163B1 (en) * 2019-09-24 2020-04-13 테고사이언스 (주) Compositions of Prevention or Treatment of Keloid or Hypertrophic scar
EP4045031A4 (en) * 2019-10-16 2023-11-29 Brown University MUSCLE REGENERATION AND GROWTH
JP7676377B2 (en) 2019-10-22 2025-05-14 アルナイラム ファーマシューティカルズ， インコーポレイテッド Complement component C3 iRNA compositions and methods of use thereof
TW202130809A (en) * 2019-10-29 2021-08-16 美商愛羅海德製藥公司 Rnai agents for inhibiting expression of beta-enac, compositions thereof, and methods of use
WO2021087325A1 (en) * 2019-11-01 2021-05-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
WO2021092459A1 (en) * 2019-11-08 2021-05-14 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing spdef expression
JP2023501352A (en) * 2019-11-08 2023-01-18 アイオーニス ファーマシューティカルズ， インコーポレーテッド Compounds and methods for reducing SPDEF expression
CN110859960B (en) * 2019-11-26 2022-03-04 深圳先进技术研究院 Application of AMPK-targeting inhibitor/siRNA in combination with proteasome inhibitor in the preparation of antitumor drugs
CA3164050A1 (en) * 2019-12-09 2021-06-17 Empirico Inc. Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases
JP7797388B2 (en) 2019-12-16 2026-01-13 アルナイラム ファーマシューティカルズ， インコーポレイテッド Patatin-like phospholipase domain-containing 3 (PNPLA3) iRNA compositions and methods of use
AR120817A1 (en) * 2019-12-20 2022-03-23 Hoffmann La Roche ENHANCED OLIGONUCLEOTIDES TO INHIBIT SCN9A EXPRESSION
MX2022007669A (en) * 2019-12-23 2022-07-19 Versameb Ag Compositions and methods for simultaneously modulating expression of genes.
AU2020415455A1 (en) * 2019-12-23 2022-07-14 University Of Massachusetts Oligonucleotides for tissue specific gene expression modulation
WO2021137506A1 (en) * 2019-12-31 2021-07-08 한국원자력연구원 Composition for inhibiting growth of cancer stem cells, containing wdr34 inhibitor, and use thereof
EP4103198A1 (en) 2020-02-11 2022-12-21 Turun yliopisto Therapy of ras-dependent cancers
CN115397989A (en) 2020-02-18 2022-11-25 阿尔尼拉姆医药品有限公司 Apolipoprotein C3 (APOC 3) iRNA compositions and methods of use thereof
JP2023515424A (en) * 2020-02-21 2023-04-13 レプリコール インコーポレーティッド Methods and compositions for inhibiting hepatitis B and hepatitis D virus infection
CN115279379B (en) 2020-02-28 2025-05-09 Ionis制药公司 Compounds and methods for modulating SMN2
EP4110913A4 (en) * 2020-02-28 2024-07-24 University of Massachusetts OLIGONUCLEOTIDES FOR PRNP MODULATION
CA3174725A1 (en) * 2020-03-06 2021-09-10 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
US20230124616A1 (en) * 2020-03-06 2023-04-20 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating kcnq2
IL296387B2 (en) 2020-03-19 2024-08-01 Avidity Biosciences Inc Compositions and methods of treating facioscapulohumeral muscular dystrophy
CN113444723A (en) * 2020-03-27 2021-09-28 北京键凯科技股份有限公司 Interfering RNA for inhibiting vascular endothelial growth factor receptor 2 gene expression and application thereof
KR20220161378A (en) 2020-03-27 2022-12-06 어비디티 바이오사이언시스 인크. Compositions and methods for the treatment of muscular dystrophy
US20230126881A1 (en) * 2020-03-27 2023-04-27 Alnylam Pharmaceuticals, Inc. Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CA3177740A1 (en) * 2020-04-14 2021-10-21 Amgen Inc. Kif18a inhibitors for treatment of neoplastic diseases
KR20230005933A (en) 2020-05-01 2023-01-10 아이오니스 파마수티컬즈, 인코포레이티드 Compounds and methods that modulate ATXN1
BR112022022889A2 (en) * 2020-05-11 2023-04-04 Stoke Therapeutics Inc OPA1 ANTI-SENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
JP2023526267A (en) * 2020-05-13 2023-06-21 エフ． ホフマン－ラ ロシュ アーゲー Progranulin Targeting Oligonucleotide Agonists
EP4150093A4 (en) * 2020-05-14 2024-06-19 Ariz Precision Medicine, Inc. Cancer treatment using sirna to modulate expression of prdm2/riz protein
CN111714510B (en) * 2020-05-18 2021-07-06 北京航空航天大学 Application of long non-coding RNA SNHG12 inhibitors in the preparation of anti-osteoporosis drugs
US20230183707A1 (en) * 2020-05-21 2023-06-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
WO2021252523A2 (en) * 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4649951A2 (en) * 2020-06-09 2025-11-19 Alnylam Pharmaceuticals, Inc. Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
EP4165185A4 (en) * 2020-06-11 2025-09-10 Genetic Intelligence Inc New York Ny COMPOSITIONS FOR FN GENE MODULATION AND METHODS THEREFOR
US11459567B2 (en) 2020-06-24 2022-10-04 Patricia Virginia Elizalde Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer
CN116096899A (en) 2020-06-29 2023-05-09 Ionis制药公司 Compounds and methods for modulating PLP1
CA3186853A1 (en) * 2020-07-23 2022-01-27 John Mansell Compositions and methods for treating pain and anxiety disorders
US12384814B2 (en) 2020-07-28 2025-08-12 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing app expression
EP4201484A4 (en) * 2020-07-28 2024-10-02 KNC Laboratories Co., Ltd. ANTISENSE NUCLEIC ACID INDUCING EXON SKIPPING OF AN ANGIOTENSIN 2 CONVERTING ENZYME GENE
WO2022031591A2 (en) * 2020-08-03 2022-02-10 University Of Massachusetts Oligonucleotides for htt-1a modulation
TW202221121A (en) * 2020-08-04 2022-06-01 美商黛瑟納製藥公司 Compositions and methods for inhibiting plp1 expression
IL300258A (en) 2020-08-07 2023-03-01 Ionis Pharmaceuticals Inc Compounds and methods for modulating scn2a
CN116096382A (en) * 2020-08-13 2023-05-09 内华达研究与创新公司 KLF11 siRNA for treating diabetes and obesity
US20240229025A1 (en) * 2020-09-09 2024-07-11 Ohara Pharmaceutical Co., Ltd. siRNA AND USE THEREOF
TW202227627A (en) * 2020-09-11 2022-07-16 美商愛羅海德製藥公司 Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
AU2021345266A1 (en) 2020-09-17 2023-04-27 Q-State Biosciences, Inc. Therapeutic compositions for treating pain via multiple targets
WO2022071367A1 (en) * 2020-09-30 2022-04-07 富士フイルム株式会社 Double-stranded rna that inhibits production of hepatitis b virus protein, and pharmaceutical composition
WO2022089486A1 (en) * 2020-10-28 2022-05-05 江苏柯菲平医药股份有限公司 Sirna for inhibiting pcsk9 gene expression and modifier thereof and use thereof
EP4244359A4 (en) * 2020-11-13 2025-05-21 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation B-SPECTRIN (SPTBN1) DEFICIENCY PROTECTS MICE AGAINST HIGH-FAT DIET-INDUCED LIVER DISEASE AND CANCER DEVELOPMENT
IL302709A (en) 2020-11-13 2023-07-01 Alnylam Pharmaceuticals Inc COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CN116615540B (en) 2020-11-18 2025-03-21 Ionis制药公司 Compounds and methods for modulating angiotensinogen expression
CN116583290A (en) * 2020-12-07 2023-08-11 奥利克斯医药有限公司 Nucleic acid molecule for inducing asymmetric RNAi inhibiting ROR-β expression
CA3205040A1 (en) 2020-12-18 2022-06-23 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating factor xii
KR20230154026A (en) * 2021-02-08 2023-11-07 락티젠 세러퓨틱스 Multivalent oligonucleotide agents and methods of use thereof
TW202302849A (en) 2021-03-04 2023-01-16 美商艾拉倫製藥股份有限公司 Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
WO2022197953A2 (en) * 2021-03-17 2022-09-22 Sirnaomics, Inc. Methods of cancer treatment by delivery of sirnas against nsd3
EP4313076A4 (en) * 2021-03-26 2025-02-05 Alnylam Pharmaceuticals, Inc. COMPOSITIONS OF RNAI AGENTS TARGETING VERY LONG CHAIN FATTY ACID ELONGATION PROTEIN 1 (ELOVL1) AND METHODS OF USE THEREOF
WO2022212208A1 (en) * 2021-03-29 2022-10-06 University Of Massachusetts Oligonucleotides for syngr-3 modulation
EP4319765A1 (en) 2021-04-08 2024-02-14 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
EP4323063A4 (en) * 2021-04-16 2025-05-14 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS FOR THE TREATMENT OF H-ABC LEUKODYSTROPHY
MX2023012086A (en) 2021-04-19 2023-10-25 Novo Nordisk As Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression.
WO2022226377A1 (en) * 2021-04-22 2022-10-27 Molecular Axiom, Llc Compositions and methods for modulating sos gene expressions
IL307926A (en) 2021-04-26 2023-12-01 Alnylam Pharmaceuticals Inc Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
EP4347836A4 (en) * 2021-05-27 2025-11-26 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHOD FOR TURNING OFF THE EXPRESSION OF CARBON ANHYDRASE 2
IL308883A (en) * 2021-05-28 2024-01-01 Arrowhead Pharmaceuticals Inc RNAi agents for suppressing myocin AC5 (MUC5AC) expression, their preparations and uses thereof
AR125992A1 (en) 2021-05-28 2023-08-30 Novo Nordisk As COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF MITOCHONDRIAL AMIDOXIMA REDUCTION COMPONENT 1 (MARC1)
WO2022256824A1 (en) * 2021-06-03 2022-12-08 The University Of Chicago Methods and compositions for treating fibrosis
US20240392299A1 (en) * 2021-06-16 2024-11-28 Empirico Inc. Treatment of mst1r related diseases and disorders
BR112023026050A2 (en) 2021-06-18 2024-03-05 Ionis Pharmaceuticals Inc COMPOUNDS AND METHODS TO REDUCE IFNAR1 EXPRESSION
BR112023026971A2 (en) * 2021-06-21 2024-03-12 Shanghai Junshi Biosciences Co Ltd SIRNA TO INHIBIT EXPRESSION OF THE ANGPTL3 GENE AND USES OF THE SAME
US11549112B1 (en) 2021-06-21 2023-01-10 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
CN113416776B (en) * 2021-06-21 2022-04-01 深圳市儿童医院 Biomarker for detecting ventricular septal defect and application thereof
AU2022299169A1 (en) 2021-06-23 2024-02-08 Beth Israel Deaconess Medical Center, Inc. Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
US20240287521A1 (en) * 2021-06-25 2024-08-29 Stichting Radboud Universitair Medisch Centrum Allele-specific silencing therapy for DFNA21 using antisense oligonucleotides
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
KR20240035563A (en) 2021-07-17 2024-03-15 서나오믹스, 인크. Products and Compositions
MX2024001194A (en) 2021-08-03 2024-02-27 Alnylam Pharmaceuticals Inc Transthyretin (ttr) irna compositions and methods of use thereof.
BR112024001923A2 (en) * 2021-08-13 2024-04-30 Alnylam Pharmaceuticals Inc FACTOR XII (F12) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP2024534840A (en) 2021-08-26 2024-09-26 ヴォラストラ セラピューティクス，インコーポレーテッド Spiroindoline inhibitors of KIF18A
MX2024002440A (en) * 2021-08-31 2024-03-08 Alnylam Pharmaceuticals Inc DNA FRAGMENTATION FACTOR SUBUNIT ALPHA-LIKE (DFFA) INTERFERING RIBONUCLEIC ACID (iRNA) COMPOSITIONS THAT INDUCE CELL DEATH (CIDEB) AND METHODS OF USING THEM.
WO2023034870A2 (en) 2021-09-01 2023-03-09 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing dmpk expression
IL311452A (en) 2021-09-16 2024-05-01 Avidity Biosciences Inc Compositions and methods for the treatment of FSHD muscular dystrophy
US12043832B2 (en) * 2021-09-16 2024-07-23 Washington University Methods and compositions for reducing pathogenic isoforms
WO2023056240A2 (en) 2021-09-28 2023-04-06 Frontaim Biomedicines, Inc. Multiple formats of molecular complexes
IL311518A (en) 2021-10-01 2024-05-01 Adarx Pharmaceuticals Inc Prekallikrein-modulating compositions and methods of use thereof
MX2024004750A (en) 2021-10-29 2024-05-13 Alnylam Pharmaceuticals Inc Complement factor b (cfb) irna compositions and methods of use thereof.
WO2023076450A2 (en) * 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
US20230167447A1 (en) * 2021-11-30 2023-06-01 Genetic Intelligence, Inc Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof
EP4444885A2 (en) * 2021-12-07 2024-10-16 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing mylip
WO2023122805A1 (en) 2021-12-20 2023-06-29 Vestaron Corporation Sorbitol driven selection pressure method
KR20240126870A (en) 2021-12-22 2024-08-21 캠프4 테라퓨틱스 코포레이션 Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
WO2023129496A2 (en) * 2021-12-27 2023-07-06 Apellis Pharmaceuticals, Inc. Rnas for complement inhibition
US20230377140A1 (en) * 2022-02-01 2023-11-23 4D Path Inc. Systems and Methods for Image-Based Disease Characterization
EP4493570A2 (en) 2022-03-16 2025-01-22 Empirico Inc. Galnac compositions for improving sirna bioavailability
AU2023245603A1 (en) 2022-03-28 2024-11-07 Empirico Inc. Modified oligonucleotides
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
US20240035027A1 (en) * 2022-05-04 2024-02-01 University Of Massachusetts Oligonucleotides for pms2 modulation
WO2023220566A1 (en) * 2022-05-09 2023-11-16 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
CN119451683A (en) * 2022-05-10 2025-02-14 艾米利克斯制药公司 Oligonucleotide compositions and methods thereof
WO2023250368A2 (en) * 2022-06-24 2023-12-28 Eli Lilly And Company Atxn2 rna interference agents
PE20250754A1 (en) * 2022-07-25 2025-03-13 Amgen Inc RNAI constructs and methods to inhibit FAM13A expression
CN116042822A (en) * 2022-09-16 2023-05-02 湖南灵康医疗科技有限公司 Application of ZNF32 to regulation of expression of CCND1 gene in resisting colorectal cancer chemotherapy drug resistance
US12152052B2 (en) 2022-09-23 2024-11-26 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing MECP2 expression
CN116004543B (en) * 2022-09-26 2025-03-11 南通大学 Application of TRAF6 inhibitor in preparation of medicines for treating human malignant melanoma
CN115844919B (en) * 2022-09-28 2025-09-09 李永 Double-nucleic acid sequence for inhibiting melanoma growth and application thereof
WO2024076934A2 (en) * 2022-10-03 2024-04-11 Cystic Fibrosis Foundation Compositions and methods for modulation of cftr
WO2024104663A1 (en) 2022-11-16 2024-05-23 Unilever Ip Holdings B.V. Method of reducing malodour
CN120603949A (en) * 2022-12-07 2025-09-05 加利福尼亚大学董事会 Inhibitory nucleic acids and methods of use thereof
EP4634391A2 (en) 2022-12-15 2025-10-22 Empirico Inc. Treatment of mst1 related diseases and disorders
AU2023417630A1 (en) * 2022-12-29 2025-05-15 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2024159113A1 (en) * 2023-01-27 2024-08-02 The Methodist Hospital Modulators of alternative polyadenylation and methods of use thereof
WO2024175586A2 (en) * 2023-02-21 2024-08-29 Vib Vzw Inhibitors of synaptogyrin-3 expression
WO2024187102A2 (en) * 2023-03-09 2024-09-12 Leal Therapeutics, Inc. Compositions and methods for modulating c3
CN121219020A (en) * 2023-03-22 2025-12-26 圣拉斐尔医院有限责任公司 Gene therapy
WO2024215825A1 (en) * 2023-04-14 2024-10-17 Avicenna Biotech Research, Llc Rna-based compositions and methods for treating breast cancer
WO2024229517A1 (en) * 2023-05-05 2024-11-14 Children's Medical Research Institute Methods of treating alt-dependent cancers
WO2024233966A2 (en) * 2023-05-10 2024-11-14 The General Hospital Corporation Modulating stromal and immune cells in atrial disease
WO2024245930A2 (en) * 2023-05-26 2024-12-05 E-Therapeutics Plc Inhibitors of expression and/or function
CN118272371A (en) * 2023-05-30 2024-07-02 北京大学 Short antisense oligonucleotides targeting PLIN2 gene and uses thereof
EP4562158A1 (en) 2023-06-13 2025-06-04 Arnatar Therapeutics, Inc Advanced rna targeting (arnatar) for angiotensinogen
CN116794325B (en) * 2023-06-15 2024-05-10 中山大学 Use of agents for knocking down or inhibiting SLC35F6 in the preparation of drugs for activating AMPK
WO2025006639A2 (en) 2023-06-27 2025-01-02 Avidity Biosciences, Inc. Compositions and methods of using prkag2-targeting antibody-oligonucleotide conjugates abstract
WO2025007063A1 (en) 2023-06-30 2025-01-02 Avidity Biosciences, Inc. Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
CN116898975A (en) * 2023-08-21 2023-10-20 中国福利会国际和平妇幼保健院 Application of YTHDC1 inhibitor in preparation of medicines for preventing and treating premature labor
TW202530408A (en) * 2023-09-29 2025-08-01 美商英西特羅公司 Compositions and methods for treating nonalcoholic fatty liver disease
CN117070583B (en) * 2023-10-16 2024-05-14 吉林凯莱英制药有限公司 Preparation method of siRNA for inhibiting PCSK9 gene expression
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025107242A1 (en) * 2023-11-23 2025-05-30 成都福实生物科技有限公司 Use of mechanical force-responsive macrophage subgroup in diagnostic or prognostic estimation for pancreatic cancer
CN117959445B (en) * 2024-02-04 2025-06-27 北京大学 Use of RNA binding protein inhibitors for the preparation of a medicament for inhibiting replication of chronic hepatitis B virus
EP4603586A1 (en) * 2024-02-16 2025-08-20 Universität zu Lübeck Inhibitory oligonucleotides against adamts7
WO2025226343A1 (en) * 2024-04-26 2025-10-30 Research Institute At Nationwide Children's Hospital Products and methods to inhibit expression of dynamin-1 variants and replace dynamin-1
WO2025231449A1 (en) * 2024-05-02 2025-11-06 Institute For Myeloma & Bone Cancer Research Prediction, diagnosis, and treatment of multiple myeloma
CN118624918B (en) * 2024-08-08 2024-11-15 中国医学科学院医药生物技术研究所 Application of host cell CXCR6 gene as an anti-flavivirus target in the preparation of anti-flavivirus drugs
CN120775978A (en) * 2025-03-14 2025-10-14 浙江省肿瘤医院 Screening method and application of papillary thyroid cancer early-stage prediction marker
CN120290720B (en) * 2025-04-11 2025-12-23 新疆医科大学第三附属医院 siRNA targeting the RPS4X gene, inhibitors of the LAMB3-PI3K-AKT signaling pathway, ovarian cancer drugs and their applications
CN120514724B (en) * 2025-07-24 2025-10-10 济南瑞隆安生物技术有限公司 Application of siRNA in preparation of postprandial hyperglycemia therapeutic preparation

Citations (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US647526A (en) * 1899-06-26 1900-04-17 William Allen Runyan Freight-car door.
US3719760A (en) * 1968-01-29 1973-03-06 Bayer Ag N-trityl-imidazolium salts as a fungicide
US3811449A (en) * 1972-03-08 1974-05-21 Becton Dickinson Co Dilating apparatus and method
US4350151A (en) * 1981-03-12 1982-09-21 Lone Star Medical Products, Inc. Expanding dilator
US4369790A (en) * 1981-03-05 1983-01-25 Mccarthy John M Catheter
US4401433A (en) * 1980-06-13 1983-08-30 Luther Ronald B Apparatus for advancing oversized catheter through cannula, and the like
US4449532A (en) * 1980-07-08 1984-05-22 Karl Storz Dilator to facilitate endoscope insertion into the body
US4451256A (en) * 1981-05-06 1984-05-29 Intermedicat Gmbh Catheter set
US4573448A (en) * 1983-10-05 1986-03-04 Pilling Co. Method for decompressing herniated intervertebral discs
US4601710A (en) * 1983-08-24 1986-07-22 Endotherapeutics Corporation Trocar assembly
US4686984A (en) * 1984-03-15 1987-08-18 Richard Wolf Gmbh Catheter for widening a puncture channel
US4802479A (en) * 1986-10-31 1989-02-07 C. R. Bard, Inc. Hand-held instrument for implanting, dispensing, and inflating an inflatable membrane
US4862891A (en) * 1988-03-14 1989-09-05 Canyon Medical Products Device for sequential percutaneous dilation
US4981482A (en) * 1987-08-20 1991-01-01 Kazuo Ichikawa Device for forming an inserting hole for an endoscope
US4994027A (en) * 1988-06-08 1991-02-19 Farrell Edward M Percutaneous femoral bypass system
US5002557A (en) * 1989-04-06 1991-03-26 Hasson Harrith M Laparoscopic cannula
US5114407A (en) * 1990-08-30 1992-05-19 Ethicon, Inc. Safety mechanism for trocar
US5176697A (en) * 1989-04-06 1993-01-05 Hasson Harrith M Laparoscopic cannula
US5176651A (en) * 1991-04-01 1993-01-05 Dexide, Inc. Combination surgical trocar housing and selective reducer sleeve assembly
US5183464A (en) * 1991-05-17 1993-02-02 Interventional Thermodynamics, Inc. Radially expandable dilator
US5188118A (en) * 1990-11-07 1993-02-23 Terwilliger Richard A Automatic biopsy instrument with independently actuated stylet and cannula
US5195506A (en) * 1991-10-18 1993-03-23 Life Medical Products, Inc. Surgical retractor for puncture operation
US5224952A (en) * 1988-07-06 1993-07-06 Ethicon, Inc. Safety trocar
US5241972A (en) * 1991-05-03 1993-09-07 Meditron Devices, Inc. Method for debulking tissue to remove pressure on a nerve
US5280782A (en) * 1991-11-15 1994-01-25 Wilk Peter J Variable length laparoscopic retractor and associated method of use
US5290243A (en) * 1992-07-16 1994-03-01 Technalytics, Inc. Trocar system
US5312417A (en) * 1992-07-29 1994-05-17 Wilk Peter J Laparoscopic cannula assembly and associated method
US5324261A (en) * 1991-01-04 1994-06-28 Medtronic, Inc. Drug delivery balloon catheter with line of weakness
US5342382A (en) * 1991-01-15 1994-08-30 Ethicon, Inc. Surgical trocar
US5407430A (en) * 1994-03-21 1995-04-18 Peters; Michael J. Intravenous catheter
US5486190A (en) * 1991-04-30 1996-01-23 United States Surgical Corporation Safety trocar
US5505710A (en) * 1994-08-22 1996-04-09 C. R. Bard, Inc. Telescoping probe
US5512037A (en) * 1994-05-12 1996-04-30 United States Surgical Corporation Percutaneous surgical retractor
US5613950A (en) * 1988-07-22 1997-03-25 Yoon; Inbae Multifunctional manipulating instrument for various surgical procedures
US5624447A (en) * 1995-03-20 1997-04-29 Othy, Inc. Surgical tool guide and entry hole positioner
US5647857A (en) * 1995-03-16 1997-07-15 Endotex Interventional Systems, Inc. Protective intraluminal sheath
US5707359A (en) * 1995-11-14 1998-01-13 Bufalini; Bruno Expanding trocar assembly
US5713870A (en) * 1991-11-27 1998-02-03 Yoon; Inbae Retractable safety penetrating instrument with laterally extendable spring strip
US5728097A (en) * 1992-03-17 1998-03-17 Sdgi Holding, Inc. Method for subcutaneous suprafascial internal fixation
US5743881A (en) * 1995-11-03 1998-04-28 Aptec Medical Corporation Laparoscopic surgical instrument and method of using same
US5752969A (en) * 1993-06-17 1998-05-19 Sofamor S.N.C. Instrument for the surgical treatment of an intervertebral disc by the anterior route
US5772678A (en) * 1995-10-20 1998-06-30 Inlet Medical, Inc. Retractable disposable tip reusable trocar obturator
US5776156A (en) * 1995-09-05 1998-07-07 United States Surgical Corporation Endoscopic cutting instrument
US5782800A (en) * 1988-07-22 1998-07-21 Yoon; Inbae Expandable multifunctional manipulating instruments for various medical procedures and methods therefor
US5792044A (en) * 1996-03-22 1998-08-11 Danek Medical, Inc. Devices and methods for percutaneous surgery
US5810866A (en) * 1991-11-27 1998-09-22 Yoon; Inbae Automatic retractable safety penetrating instrument for portal sleeve introduction
US5810721A (en) * 1996-03-04 1998-09-22 Heartport, Inc. Soft tissue retractor and method for providing surgical access
US5957902A (en) * 1998-09-28 1999-09-28 Teves; Leonides Y. Surgical tool for enlarging puncture opening made by trocar
US6030364A (en) * 1997-10-03 2000-02-29 Boston Scientific Corporation Apparatus and method for percutaneous placement of gastro-intestinal tubes
US6048309A (en) * 1996-03-04 2000-04-11 Heartport, Inc. Soft tissue retractor and delivery device therefor
US6053935A (en) * 1996-11-08 2000-04-25 Boston Scientific Corporation Transvaginal anchor implantation device
US6117174A (en) * 1998-09-16 2000-09-12 Nolan; Wesley A. Spinal implant device
US6197041B1 (en) * 1991-06-26 2001-03-06 United States Surgical Corporation Trocar
US6200322B1 (en) * 1999-08-13 2001-03-13 Sdgi Holdings, Inc. Minimal exposure posterior spinal interbody instrumentation and technique
US6206922B1 (en) * 1995-03-27 2001-03-27 Sdgi Holdings, Inc. Methods and instruments for interbody fusion
US6206826B1 (en) * 1997-12-18 2001-03-27 Sdgi Holdings, Inc. Devices and methods for percutaneous surgery
US6213957B1 (en) * 1995-09-08 2001-04-10 United States Surgical Corporation Apparatus and method for removing tissue
US6217509B1 (en) * 1996-03-22 2001-04-17 Sdgi Holdings, Inc. Devices and methods for percutaneous surgery
US6228058B1 (en) * 1997-04-03 2001-05-08 Core Dynamics, Inc. Sleeve trocar with penetration indicator
US6264676B1 (en) * 1996-11-08 2001-07-24 Scimed Life Systems, Inc. Protective sheath for transvaginal anchor implantation devices
US20010012950A1 (en) * 1997-10-01 2001-08-09 Srinivas Nishtala Dilation systems and related methods
US6293909B1 (en) * 1998-08-07 2001-09-25 Scimed Life Systems, Inc. Device and method of using a surgical assembly with mesh sheath
US6293952B1 (en) * 1997-07-31 2001-09-25 Circon Corporation Medical instrument system for piercing through tissue
US20020001476A1 (en) * 1998-06-26 2002-01-03 Tomoyuki Nagamine Image forming apparatus
US6348053B1 (en) * 1996-11-12 2002-02-19 Triage Medical, Inc. Bone fixation device
US6364897B1 (en) * 1993-02-04 2002-04-02 Peter M. Bonutti Method and apparatus for positioning a suture anchor
US20020087152A1 (en) * 2001-01-04 2002-07-04 Endocare, Inc. Systems and methods for delivering a probe into tissue
US6428541B1 (en) * 1998-04-09 2002-08-06 Sdgi Holdings, Inc. Method and instrumentation for vertebral interbody fusion
US6428556B1 (en) * 1999-08-25 2002-08-06 Origin Medsystems, Inc. Longitudinal dilator and method
US6447540B1 (en) * 1996-11-15 2002-09-10 Cook Incorporated Stent deployment device including splittable sleeve containing the stent
US6447527B1 (en) * 1998-04-23 2002-09-10 Ronald J. Thompson Apparatus and methods for the penetration of tissue
US6511481B2 (en) * 2001-03-30 2003-01-28 Triage Medical, Inc. Method and apparatus for fixation of proximal femoral fractures
US20030083688A1 (en) * 2001-10-30 2003-05-01 Simonson Robert E. Configured and sized cannula
US6562049B1 (en) * 2000-03-01 2003-05-13 Cook Vascular Incorporated Medical introducer apparatus
US6562046B2 (en) * 1999-11-23 2003-05-13 Sdgi Holdings, Inc. Screw delivery system and method
US6582437B2 (en) * 1999-08-26 2003-06-24 Sdgi Holdings, Inc. Devices and methods for implanting fusion cages
US6582441B1 (en) * 2000-02-24 2003-06-24 Advanced Bionics Corporation Surgical insertion tool
US6589240B2 (en) * 2001-08-28 2003-07-08 Rex Medical, L.P. Tissue biopsy apparatus with collapsible cutter
US6592553B2 (en) * 2000-07-05 2003-07-15 Cardiac Pacemakers, Inc. Introducer assembly and method therefor
US6607530B1 (en) * 1999-05-10 2003-08-19 Highgate Orthopedics, Inc. Systems and methods for spinal fixation
US6679833B2 (en) * 1996-03-22 2004-01-20 Sdgi Holdings, Inc. Devices and methods for percutaneous surgery
US20040019359A1 (en) * 2002-07-24 2004-01-29 Worley Seth J. Telescopic introducer with a compound curvature for inducing alignment and method of using the same
US6685706B2 (en) * 2001-11-19 2004-02-03 Triage Medical, Inc. Proximal anchors for bone fixation system
US6689152B2 (en) * 1998-09-09 2004-02-10 Edwards Lifesciences Corp. Introducer/dilator with balloon protection and methods of use
US20040059350A1 (en) * 1992-09-04 2004-03-25 Scimed Life Systems, Inc. Suturing instruments and methods of use
US20040059339A1 (en) * 2002-09-19 2004-03-25 Roehm Thomas E. Oval dilator and retractor set and method
US6743166B2 (en) * 1999-02-12 2004-06-01 Karl Storz Gmbh & Co. Kg Apparatus for introducing an intubation tube into the trachea
US6746451B2 (en) * 2001-06-01 2004-06-08 Lance M. Middleton Tissue cavitation device and method
US20040147877A1 (en) * 2003-01-27 2004-07-29 Heuser Richard R Catheter introducer system
US20040158258A1 (en) * 2003-02-12 2004-08-12 Bonati Alfred O. Method for removing orthopaedic hardware
US7025746B2 (en) * 2001-12-26 2006-04-11 Yale University Vascular access device
US7172612B2 (en) * 2000-12-12 2007-02-06 Olympus Corporation Trocar and trocar system

Family Cites Families (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1541453A (en) * 1922-12-20 1925-06-09 Watkins Clayton Stuart Demountable rim and wheell for automobiles and other vehicles
US3260656A (en) * 1962-09-27 1966-07-12 Corning Glass Works Method and apparatus for electrolytically determining a species in a fluid
US3653841A (en) * 1969-12-19 1972-04-04 Hoffmann La Roche Methods and compositions for determining glucose in blood
US3719564A (en) * 1971-05-10 1973-03-06 Philip Morris Inc Method of determining a reducible gas concentration and sensor therefor
US3837339A (en) * 1972-02-03 1974-09-24 Whittaker Corp Blood glucose level monitoring-alarm system and method therefor
US4184429A (en) * 1972-02-09 1980-01-22 Max Datwyler & Co. Constant bevel doctor blade and method and apparatus using same
US3908657A (en) * 1973-01-15 1975-09-30 Univ Johns Hopkins System for continuous withdrawal of blood
US4100048A (en) * 1973-09-20 1978-07-11 U.S. Philips Corporation Polarographic cell
US3911901A (en) * 1974-07-24 1975-10-14 Gen Electric In vivo hydrogen ion sensor
US3972320A (en) * 1974-08-12 1976-08-03 Gabor Ujhelyi Kalman Patient monitoring system
US3979274A (en) * 1975-09-24 1976-09-07 The Yellow Springs Instrument Company, Inc. Membrane for enzyme electrodes
US4016866A (en) * 1975-12-18 1977-04-12 General Electric Company Implantable electrochemical sensor
US4055175A (en) * 1976-05-07 1977-10-25 Miles Laboratories, Inc. Blood glucose control apparatus
DE2625834B2 (en) * 1976-06-09 1978-10-12 Boehringer Mannheim Gmbh, 6800 Mannheim Method for the determination of substrates or enzyme activities
US4076596A (en) * 1976-10-07 1978-02-28 Leeds & Northrup Company Apparatus for electrolytically determining a species in a fluid and method of use
FR2387659A1 (en) * 1977-04-21 1978-11-17 Armines GLYCEMIA CONTROL AND REGULATION DEVICE
US4098574A (en) * 1977-08-01 1978-07-04 Eastman Kodak Company Glucose detection system free from fluoride-ion interference
JPS5912135B2 (en) * 1977-09-28 1984-03-21 松下電器産業株式会社 enzyme electrode
US4151845A (en) * 1977-11-25 1979-05-01 Miles Laboratories, Inc. Blood glucose control apparatus
DK151000C (en) * 1978-02-17 1988-06-13 Radiometer As PROCEDURE AND APPARATUS FOR DETERMINING A PATIENT'S IN VIVO PLASMA-PH VALUE
US4172770A (en) * 1978-03-27 1979-10-30 Technicon Instruments Corporation Flow-through electrochemical system analytical method
HU177369B (en) * 1978-09-08 1981-09-28 Radelkis Electrokemiai Industrial molecule-selective sensing device and method for producing same
US4247297A (en) * 1979-02-23 1981-01-27 Miles Laboratories, Inc. Test means and method for interference resistant determination of oxidizing substances
US4573994A (en) * 1979-04-27 1986-03-04 The Johns Hopkins University Refillable medication infusion apparatus
US4458686A (en) * 1979-08-02 1984-07-10 Children's Hospital Medical Center Cutaneous methods of measuring body substances
US4401122A (en) * 1979-08-02 1983-08-30 Children's Hospital Medical Center Cutaneous methods of measuring body substances
US4450842A (en) * 1980-04-25 1984-05-29 Cordis Corporation Solid state reference electrode
US4340458A (en) * 1980-06-02 1982-07-20 Joslin Diabetes Center, Inc. Glucose sensor
US4404066A (en) * 1980-08-25 1983-09-13 The Yellow Springs Instrument Company Method for quantitatively determining a particular substrate catalyzed by a multisubstrate enzyme
US4356074A (en) * 1980-08-25 1982-10-26 The Yellow Springs Instrument Company, Inc. Substrate specific galactose oxidase enzyme electrodes
US4352960A (en) * 1980-09-30 1982-10-05 Baptist Medical Center Of Oklahoma, Inc. Magnetic transcutaneous mount for external device of an associated implant
US4390621A (en) * 1980-12-15 1983-06-28 Miles Laboratories, Inc. Method and device for detecting glucose concentration
US4436094A (en) * 1981-03-09 1984-03-13 Evreka, Inc. Monitor for continuous in vivo measurement of glucose concentration
AT369254B (en) * 1981-05-07 1982-12-27 Otto Dipl Ing Dr Tech Prohaska MEDICAL PROBE
FR2508305B1 (en) * 1981-06-25 1986-04-11 Slama Gerard DEVICE FOR CAUSING A LITTLE BITE TO COLLECT A BLOOD DROP
US4440175A (en) * 1981-08-10 1984-04-03 University Patents, Inc. Membrane electrode for non-ionic species
DE3278334D1 (en) * 1981-10-23 1988-05-19 Genetics Int Inc Sensor for components of a liquid mixture
US4431004A (en) * 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
JPS58153154A (en) * 1982-03-09 1983-09-12 Ajinomoto Co Inc Qualified electrode
US4581336A (en) * 1982-04-26 1986-04-08 Uop Inc. Surface-modified electrodes
DE3221339A1 (en) * 1982-06-05 1983-12-08 Basf Ag, 6700 Ludwigshafen METHOD FOR THE ELECTROCHEMICAL HYDRATION OF NICOTINAMIDADENINE-DINUCLEOTIDE
US4427770A (en) * 1982-06-14 1984-01-24 Miles Laboratories, Inc. High glucose-determining analytical element
DE3228551A1 (en) * 1982-07-30 1984-02-02 Siemens AG, 1000 Berlin und 8000 München METHOD FOR DETERMINING SUGAR CONCENTRATION
US4534356A (en) * 1982-07-30 1985-08-13 Diamond Shamrock Chemicals Company Solid state transcutaneous blood gas sensors
US4571292A (en) * 1982-08-12 1986-02-18 Case Western Reserve University Apparatus for electrochemical measurements
US4461691A (en) * 1983-02-10 1984-07-24 The United States Of America As Represented By The United States Department Of Energy Organic conductive films for semiconductor electrodes
US4679562A (en) * 1983-02-16 1987-07-14 Cardiac Pacemakers, Inc. Glucose sensor
IT1170375B (en) * 1983-04-19 1987-06-03 Giuseppe Bombardieri APPARATUS THAT INFUSES INSULIN OR GLUCOSE IN THE DIABETIC SUBJECT ON THE BASIS OF DETERMINATIONS OF GLUCOSE CONCENTRATIONS OBTAINED WITHOUT THE NEED FOR PATIENT BLOOD COLLECTION
CA1218704A (en) * 1983-05-05 1987-03-03 Graham Davis Assay systems using more than one enzyme
US4650547A (en) * 1983-05-19 1987-03-17 The Regents Of The University Of California Method and membrane applicable to implantable sensor
US4524114A (en) * 1983-07-05 1985-06-18 Allied Corporation Bifunctional air electrode
US4538616A (en) * 1983-07-25 1985-09-03 Robert Rogoff Blood sugar level sensing and monitoring transducer
US4655880A (en) * 1983-08-01 1987-04-07 Case Western Reserve University Apparatus and method for sensing species, substances and substrates using oxidase
US4543955A (en) * 1983-08-01 1985-10-01 Cordis Corporation System for controlling body implantable action device
US4522690A (en) * 1983-12-01 1985-06-11 Honeywell Inc. Electrochemical sensing of carbon monoxide
EP0149339B1 (en) * 1983-12-16 1989-08-23 MediSense, Inc. Assay for nucleic acids
JPS60135756A (en) * 1983-12-24 1985-07-19 Ngk Insulators Ltd Production of electrochemical cell
EP0179823B1 (en) * 1984-04-30 1989-07-12 Stiftung, R. E. Process for the sensitization of an oxidoreduction photocalatyst, and photocatalyst thus obtained
DK8601218A (en) * 1984-07-18 1986-03-17
US4820399A (en) * 1984-08-31 1989-04-11 Shimadzu Corporation Enzyme electrodes
CA1254091A (en) * 1984-09-28 1989-05-16 Vladimir Feingold Implantable medication infusion system
US4721601A (en) * 1984-11-23 1988-01-26 Massachusetts Institute Of Technology Molecule-based microelectronic devices
US4717673A (en) * 1984-11-23 1988-01-05 Massachusetts Institute Of Technology Microelectrochemical devices
JPH0617889B2 (en) * 1984-11-27 1994-03-09 株式会社日立製作所 Biochemical sensor
GB8500729D0 (en) * 1985-01-11 1985-02-13 Hill H A O Surface-modified electrode
US4627445A (en) * 1985-04-08 1986-12-09 Garid, Inc. Glucose medical monitoring system
US4671288A (en) * 1985-06-13 1987-06-09 The Regents Of The University Of California Electrochemical cell sensor for continuous short-term use in tissues and blood
EP0230472B2 (en) * 1985-06-21 2000-12-13 Matsushita Electric Industrial Co., Ltd. Biosensor and method of manufacturing same
US4796634A (en) * 1985-08-09 1989-01-10 Lawrence Medical Systems, Inc. Methods and apparatus for monitoring cardiac output
US4805624A (en) * 1985-09-09 1989-02-21 The Montefiore Hospital Association Of Western Pa Low-potential electrochemical redox sensors
US4680268A (en) * 1985-09-18 1987-07-14 Children's Hospital Medical Center Implantable gas-containing biosensor and method for measuring an analyte such as glucose
US4890620A (en) * 1985-09-20 1990-01-02 The Regents Of The University Of California Two-dimensional diffusion glucose substrate sensing electrode
US4830959A (en) * 1985-11-11 1989-05-16 Medisense, Inc. Electrochemical enzymic assay procedures
GB8529300D0 (en) * 1985-11-28 1986-01-02 Ici Plc Membrane
US4776944A (en) * 1986-03-20 1988-10-11 Jiri Janata Chemical selective sensors utilizing admittance modulated membranes
US4685463A (en) * 1986-04-03 1987-08-11 Williams R Bruce Device for continuous in vivo measurement of blood glucose concentrations
US4726378A (en) * 1986-04-11 1988-02-23 Minnesota Mining And Manufacturing Company Adjustable magnetic supercutaneous device and transcutaneous coupling apparatus
US4757022A (en) * 1986-04-15 1988-07-12 Markwell Medical Institute, Inc. Biological fluid measuring device
US4909908A (en) * 1986-04-24 1990-03-20 Pepi Ross Electrochemical cncentration detector method
US4795542A (en) * 1986-04-24 1989-01-03 St. Jude Medical, Inc. Electrochemical concentration detector device
DE3614821A1 (en) * 1986-05-02 1987-11-05 Siemens Ag IMPLANTABLE, CALIBRABLE MEASURING DEVICE FOR A BODY SUBSTANCE AND CALIBRATION METHOD
CA1283447C (en) * 1986-06-20 1991-04-23 John W. Parce Zero volume electrochemical cell
DE3721799C2 (en) * 1986-07-01 1993-12-23 Mitsubishi Electric Corp Integrated redox component circuit and method of manufacture
US4917800A (en) * 1986-07-07 1990-04-17 Bend Research, Inc. Functional, photochemically active, and chemically asymmetric membranes by interfacial polymerization of derivatized multifunctional prepolymers
US4726716A (en) * 1986-07-21 1988-02-23 Mcguire Thomas V Fastener for catheter
US4894137A (en) * 1986-09-12 1990-01-16 Omron Tateisi Electronics Co. Enzyme electrode
DE3700119A1 (en) * 1987-01-03 1988-07-14 Inst Diabetestechnologie Gemei IMPLANTABLE ELECTROCHEMICAL SENSOR
US4848351A (en) * 1987-03-04 1989-07-18 Sentry Medical Products, Inc. Medical electrode assembly
US4759828A (en) * 1987-04-09 1988-07-26 Nova Biomedical Corporation Glucose electrode and method of determining glucose
US4822337A (en) * 1987-06-22 1989-04-18 Stanley Newhouse Insulin delivery method and apparatus
JPH07122624B2 (en) * 1987-07-06 1995-12-25 ダイキン工業株式会社 Biosensor
GB8718430D0 (en) * 1987-08-04 1987-09-09 Ici Plc Sensor
US4874500A (en) * 1987-07-15 1989-10-17 Sri International Microelectrochemical sensor and sensor array
US4815469A (en) * 1987-10-08 1989-03-28 Siemens-Pacesetter, Inc. Implantable blood oxygen sensor and method of use
US4813424A (en) * 1987-12-23 1989-03-21 University Of New Mexico Long-life membrane electrode for non-ionic species
US4923442A (en) * 1988-05-02 1990-05-08 Cryomedical Sciences Inc. Blood substitute
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
WO1991004753A1 (en) * 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
GB9123947D0 (en) * 1991-11-12 1992-01-02 Imp Cancer Res Tech Therapeutic compounds
JPH07509133A (en) * 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド Methods and agents for the treatment of animal diseases
US20040204380A1 (en) 1999-01-07 2004-10-14 Ackermann Elizabeth J Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US6001992A (en) 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US20020086321A1 (en) 1993-02-02 2002-07-04 Craig Ruth W. Myeloid cell leukemia associated gene MCL-1
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
EP0745124B1 (en) 1994-02-14 1998-06-17 Amgen Inc. Mammalian cell cycle protein
US6150092A (en) 1994-06-27 2000-11-21 Taogosei Company, Ltd. Antisense nucleic acid compound targeted to VEGF
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
WO1997021808A1 (en) * 1995-12-08 1997-06-19 Hybridon, Inc. Modified vegf antisense oligonucleotides
WO1997020925A1 (en) * 1995-12-08 1997-06-12 Hybridon, Inc. Modified vegf antisense oligonucleotides for treatment of skin disorders
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
WO1997039120A2 (en) * 1996-04-17 1997-10-23 Aronex Pharmaceuticals, Inc. Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression
US20050261485A1 (en) 1996-05-23 2005-11-24 Toagosei Co., Ltd., A Japan Corporation Method of producing antisense oligonucleotide
JP2000513230A (en) 1996-07-01 2000-10-10 エイ． ライト，ジム Oligonucleotides from the untranslated region of a housekeeping gene and methods of using the same to regulate cell growth
AU6237198A (en) * 1996-12-19 1998-07-15 Isis Pharmaceuticals, Inc. Large-scale purification of full length oligonucleotides by solid-liquid affinity extraction
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
JPH1142091A (en) * 1997-07-25 1999-02-16 Toagosei Co Ltd Anti-sense nucleic acid compound
WO1999010009A1 (en) * 1997-08-26 1999-03-04 Gliatech Inc. A process for inhibiting complement activation via the alternative pathway
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1053315A4 (en) 1998-01-29 2003-07-30 Univ Columbia GENE OF CALVITIS IN MEN, PROTEIN AND USES THEREOF
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
JP2002510487A (en) * 1998-04-03 2002-04-09 ウイスコンシン アラムニ リサーチ ファンデーション Mammalian tolloid-like genes and proteins
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
CA2334960C (en) * 1998-06-10 2012-01-03 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Combination of tgf-.beta. inhibition and immune stimulation to treat hyperproliferative diseases
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US20030096775A1 (en) * 2001-10-23 2003-05-22 Isis Pharmaceuticals Inc. Antisense modulation of complement component C3 expression
WO2000001393A2 (en) 1998-07-02 2000-01-13 The Trustees Of Columbia University In The City Of New York OLIGONUCLEOTIDE INHIBITORS OF bcl-xL
US6228642B1 (en) * 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
WO2000021559A2 (en) 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
DE69932346T2 (en) * 1998-10-26 2007-07-05 Avi Biopharma, Inc., Portland Morpholine-based p53 antisense oligonucleotide and its uses
CN1342077A (en) * 1998-11-06 2002-03-27 诺尔股份公司 Inhibition of formation of vascular hyperpermeability
US5958773A (en) 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
CA2371818C (en) * 1999-02-18 2009-01-06 The Regents Of The University Of California Salicylamide-lanthanide complexes for use as luminescent markers
WO2000061770A2 (en) * 1999-04-08 2000-10-19 Chiron Corporation Enhancement of the immune response for vaccine and gene therapy applications
ATE324888T1 (en) 1999-06-14 2006-06-15 Cancer Rec Tech Ltd CANCER THERAPY
US6770633B1 (en) * 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
PT1309726E (en) 2000-03-30 2010-03-08 Whitehead Biomedical Inst RNA INTERFERENCE-SPECIFIC RNA INTERFERENCE MEDIATORS
JP2004501637A (en) * 2000-06-26 2004-01-22 スージェン・インコーポレーテッド New protease
AU2002210295A1 (en) * 2000-10-13 2002-04-22 Institut De Cardiologie De Montreal Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
AU2002243429A1 (en) * 2000-10-24 2002-06-24 Isis Pharmaceuticals, Inc. Antisense modulation of tnfr1 expression
JP4195289B2 (en) 2000-11-01 2008-12-10 ビーケイアイ・ホールディング・コーポレーション Cellulose ether and method for producing the same
DE60130583T3 (en) 2000-12-01 2018-03-22 Europäisches Laboratorium für Molekularbiologie SMALL RNA MOLECULES TRANSFERRING RNA INTERFERENCE
US20030143597A1 (en) 2000-12-28 2003-07-31 Finney Robert E. Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis
US20020150945A1 (en) 2000-12-28 2002-10-17 Cell Therapeutics, Inc. Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis
EP1353676A4 (en) 2000-12-29 2006-05-31 Alteon Inc Method for treating fibrotic diseases or other indications
WO2003035869A1 (en) 2001-10-26 2003-05-01 Ribopharma Ag Use of a double-stranded ribonucleic acid for specifically inhibiting the expression of a given target gene
WO2002070657A2 (en) * 2001-03-01 2002-09-12 Millennium Pharmaceuticals, Inc. 93870, a human g-protein coupled receptor and uses therefor
US20030087259A1 (en) 2001-04-18 2003-05-08 Clancy Brian M. Methods and compositions for regulating bone and cartilage formation
WO2002085309A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
WO2002085308A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US20040219671A1 (en) 2002-02-20 2004-11-04 Sirna Therapeutics, Inc. RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
US20050227935A1 (en) 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050048529A1 (en) 2002-02-20 2005-03-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20050130181A1 (en) 2001-05-18 2005-06-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
US20050239731A1 (en) 2001-05-18 2005-10-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA)
WO2002097114A2 (en) 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
AU2002344237B8 (en) * 2001-05-29 2008-11-06 Sirna Therapeutics, Inc. Nucleic Acid Based Modulation of Female Reproductive Diseases and Conditions
MXPA04000224A (en) 2001-07-10 2005-07-25 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
US6734017B2 (en) * 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
JP4917225B2 (en) 2001-09-28 2012-04-18 ローム株式会社 Semiconductor device
WO2003035870A1 (en) 2001-10-26 2003-05-01 Ribopharma Ag Drug for treating a carcinoma of the pancreas
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
IL161733A0 (en) 2001-11-02 2005-11-20 Insert Therapeutics Inc Methods and compositions for therapeutic use of rna interference
FR2832154B1 (en) * 2001-11-09 2007-03-16 Centre Nat Rech Scient OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE
US20030186903A1 (en) 2001-11-23 2003-10-02 Isis Pharmaceuticals Inc. Antisense modulation of MyD88 expression
WO2003046176A2 (en) 2001-11-26 2003-06-05 Hybrigenics Protein-protein interactions in human immunodeficiency virus
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
GB0130955D0 (en) * 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
KR100441894B1 (en) * 2002-01-26 2004-07-27 한국전자통신연구원 Micro-integrated near-field optical recording head and optical recording system using the same
WO2003064626A2 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
EP1442143A4 (en) * 2002-02-20 2005-02-16 Sirna Therapeutics Inc INHIBITION OF RNA INTERFERENCE-INDUCED BCL2 GENE EXPRESSION USING SMALL INTERFERING NUCLEIC ACIDS (SINA)
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
EP1436314A4 (en) 2002-02-20 2005-08-10 Sirna Therapeutics Inc RNA MEDIATION INHIBITION OF GENE EXPRESSION OF CYCLIN D1 USING SHORT INTERFERENCE NUCLEIC ACID (SINA)
JP2005517433A (en) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド RNA interference-mediated inhibition of TNF and TNF receptor superfamily gene expression using short interfering nucleic acids (siNA)
US20040248296A1 (en) 2002-03-20 2004-12-09 Beresford Paul J. HIV therapeutic
WO2003085090A2 (en) 2002-03-29 2003-10-16 Yun Yen A human ribonucleotide reductase m2 subunit
US20030224512A1 (en) 2002-05-31 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of beta-site APP-cleaving enzyme expression
US20040006365A1 (en) 2002-05-13 2004-01-08 Salviac Limited Embolic protection system
US20040101857A1 (en) 2002-11-23 2004-05-27 Isis Pharmaceuticals Inc. Modulation of cytokine-inducible kinase expression
CA2525976A1 (en) 2002-05-23 2003-12-04 Ceptyr, Inc. Modulation of ptp1b signal transduction by rna interference
US20040102391A1 (en) 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Gankyrin expression
US20040101915A1 (en) 2002-06-18 2004-05-27 Irm Llc, A Delaware Limited Liability Company Diagnosis and treatment of chemoresistant tumors
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US6906186B1 (en) 2002-07-30 2005-06-14 Isis Pharmaceuticals, Inc. Antisense modulation of polo-like kinase expression
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
US20040137471A1 (en) 2002-09-18 2004-07-15 Timothy Vickers Efficient reduction of target RNA's by single-and double-stranded oligomeric compounds
JP2006517783A (en) 2002-09-30 2006-08-03 オンコセラピー・サイエンス株式会社 Genes and polypeptides related to human myeloid leukemia
WO2005013886A2 (en) 2002-10-30 2005-02-17 The Center For Blood Research, Inc. Methods for treating and preventing apoptosis-related diseases using rna interfering agents
US7521431B2 (en) 2002-11-01 2009-04-21 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
EP1567539B1 (en) 2002-11-04 2009-09-23 University of Massachusetts Allele-specific rna interference
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US7592442B2 (en) 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
EP1560931B1 (en) 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US7582747B2 (en) 2002-11-14 2009-09-01 Dharmacon, Inc. siRNA targeting inner centromere protein antigens (INCENP)
US20040214198A1 (en) 2002-11-15 2004-10-28 University Of Massachusetts Allele-targeted RNA interference
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
WO2004052920A2 (en) 2002-12-12 2004-06-24 The Burnham Institute Conversion of apoptotic proteins
US20040248299A1 (en) * 2002-12-27 2004-12-09 Sumedha Jayasena RNA interference
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
FR2835838B1 (en) * 2003-02-06 2007-11-16 Centre Nat Rech Scient OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE ENCODING A TRANSCRIPTION FACTOR
FR2835837B1 (en) * 2003-02-06 2007-03-16 Centre Nat Rech Scient INHIBITORY OLIGONUCLEOTIDES AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE ENCODING A GROWTH FACTOR
US20040191818A1 (en) 2003-02-26 2004-09-30 O'toole Margot Mary Compositions and methods for diagnosing and treating autoimmune diseases
EP1608733B1 (en) 2003-04-02 2011-12-07 Dharmacon, Inc. Modified polynucleotides for use in rna interference
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
EP1640452A4 (en) * 2003-05-30 2009-12-23 Nippon Shinyaku Co Ltd OLIGO DOUBLE-STRANDED RNA INHIBITING THE EXPRESSION OF Bcl-2 AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
KR20060063788A (en) * 2003-05-30 2006-06-12 니뽄 신야쿠 가부시키가이샤 Oligonucleotide Support Complex, Pharmaceutical Composition Containing the Complex
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
ES2864206T3 (en) 2003-06-02 2021-10-13 Univ Massachusetts Methods and compositions to improve the efficacy and specificity of RNAi
DK1633767T3 (en) 2003-06-02 2019-03-25 Univ Massachusetts METHODS AND COMPOSITIONS FOR MANAGING THE EFFECT OF RNA SILENCING
DK3604537T3 (en) 2003-06-13 2022-02-28 Alnylam Europe Ag Double-stranded ribonucleic acid with increased efficiency in an organism
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
DE10341333B4 (en) * 2003-09-08 2006-06-08 Siemens Ag Piezoelectric actuator and method for producing a piezoelectric actuator
KR100568246B1 (en) * 2003-11-19 2006-04-05 삼성전자주식회사 Computer system and its control method
US20050176045A1 (en) 2004-02-06 2005-08-11 Dharmacon, Inc. SNP discriminatory siRNA
ES2423060T3 (en) 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. IRNA agents that target VEGF
KR101147147B1 (en) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Modified polynucleotides for reducing off-target effects in rna interference
AU2005238034A1 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Of New York Inhibition of hairless protein mRNA
WO2005117991A2 (en) 2004-05-04 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
JP2006013252A (en) * 2004-06-28 2006-01-12 Hitachi Cable Ltd Laser diode control method, control circuit, and optical transmitter
MX2007003795A (en) 2004-09-28 2007-07-11 Quark Biotech Inc Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases.
WO2006053430A1 (en) 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
CA2604441A1 (en) 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
US20060286575A1 (en) 2005-04-16 2006-12-21 Cylene Pharmaceuticals, Inc. MCL-1 quadruplex nucleic acids and uses thereof
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
CA2650416A1 (en) 2006-05-19 2007-11-29 Alcon Research, Ltd. Rnai-mediated inhibition of tumor necrosis factor .alpha.-related conditions
US8523707B2 (en) * 2006-05-31 2013-09-03 Bridgestone Sports Co., Ltd. Multi-piece solid golf ball
US8138160B2 (en) 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
CN101640467B (en) 2008-07-28 2012-05-30 鸿富锦精密工业（深圳）有限公司 Shrapnel and Voice Coil Motors

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US647526A (en) * 1899-06-26 1900-04-17 William Allen Runyan Freight-car door.
US3719760A (en) * 1968-01-29 1973-03-06 Bayer Ag N-trityl-imidazolium salts as a fungicide
US3811449A (en) * 1972-03-08 1974-05-21 Becton Dickinson Co Dilating apparatus and method
US4401433A (en) * 1980-06-13 1983-08-30 Luther Ronald B Apparatus for advancing oversized catheter through cannula, and the like
US4449532A (en) * 1980-07-08 1984-05-22 Karl Storz Dilator to facilitate endoscope insertion into the body
US4369790A (en) * 1981-03-05 1983-01-25 Mccarthy John M Catheter
US4350151A (en) * 1981-03-12 1982-09-21 Lone Star Medical Products, Inc. Expanding dilator
US4451256A (en) * 1981-05-06 1984-05-29 Intermedicat Gmbh Catheter set
US4601710B1 (en) * 1983-08-24 1998-05-05 United States Surgical Corp Trocar assembly
US4601710A (en) * 1983-08-24 1986-07-22 Endotherapeutics Corporation Trocar assembly
US4573448A (en) * 1983-10-05 1986-03-04 Pilling Co. Method for decompressing herniated intervertebral discs
US4686984A (en) * 1984-03-15 1987-08-18 Richard Wolf Gmbh Catheter for widening a puncture channel
US4802479A (en) * 1986-10-31 1989-02-07 C. R. Bard, Inc. Hand-held instrument for implanting, dispensing, and inflating an inflatable membrane
US4981482A (en) * 1987-08-20 1991-01-01 Kazuo Ichikawa Device for forming an inserting hole for an endoscope
US4862891A (en) * 1988-03-14 1989-09-05 Canyon Medical Products Device for sequential percutaneous dilation
US4994027A (en) * 1988-06-08 1991-02-19 Farrell Edward M Percutaneous femoral bypass system
US5224952A (en) * 1988-07-06 1993-07-06 Ethicon, Inc. Safety trocar
US5613950A (en) * 1988-07-22 1997-03-25 Yoon; Inbae Multifunctional manipulating instrument for various surgical procedures
US5782800A (en) * 1988-07-22 1998-07-21 Yoon; Inbae Expandable multifunctional manipulating instruments for various medical procedures and methods therefor
US5002557A (en) * 1989-04-06 1991-03-26 Hasson Harrith M Laparoscopic cannula
US5176697A (en) * 1989-04-06 1993-01-05 Hasson Harrith M Laparoscopic cannula
US5114407A (en) * 1990-08-30 1992-05-19 Ethicon, Inc. Safety mechanism for trocar
US5188118A (en) * 1990-11-07 1993-02-23 Terwilliger Richard A Automatic biopsy instrument with independently actuated stylet and cannula
US5324261A (en) * 1991-01-04 1994-06-28 Medtronic, Inc. Drug delivery balloon catheter with line of weakness
US5342382A (en) * 1991-01-15 1994-08-30 Ethicon, Inc. Surgical trocar
US5176651A (en) * 1991-04-01 1993-01-05 Dexide, Inc. Combination surgical trocar housing and selective reducer sleeve assembly
US5486190A (en) * 1991-04-30 1996-01-23 United States Surgical Corporation Safety trocar
US5241972A (en) * 1991-05-03 1993-09-07 Meditron Devices, Inc. Method for debulking tissue to remove pressure on a nerve
US5183464A (en) * 1991-05-17 1993-02-02 Interventional Thermodynamics, Inc. Radially expandable dilator
US6197041B1 (en) * 1991-06-26 2001-03-06 United States Surgical Corporation Trocar
US5195506A (en) * 1991-10-18 1993-03-23 Life Medical Products, Inc. Surgical retractor for puncture operation
US5280782A (en) * 1991-11-15 1994-01-25 Wilk Peter J Variable length laparoscopic retractor and associated method of use
US5810866A (en) * 1991-11-27 1998-09-22 Yoon; Inbae Automatic retractable safety penetrating instrument for portal sleeve introduction
US5713870A (en) * 1991-11-27 1998-02-03 Yoon; Inbae Retractable safety penetrating instrument with laterally extendable spring strip
US6033406A (en) * 1992-03-17 2000-03-07 Sdgi Holdings, Inc. Method for subcutaneous suprafascial pedicular internal fixation
US5728097A (en) * 1992-03-17 1998-03-17 Sdgi Holding, Inc. Method for subcutaneous suprafascial internal fixation
US5290243A (en) * 1992-07-16 1994-03-01 Technalytics, Inc. Trocar system
US5312417A (en) * 1992-07-29 1994-05-17 Wilk Peter J Laparoscopic cannula assembly and associated method
US20040059350A1 (en) * 1992-09-04 2004-03-25 Scimed Life Systems, Inc. Suturing instruments and methods of use
US6364897B1 (en) * 1993-02-04 2002-04-02 Peter M. Bonutti Method and apparatus for positioning a suture anchor
US5752969A (en) * 1993-06-17 1998-05-19 Sofamor S.N.C. Instrument for the surgical treatment of an intervertebral disc by the anterior route
US5407430A (en) * 1994-03-21 1995-04-18 Peters; Michael J. Intravenous catheter
US5512037A (en) * 1994-05-12 1996-04-30 United States Surgical Corporation Percutaneous surgical retractor
US5505710A (en) * 1994-08-22 1996-04-09 C. R. Bard, Inc. Telescoping probe
US5647857A (en) * 1995-03-16 1997-07-15 Endotex Interventional Systems, Inc. Protective intraluminal sheath
US5624447A (en) * 1995-03-20 1997-04-29 Othy, Inc. Surgical tool guide and entry hole positioner
US6206922B1 (en) * 1995-03-27 2001-03-27 Sdgi Holdings, Inc. Methods and instruments for interbody fusion
US6695851B2 (en) * 1995-03-27 2004-02-24 Sdgi Holdings, Inc. Methods and instruments for interbody fusion
US5776156A (en) * 1995-09-05 1998-07-07 United States Surgical Corporation Endoscopic cutting instrument
US6213957B1 (en) * 1995-09-08 2001-04-10 United States Surgical Corporation Apparatus and method for removing tissue
US5772678A (en) * 1995-10-20 1998-06-30 Inlet Medical, Inc. Retractable disposable tip reusable trocar obturator
US5743881A (en) * 1995-11-03 1998-04-28 Aptec Medical Corporation Laparoscopic surgical instrument and method of using same
US5707359A (en) * 1995-11-14 1998-01-13 Bufalini; Bruno Expanding trocar assembly
US6048309A (en) * 1996-03-04 2000-04-11 Heartport, Inc. Soft tissue retractor and delivery device therefor
US5810721A (en) * 1996-03-04 1998-09-22 Heartport, Inc. Soft tissue retractor and method for providing surgical access
US6217509B1 (en) * 1996-03-22 2001-04-17 Sdgi Holdings, Inc. Devices and methods for percutaneous surgery
US6520907B1 (en) * 1996-03-22 2003-02-18 Sdgi Holdings, Inc. Methods for accessing the spinal column
US5902231A (en) * 1996-03-22 1999-05-11 Sdgi Holdings, Inc. Devices and methods for percutaneous surgery
US5792044A (en) * 1996-03-22 1998-08-11 Danek Medical, Inc. Devices and methods for percutaneous surgery
US6679833B2 (en) * 1996-03-22 2004-01-20 Sdgi Holdings, Inc. Devices and methods for percutaneous surgery
US6264676B1 (en) * 1996-11-08 2001-07-24 Scimed Life Systems, Inc. Protective sheath for transvaginal anchor implantation devices
US6053935A (en) * 1996-11-08 2000-04-25 Boston Scientific Corporation Transvaginal anchor implantation device
US6440154B2 (en) * 1996-11-08 2002-08-27 Scimed Life Systems, Inc. Protective sheath for transvaginal anchor implantation device
US6348053B1 (en) * 1996-11-12 2002-02-19 Triage Medical, Inc. Bone fixation device
US6447540B1 (en) * 1996-11-15 2002-09-10 Cook Incorporated Stent deployment device including splittable sleeve containing the stent
US6228058B1 (en) * 1997-04-03 2001-05-08 Core Dynamics, Inc. Sleeve trocar with penetration indicator
US6293952B1 (en) * 1997-07-31 2001-09-25 Circon Corporation Medical instrument system for piercing through tissue
US20040049223A1 (en) * 1997-10-01 2004-03-11 Scimed Life Systems, Inc. Dilation systems and related methods
US20010012950A1 (en) * 1997-10-01 2001-08-09 Srinivas Nishtala Dilation systems and related methods
US6030364A (en) * 1997-10-03 2000-02-29 Boston Scientific Corporation Apparatus and method for percutaneous placement of gastro-intestinal tubes
US6206826B1 (en) * 1997-12-18 2001-03-27 Sdgi Holdings, Inc. Devices and methods for percutaneous surgery
US6428541B1 (en) * 1998-04-09 2002-08-06 Sdgi Holdings, Inc. Method and instrumentation for vertebral interbody fusion
US6447527B1 (en) * 1998-04-23 2002-09-10 Ronald J. Thompson Apparatus and methods for the penetration of tissue
US20020001476A1 (en) * 1998-06-26 2002-01-03 Tomoyuki Nagamine Image forming apparatus
US6293909B1 (en) * 1998-08-07 2001-09-25 Scimed Life Systems, Inc. Device and method of using a surgical assembly with mesh sheath
US6689152B2 (en) * 1998-09-09 2004-02-10 Edwards Lifesciences Corp. Introducer/dilator with balloon protection and methods of use
US6117174A (en) * 1998-09-16 2000-09-12 Nolan; Wesley A. Spinal implant device
US5957902A (en) * 1998-09-28 1999-09-28 Teves; Leonides Y. Surgical tool for enlarging puncture opening made by trocar
US6743166B2 (en) * 1999-02-12 2004-06-01 Karl Storz Gmbh & Co. Kg Apparatus for introducing an intubation tube into the trachea
US6607530B1 (en) * 1999-05-10 2003-08-19 Highgate Orthopedics, Inc. Systems and methods for spinal fixation
US6200322B1 (en) * 1999-08-13 2001-03-13 Sdgi Holdings, Inc. Minimal exposure posterior spinal interbody instrumentation and technique
US6428556B1 (en) * 1999-08-25 2002-08-06 Origin Medsystems, Inc. Longitudinal dilator and method
US6582437B2 (en) * 1999-08-26 2003-06-24 Sdgi Holdings, Inc. Devices and methods for implanting fusion cages
US6723096B1 (en) * 1999-08-26 2004-04-20 Sdgi Holdings, Inc. Devices and methods for implanting fusion cages
US6562046B2 (en) * 1999-11-23 2003-05-13 Sdgi Holdings, Inc. Screw delivery system and method
US6582441B1 (en) * 2000-02-24 2003-06-24 Advanced Bionics Corporation Surgical insertion tool
US6562049B1 (en) * 2000-03-01 2003-05-13 Cook Vascular Incorporated Medical introducer apparatus
US6592553B2 (en) * 2000-07-05 2003-07-15 Cardiac Pacemakers, Inc. Introducer assembly and method therefor
US7172612B2 (en) * 2000-12-12 2007-02-06 Olympus Corporation Trocar and trocar system
US20020087152A1 (en) * 2001-01-04 2002-07-04 Endocare, Inc. Systems and methods for delivering a probe into tissue
US6511481B2 (en) * 2001-03-30 2003-01-28 Triage Medical, Inc. Method and apparatus for fixation of proximal femoral fractures
US6746451B2 (en) * 2001-06-01 2004-06-08 Lance M. Middleton Tissue cavitation device and method
US6589240B2 (en) * 2001-08-28 2003-07-08 Rex Medical, L.P. Tissue biopsy apparatus with collapsible cutter
US20030083688A1 (en) * 2001-10-30 2003-05-01 Simonson Robert E. Configured and sized cannula
US6685706B2 (en) * 2001-11-19 2004-02-03 Triage Medical, Inc. Proximal anchors for bone fixation system
US7025746B2 (en) * 2001-12-26 2006-04-11 Yale University Vascular access device
US20040019359A1 (en) * 2002-07-24 2004-01-29 Worley Seth J. Telescopic introducer with a compound curvature for inducing alignment and method of using the same
US20040059339A1 (en) * 2002-09-19 2004-03-25 Roehm Thomas E. Oval dilator and retractor set and method
US20040147877A1 (en) * 2003-01-27 2004-07-29 Heuser Richard R Catheter introducer system
US20040158258A1 (en) * 2003-02-12 2004-08-12 Bonati Alfred O. Method for removing orthopaedic hardware

Cited By (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11051862B2 (en) 2001-11-03 2021-07-06 DePuy Synthes Products, Inc. Device for straightening and stabilizing the vertebral column
USD666294S1 (en) * 2002-06-26 2012-08-28 Nuvasive, Inc. Dilator
USD666292S1 (en) * 2002-06-26 2012-08-28 Nuvasive, Inc. Dilator
USD666293S1 (en) * 2002-06-26 2012-08-28 Nuvasive, Inc. Dilator
US9993349B2 (en) 2002-06-27 2018-06-12 DePuy Synthes Products, Inc. Intervertebral disc
US8945190B2 (en) 2002-07-19 2015-02-03 Interventional Spine, Inc. Method and apparatus for spinal fixation
US9713486B2 (en) 2002-07-19 2017-07-25 DePuy Synthes Products, Inc. Method and apparatus for spinal fixation
US8109977B2 (en) 2002-07-19 2012-02-07 Interventional Spine, Inc. Method and apparatus for spinal fixation
US20060004398A1 (en) * 2004-07-02 2006-01-05 Binder Lawrence J Jr Sequential dilator system
US8206157B2 (en) * 2004-09-21 2012-06-26 Keymed (Medical & Industrial Equipment) Limited Instrument for use in a medical simulator
US20060069384A1 (en) * 2004-09-21 2006-03-30 Daniel Wallaker Instrument for use in a medical simulator
US8066730B2 (en) * 2005-11-14 2011-11-29 Scapa Flow, Llc Medical dilator system or dilator device
US20070129747A1 (en) * 2005-11-14 2007-06-07 Scapa Flow, Llc Medical dilator system or dilator device
US20110218575A1 (en) * 2006-04-21 2011-09-08 Interventional Spine, Inc. Method and apparatus for spinal fixation
US9101411B2 (en) 2006-04-21 2015-08-11 Interventional Spine, Inc. Method and apparatus for spinal fixation
US7938832B2 (en) 2006-04-21 2011-05-10 Interventional Spine, Inc. Method and apparatus for spinal fixation
US20080097436A1 (en) * 2006-04-21 2008-04-24 Culbert Brad S Method and apparatus for spinal fixation
US8430813B2 (en) 2006-05-26 2013-04-30 Depuy Spine, Inc. Illuminated surgical access system including a surgical access device and integrated light emitter
USD648021S1 (en) 2006-11-14 2011-11-01 Scapa Flow, Llc Medical dilator
USD631962S1 (en) 2006-11-14 2011-02-01 Scapa Flow, Llc Medical dilator
US11712345B2 (en) 2006-12-07 2023-08-01 DePuy Synthes Products, Inc. Intervertebral implant
US11660206B2 (en) 2006-12-07 2023-05-30 DePuy Synthes Products, Inc. Intervertebral implant
US11642229B2 (en) 2006-12-07 2023-05-09 DePuy Synthes Products, Inc. Intervertebral implant
US10583015B2 (en) 2006-12-07 2020-03-10 DePuy Synthes Products, Inc. Intervertebral implant
US10398566B2 (en) 2006-12-07 2019-09-03 DePuy Synthes Products, Inc. Intervertebral implant
US11497618B2 (en) 2006-12-07 2022-11-15 DePuy Synthes Products, Inc. Intervertebral implant
US11432942B2 (en) 2006-12-07 2022-09-06 DePuy Synthes Products, Inc. Intervertebral implant
US11273050B2 (en) 2006-12-07 2022-03-15 DePuy Synthes Products, Inc. Intervertebral implant
US10390963B2 (en) 2006-12-07 2019-08-27 DePuy Synthes Products, Inc. Intervertebral implant
US11045324B2 (en) 2006-12-08 2021-06-29 DePuy Synthes Products, Inc. Method of implanting a curable implant material
US8425525B2 (en) * 2007-05-23 2013-04-23 Rainer Baumgart Instrument set for minimally invasive preparation for bone nailing
US20080294172A1 (en) * 2007-05-23 2008-11-27 Rainer Baumgart Instrument set for minimally invasive preparation for bone nailing
US10973652B2 (en) 2007-06-26 2021-04-13 DePuy Synthes Products, Inc. Highly lordosed fusion cage
US11622868B2 (en) 2007-06-26 2023-04-11 DePuy Synthes Products, Inc. Highly lordosed fusion cage
US9839530B2 (en) 2007-06-26 2017-12-12 DePuy Synthes Products, Inc. Highly lordosed fusion cage
US8043343B2 (en) 2007-06-28 2011-10-25 Zimmer Spine, Inc. Stabilization system and method
US12426868B2 (en) 2007-09-28 2025-09-30 DePuy Synthes Products, Inc. Balloon with shape control for spinal procedures
US9974533B2 (en) 2007-10-05 2018-05-22 DePuy Synthes Products, Inc. Dilation system and method of using the same
US10925594B2 (en) 2007-10-05 2021-02-23 DePuy Synthes Products, Inc. Dilation system and method of using the same
US9737290B2 (en) 2007-10-05 2017-08-22 DePuy Synthes Products, Inc. Dilation system and method of using the same
US9387009B2 (en) 2007-10-05 2016-07-12 DePuy Synthes Products, Inc. Dilation system and method of using the same
US11737743B2 (en) 2007-10-05 2023-08-29 DePuy Synthes Products, Inc. Dilation system and method of using the same
US10194895B2 (en) 2007-10-05 2019-02-05 DePuy Synhes Products, Inc. Dilation system and method of using the same
US10449058B2 (en) 2008-01-17 2019-10-22 DePuy Synthes Products, Inc. Expandable intervertebral implant and associated method of manufacturing the same
US11737881B2 (en) 2008-01-17 2023-08-29 DePuy Synthes Products, Inc. Expandable intervertebral implant and associated method of manufacturing the same
US10433977B2 (en) 2008-01-17 2019-10-08 DePuy Synthes Products, Inc. Expandable intervertebral implant and associated method of manufacturing the same
US11712341B2 (en) 2008-04-05 2023-08-01 DePuy Synthes Products, Inc. Expandable intervertebral implant
US11712342B2 (en) 2008-04-05 2023-08-01 DePuy Synthes Products, Inc. Expandable intervertebral implant
US12023255B2 (en) 2008-04-05 2024-07-02 DePuy Synthes Products, Inc. Expandable inter vertebral implant
US12440346B2 (en) 2008-04-05 2025-10-14 DePuy Synthes Products, Inc. Expandable intervertebral implant
US10449056B2 (en) 2008-04-05 2019-10-22 DePuy Synthes Products, Inc. Expandable intervertebral implant
US11617655B2 (en) 2008-04-05 2023-04-04 DePuy Synthes Products, Inc. Expandable intervertebral implant
US12011361B2 (en) 2008-04-05 2024-06-18 DePuy Synthes Products, Inc. Expandable intervertebral implant
US11602438B2 (en) 2008-04-05 2023-03-14 DePuy Synthes Products, Inc. Expandable intervertebral implant
US9993350B2 (en) 2008-04-05 2018-06-12 DePuy Synthes Products, Inc. Expandable intervertebral implant
US11707359B2 (en) 2008-04-05 2023-07-25 DePuy Synthes Products, Inc. Expandable intervertebral implant
US11701234B2 (en) 2008-04-05 2023-07-18 DePuy Synthes Products, Inc. Expandable intervertebral implant
US9931223B2 (en) 2008-04-05 2018-04-03 DePuy Synthes Products, Inc. Expandable intervertebral implant
WO2009147527A2 (en) 2008-05-26 2009-12-10 Rudolf Morgernstern Lopez Intervertebral implant and installation tool
US11612491B2 (en) 2009-03-30 2023-03-28 DePuy Synthes Products, Inc. Zero profile spinal fusion cage
US12097124B2 (en) 2009-03-30 2024-09-24 DePuy Synthes Products, Inc. Zero profile spinal fusion cage
US9149308B2 (en) * 2009-04-07 2015-10-06 Biedermann Technologies Gmbh & Co. Kg Tool for use with a bone anchor, in particular for spinal surgery
US20110004222A1 (en) * 2009-04-07 2011-01-06 Lutz Biedermann Tool for Use with a Bone Anchor, in Particular for Spinal Surgery
US11224471B2 (en) 2009-08-27 2022-01-18 Silver Bullet Therapeutics, Inc. Bone implants for the treatment of infection
US10004548B2 (en) 2009-08-27 2018-06-26 Silver Bullet Therapeutics, Inc. Bone implants for the treatment of infection
US11925723B2 (en) 2009-08-27 2024-03-12 Silver Bullet Therapeutics, Inc. Bone implant and systems and coatings for the controllable release of antimicrobial metal ions
US8221396B2 (en) 2009-08-27 2012-07-17 Silver Bullet Therapeutics, Inc. Bone implants for the treatment of infection
US9248254B2 (en) 2009-08-27 2016-02-02 Silver Bullet Therapeutics, Inc. Bone implants for the treatment of infection
US9889284B2 (en) 2009-08-27 2018-02-13 Silver Bullet Therapeutics, Inc. Bone implant and systems that controllably releases silver
US10368929B2 (en) 2009-08-27 2019-08-06 Silver Bullet Therapeutics, Inc. Bone implants for the treatment of infection
US10265435B2 (en) 2009-08-27 2019-04-23 Silver Bullet Therapeutics, Inc. Bone implant and systems and coatings for the controllable release of antimicrobial metal ions
US11020508B2 (en) 2009-08-27 2021-06-01 Silver Bullet Therapeutics, Inc. Bone implant and systems and coatings for the controllable release of antimicrobial metal ions
US20110144687A1 (en) * 2009-12-10 2011-06-16 Kleiner Jeffrey Lateral Based Retractor System
US10500062B2 (en) 2009-12-10 2019-12-10 DePuy Synthes Products, Inc. Bellows-like expandable interbody fusion cage
US11607321B2 (en) 2009-12-10 2023-03-21 DePuy Synthes Products, Inc. Bellows-like expandable interbody fusion cage
US12318304B2 (en) 2010-06-24 2025-06-03 DePuy Synthes Products, Inc. Lateral spondylolisthesis reduction cage
US11872139B2 (en) 2010-06-24 2024-01-16 DePuy Synthes Products, Inc. Enhanced cage insertion assembly
US11911287B2 (en) 2010-06-24 2024-02-27 DePuy Synthes Products, Inc. Lateral spondylolisthesis reduction cage
US10966840B2 (en) 2010-06-24 2021-04-06 DePuy Synthes Products, Inc. Enhanced cage insertion assembly
US9895236B2 (en) 2010-06-24 2018-02-20 DePuy Synthes Products, Inc. Enhanced cage insertion assembly
US11654033B2 (en) 2010-06-29 2023-05-23 DePuy Synthes Products, Inc. Distractible intervertebral implant
US10548741B2 (en) 2010-06-29 2020-02-04 DePuy Synthes Products, Inc. Distractible intervertebral implant
US11452607B2 (en) 2010-10-11 2022-09-27 DePuy Synthes Products, Inc. Expandable interspinous process spacer implant
US9108051B2 (en) 2010-11-12 2015-08-18 Silver Bullet Therapeutics, Inc. Bone implant and systems that controllably releases silver
US8771323B2 (en) 2010-11-12 2014-07-08 Silver Bullet Therapeutics, Inc. Bone implant and systems that controllably releases silver
US9789298B2 (en) 2010-11-12 2017-10-17 Silver Bullet Therapeutics, Inc. Bone implant and systems that controllably releases silver
WO2012102842A1 (en) * 2011-01-28 2012-08-02 Laser Spine Surgical Center, LLC Foraminoplasty device
US20150112398A1 (en) * 2011-03-10 2015-04-23 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US11484418B2 (en) 2011-03-10 2022-11-01 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US10729462B2 (en) 2011-03-10 2020-08-04 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US10736661B2 (en) 2011-03-10 2020-08-11 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US10743915B2 (en) 2011-03-10 2020-08-18 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US10743914B2 (en) 2011-03-10 2020-08-18 DePuy Snythes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US10743913B2 (en) 2011-03-10 2020-08-18 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US10744004B2 (en) 2011-03-10 2020-08-18 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
AU2016247198B2 (en) * 2011-03-10 2019-04-04 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US11547443B2 (en) 2011-03-10 2023-01-10 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US11547442B2 (en) * 2011-03-10 2023-01-10 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US10182842B2 (en) 2011-03-10 2019-01-22 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US10111759B2 (en) 2011-03-10 2018-10-30 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US20150094610A1 (en) * 2011-03-10 2015-04-02 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US11484419B2 (en) 2011-03-10 2022-11-01 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US9486149B2 (en) * 2011-03-10 2016-11-08 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US9492194B2 (en) * 2011-03-10 2016-11-15 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
AU2012225473B2 (en) * 2011-03-10 2016-07-21 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US11484420B2 (en) 2011-03-10 2022-11-01 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US11234736B2 (en) 2011-10-27 2022-02-01 DePuy Synthes Products, Inc. Method and devices for a sub-splenius/supra-levator scapulae surgical access technique
US11134987B2 (en) 2011-10-27 2021-10-05 DePuy Synthes Products, Inc. Method and devices for a sub-splenius/supra-levator scapulae surgical access technique
US11241255B2 (en) 2011-10-27 2022-02-08 DePuy Synthes Products, Inc. Method and devices for a sub-splenius/supra-levator scapulae surgical access technique
US11911017B2 (en) 2011-10-27 2024-02-27 DePuy Synthes Products, Inc. Method and devices for a sub-splenius/supra-levator scapulae surgical access technique
US11278323B2 (en) 2011-10-27 2022-03-22 DePuy Synthes Products, Inc. Method and devices for a sub-splenius/supra-levator scapulae surgical access technique
US11937797B2 (en) 2011-10-27 2024-03-26 DePuy Synthes Products, Inc. Method and devices for a sub-splenius/supra-levator scapulae surgical access technique
US11660082B2 (en) 2011-11-01 2023-05-30 DePuy Synthes Products, Inc. Dilation system
USRE48534E1 (en) 2012-04-16 2021-04-27 DePuy Synthes Products, Inc. Detachable dilator blade
US10058433B2 (en) 2012-07-26 2018-08-28 DePuy Synthes Products, Inc. Expandable implant
US9883951B2 (en) 2012-08-30 2018-02-06 Interventional Spine, Inc. Artificial disc
US11219439B2 (en) 2012-09-26 2022-01-11 DePuy Synthes Products, Inc. NIR/RED light for lateral neuroprotection
US11559295B2 (en) 2012-09-26 2023-01-24 DePuy Synthes Products, Inc. NIR/red light for lateral neuroprotection
US20140171946A1 (en) * 2012-12-14 2014-06-19 Warsaw Orthopedic, Inc. Surgical instrument and method
US9198674B2 (en) * 2012-12-14 2015-12-01 Warsaw Orthopedic, Inc. Surgical instrument and method
USRE49973E1 (en) 2013-02-28 2024-05-21 DePuy Synthes Products, Inc. Expandable intervertebral implant, system, kit and method
US11497619B2 (en) 2013-03-07 2022-11-15 DePuy Synthes Products, Inc. Intervertebral implant
US11850164B2 (en) 2013-03-07 2023-12-26 DePuy Synthes Products, Inc. Intervertebral implant
US9522070B2 (en) 2013-03-07 2016-12-20 Interventional Spine, Inc. Intervertebral implant
US10413422B2 (en) 2013-03-07 2019-09-17 DePuy Synthes Products, Inc. Intervertebral implant
US10898341B2 (en) 2013-03-11 2021-01-26 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US12004960B2 (en) 2013-03-11 2024-06-11 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US9855058B2 (en) 2013-03-11 2018-01-02 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US9277928B2 (en) 2013-03-11 2016-03-08 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US10813772B2 (en) 2013-03-11 2020-10-27 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US10898342B2 (en) 2013-03-11 2021-01-26 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US11759329B2 (en) 2013-03-11 2023-09-19 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US10918495B2 (en) 2013-03-11 2021-02-16 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US12285342B2 (en) 2013-03-14 2025-04-29 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
USRE49994E1 (en) 2013-03-14 2024-06-04 Spinal Elements, Inc. Spinal fusion implants and devices and methods for deploying such implants
US11590002B2 (en) 2013-03-14 2023-02-28 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US9993353B2 (en) 2013-03-14 2018-06-12 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US10537443B2 (en) 2013-03-14 2020-01-21 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US10166056B2 (en) 2013-07-03 2019-01-01 DePuy Synthes Products, Inc. Method and apparatus for sacroiliac joint fixation
US9522028B2 (en) 2013-07-03 2016-12-20 Interventional Spine, Inc. Method and apparatus for sacroiliac joint fixation
US11006991B2 (en) 2013-07-03 2021-05-18 DePuy Synthes Products, Inc. Method and apparatus for sacroiliac joint fixation
US8999367B1 (en) 2014-06-11 2015-04-07 Silver Bullet Therapeutics, Inc. Bioabsorbable substrates and systems that controllably release antimicrobial metal ions
US8927004B1 (en) 2014-06-11 2015-01-06 Silver Bullet Therapeutics, Inc. Bioabsorbable substrates and systems that controllably release antimicrobial metal ions
US9452242B2 (en) 2014-06-11 2016-09-27 Silver Bullet Therapeutics, Inc. Enhancement of antimicrobial silver, silver coatings, or silver platings
US9821094B2 (en) 2014-06-11 2017-11-21 Silver Bullet Therapeutics, Inc. Coatings for the controllable release of antimicrobial metal ions
US9114197B1 (en) 2014-06-11 2015-08-25 Silver Bullett Therapeutics, Inc. Coatings for the controllable release of antimicrobial metal ions
US12053196B2 (en) 2014-07-08 2024-08-06 Spinal Elements, Inc. Apparatus and methods for disrupting inter vertebral disc tissue
US11224453B2 (en) 2014-07-08 2022-01-18 Spinal Elements, Inc. Apparatus and methods for disrupting intervertebral disc tissue
US9980737B2 (en) 2014-08-04 2018-05-29 Medos International Sarl Flexible transport auger
US10863994B2 (en) 2014-08-04 2020-12-15 Medos International Sàrl Flexible transport auger
US12433610B2 (en) 2014-08-04 2025-10-07 Medos International Sarl Flexible transport auger
US11712252B2 (en) 2014-08-04 2023-08-01 Medos International Sarl Flexible transport auger
US10786330B2 (en) 2014-09-09 2020-09-29 Medos International Sarl Proximal-end securement of a minimally invasive working channel
US10264959B2 (en) 2014-09-09 2019-04-23 Medos International Sarl Proximal-end securement of a minimally invasive working channel
US9924979B2 (en) 2014-09-09 2018-03-27 Medos International Sarl Proximal-end securement of a minimally invasive working channel
US10111712B2 (en) 2014-09-09 2018-10-30 Medos International Sarl Proximal-end securement of a minimally invasive working channel
US11213196B2 (en) 2014-09-09 2022-01-04 Medos International Sarl Proximal-end securement of a minimally invasive working channel
US11564811B2 (en) 2015-02-06 2023-01-31 Spinal Elements, Inc. Graft material injector system and method
US12121456B2 (en) 2015-02-06 2024-10-22 Spinal Elements, Inc. Graft material injector system and method
US11426290B2 (en) 2015-03-06 2022-08-30 DePuy Synthes Products, Inc. Expandable intervertebral implant, system, kit and method
US10786264B2 (en) 2015-03-31 2020-09-29 Medos International Sarl Percutaneous disc clearing device
US12042158B2 (en) 2015-03-31 2024-07-23 Medos International Sarl Percutaneous disc clearing device
US12343021B2 (en) 2015-03-31 2025-07-01 Medos International Sàrl Percutaneous disc clearing device
US11464523B2 (en) 2015-03-31 2022-10-11 Medos International Sarl Percutaneous disc clearing device
US9833338B2 (en) * 2015-06-30 2017-12-05 Expanding Orthopedics Inc. Tool for intervertebral cage
US20170000627A1 (en) * 2015-06-30 2017-01-05 Mark M Levy Tool for intervertebral cage
US9913727B2 (en) 2015-07-02 2018-03-13 Medos International Sarl Expandable implant
US11000312B2 (en) 2015-09-04 2021-05-11 Medos International Sarl Multi-shield spinal access system
US11801070B2 (en) 2015-09-04 2023-10-31 Medos International Sarl Surgical access port stabilization
US12496093B2 (en) 2015-09-04 2025-12-16 Medos International Sàrl Multi-shield spinal access system
US11439380B2 (en) 2015-09-04 2022-09-13 Medos International Sarl Surgical instrument connectors and related methods
US10758220B2 (en) 2015-09-04 2020-09-01 Medos International Sarl Devices and methods for providing surgical access
US11344190B2 (en) 2015-09-04 2022-05-31 Medos International Sarl Surgical visualization systems and related methods
US11712264B2 (en) 2015-09-04 2023-08-01 Medos International Sarl Multi-shield spinal access system
US10779810B2 (en) 2015-09-04 2020-09-22 Medos International Sarl Devices and methods for surgical retraction
US11331090B2 (en) 2015-09-04 2022-05-17 Medos International Sarl Surgical visualization systems and related methods
US12402909B2 (en) 2015-09-04 2025-09-02 Medos International Sàrl Multi-shield spinal access system
US10869659B2 (en) 2015-09-04 2020-12-22 Medos International Sarl Surgical instrument connectors and related methods
US11744447B2 (en) 2015-09-04 2023-09-05 Medos International Surgical visualization systems and related methods
US12383302B2 (en) 2015-09-04 2025-08-12 Medos International Sàrl Surgical visualization systems and related methods
US11950766B2 (en) 2015-09-04 2024-04-09 Medos International Sàrl Surgical visualization systems and related methods
US11559328B2 (en) 2015-09-04 2023-01-24 Medos International Sarl Multi-shield spinal access system
US10874425B2 (en) 2015-09-04 2020-12-29 Medos International Sarl Multi-shield spinal access system
US11793546B2 (en) 2015-09-04 2023-10-24 Medos International Sarl Surgical visualization systems and related methods
US11672562B2 (en) 2015-09-04 2023-06-13 Medos International Sarl Multi-shield spinal access system
US11806043B2 (en) 2015-09-04 2023-11-07 Medos International Sarl Devices and methods for providing surgical access
US12193704B2 (en) 2015-09-04 2025-01-14 Medos International Sàrl Multi-shield spinal access system
US12150636B2 (en) 2015-09-04 2024-11-26 Medos International Sárl Surgical instrument connectors and related methods
US10682130B2 (en) 2015-09-04 2020-06-16 Medos International Sarl Surgical access port stabilization
US10987129B2 (en) 2015-09-04 2021-04-27 Medos International Sarl Multi-shield spinal access system
US12507880B2 (en) 2015-09-04 2025-12-30 Medos International Sàrl Devices and methods for providing surgical access
US11883064B2 (en) 2015-09-04 2024-01-30 Medos International Sarl Multi-shield spinal access system
US12144527B2 (en) 2016-02-05 2024-11-19 Medos International Sarl Method and instruments for interbody fusion and posterior fixation through a single incision
US10299838B2 (en) 2016-02-05 2019-05-28 Medos International Sarl Method and instruments for interbody fusion and posterior fixation through a single incision
US11020153B2 (en) 2016-02-05 2021-06-01 Medos International Sarl Method and instruments for interbody fusion and posterior fixation through a single incision
US11596522B2 (en) 2016-06-28 2023-03-07 Eit Emerging Implant Technologies Gmbh Expandable and angularly adjustable intervertebral cages with articulating joint
US12390343B2 (en) 2016-06-28 2025-08-19 Eit Emerging Implant Technologies Gmbh Expandable, angularly adjustable intervertebral cages
US11596523B2 (en) 2016-06-28 2023-03-07 Eit Emerging Implant Technologies Gmbh Expandable and angularly adjustable articulating intervertebral cages
US11510788B2 (en) 2016-06-28 2022-11-29 Eit Emerging Implant Technologies Gmbh Expandable, angularly adjustable intervertebral cages
US12433757B2 (en) 2016-06-28 2025-10-07 Eit Emerging Implant Technologies Gmbh Expandable, angularly adjustable and articulating intervertebral cages
US10537436B2 (en) 2016-11-01 2020-01-21 DePuy Synthes Products, Inc. Curved expandable cage
US10888433B2 (en) 2016-12-14 2021-01-12 DePuy Synthes Products, Inc. Intervertebral implant inserter and related methods
US20180271574A1 (en) * 2017-03-22 2018-09-27 Benvenue Medical, Inc. Minimal Impact Access System To Disc Space
US10758286B2 (en) * 2017-03-22 2020-09-01 Benvenue Medical, Inc. Minimal impact access system to disc space
US11771483B2 (en) 2017-03-22 2023-10-03 Spinal Elements, Inc. Minimal impact access system to disc space
US10398563B2 (en) 2017-05-08 2019-09-03 Medos International Sarl Expandable cage
US12427031B2 (en) 2017-05-08 2025-09-30 Medos International Sarl Expandable cage
US11446155B2 (en) 2017-05-08 2022-09-20 Medos International Sarl Expandable cage
US11344424B2 (en) 2017-06-14 2022-05-31 Medos International Sarl Expandable intervertebral implant and related methods
US10940016B2 (en) 2017-07-05 2021-03-09 Medos International Sarl Expandable intervertebral fusion cage
US12207856B2 (en) 2018-01-29 2025-01-28 Spinal Elements, Inc. Minimally invasive interbody fusion
US11583327B2 (en) 2018-01-29 2023-02-21 Spinal Elements, Inc. Minimally invasive interbody fusion
US11471145B2 (en) 2018-03-16 2022-10-18 Spinal Elements, Inc. Articulated instrumentation and methods of using the same
US12357291B2 (en) 2018-03-16 2025-07-15 Spinal Elements, Inc. Articulated instrumentation and methods of using the same
US11446156B2 (en) 2018-10-25 2022-09-20 Medos International Sarl Expandable intervertebral implant, inserter instrument, and related methods
US11013530B2 (en) 2019-03-08 2021-05-25 Medos International Sarl Surface features for device retention
US11241252B2 (en) 2019-03-22 2022-02-08 Medos International Sarl Skin foundation access portal
US12089873B2 (en) 2019-03-22 2024-09-17 Medos International Sàrl Skin foundation access portal
US11129727B2 (en) 2019-03-29 2021-09-28 Medos International Sari Inflatable non-distracting intervertebral implants and related methods
US11813026B2 (en) 2019-04-05 2023-11-14 Medos International Sarl Systems, devices, and methods for providing surgical trajectory guidance
US11806245B2 (en) 2020-03-06 2023-11-07 Eit Emerging Implant Technologies Gmbh Expandable intervertebral implant
US11426286B2 (en) 2020-03-06 2022-08-30 Eit Emerging Implant Technologies Gmbh Expandable intervertebral implant
US12303341B2 (en) 2021-03-12 2025-05-20 Medos International Srl Camera position indication systems and methods
US11771517B2 (en) 2021-03-12 2023-10-03 Medos International Sarl Camera position indication systems and methods
US11850160B2 (en) 2021-03-26 2023-12-26 Medos International Sarl Expandable lordotic intervertebral fusion cage
US11752009B2 (en) 2021-04-06 2023-09-12 Medos International Sarl Expandable intervertebral fusion cage
US12447026B2 (en) 2021-04-06 2025-10-21 Medos International Sarl Expandable inter vertebral fusion cage
US12023258B2 (en) 2021-04-06 2024-07-02 Medos International Sarl Expandable intervertebral fusion cage
US12090064B2 (en) 2022-03-01 2024-09-17 Medos International Sarl Stabilization members for expandable intervertebral implants, and related systems and methods

Also Published As

Publication number Publication date
US7514550B2 (en) 2009-04-07
EP2213738A2 (en) 2010-08-04
US20100004142A1 (en) 2010-01-07
US20070039072A1 (en) 2007-02-15
US7576196B2 (en) 2009-08-18
EP2213738A3 (en) 2010-11-17
US7511132B2 (en) 2009-03-31
US20190345573A1 (en) 2019-11-14
US20110319474A1 (en) 2011-12-29
US7820809B2 (en) 2010-10-26
US7795420B2 (en) 2010-09-14
EP2305813A3 (en) 2012-03-28
US20070088153A1 (en) 2007-04-19
US20080097090A1 (en) 2008-04-24
EP2284266A2 (en) 2011-02-16
US20090203895A1 (en) 2009-08-13
US20070031844A1 (en) 2007-02-08
US20090298176A1 (en) 2009-12-03
JP2010187668A (en) 2010-09-02
EP2314691A3 (en) 2012-01-18
US20080108802A1 (en) 2008-05-08
EP1560931B1 (en) 2011-07-27
PT2284266E (en) 2013-12-17
US7645869B2 (en) 2010-01-12
US20090088563A1 (en) 2009-04-02
US8000902B2 (en) 2011-08-16
US20050245475A1 (en) 2005-11-03
US7507811B2 (en) 2009-03-24
US8090542B2 (en) 2012-01-03
US20100331214A1 (en) 2010-12-30
US7745611B2 (en) 2010-06-29
JP2006507841A (en) 2006-03-09
EP2284266B1 (en) 2013-11-06
EP2305813A2 (en) 2011-04-06
EP2314691A2 (en) 2011-04-27
US20080091002A1 (en) 2008-04-17
WO2004045543A3 (en) 2005-04-21
US20100267586A1 (en) 2010-10-21
US20070093653A1 (en) 2007-04-26
US7595389B2 (en) 2009-09-29
US20090149644A1 (en) 2009-06-11
US20100323922A1 (en) 2010-12-23
US20100087335A1 (en) 2010-04-08
US20080221317A1 (en) 2008-09-11
US20090291497A1 (en) 2009-11-26
EP2284266A3 (en) 2012-01-25
US7674896B2 (en) 2010-03-09
US20100152064A1 (en) 2010-06-17
EP2278005A3 (en) 2012-05-23
US20080300395A1 (en) 2008-12-04
ES2440284T3 (en) 2014-01-28
AU2003295600A8 (en) 2004-06-15
US20090163701A1 (en) 2009-06-25
US7655788B2 (en) 2010-02-02
US7642349B2 (en) 2010-01-05
AU2003295600A1 (en) 2004-06-15
US20070207974A1 (en) 2007-09-06
US20080114162A1 (en) 2008-05-15
US20070088154A1 (en) 2007-04-19
US20070072823A1 (en) 2007-03-29
US20100029510A1 (en) 2010-02-04
US8093370B2 (en) 2012-01-10
US20080293595A1 (en) 2008-11-27
US20070088152A1 (en) 2007-04-19
US7592444B2 (en) 2009-09-22
US20120135892A1 (en) 2012-05-31
US20080306015A1 (en) 2008-12-11
US20110111983A1 (en) 2011-05-12
EP2278005A2 (en) 2011-01-26
US20080188648A1 (en) 2008-08-07
US7834170B2 (en) 2010-11-16
US20100291681A1 (en) 2010-11-18
US20090082556A1 (en) 2009-03-26
US7696344B2 (en) 2010-04-13
EP2305812A3 (en) 2012-06-06
WO2004045543A2 (en) 2004-06-03
EP2305812A2 (en) 2011-04-06
ATE517992T1 (en) 2011-08-15
EP2213738B1 (en) 2012-10-10
US20080091003A1 (en) 2008-04-17
US20100075869A1 (en) 2010-03-25
US20080293593A1 (en) 2008-11-27
DK2284266T3 (en) 2014-01-13
US20050246794A1 (en) 2005-11-03
US20070088155A1 (en) 2007-04-19
US20080091004A1 (en) 2008-04-17
US20080188647A1 (en) 2008-08-07
EP1560931A4 (en) 2006-08-02
US7608707B2 (en) 2009-10-27
US7576197B2 (en) 2009-08-18
US20080139798A1 (en) 2008-06-12
US8030474B2 (en) 2011-10-04
US7807819B2 (en) 2010-10-05
US20090163702A1 (en) 2009-06-25
US7691997B2 (en) 2010-04-06
US20050255487A1 (en) 2005-11-17
US7893247B2 (en) 2011-02-22
US20080108803A1 (en) 2008-05-08
US20070099862A1 (en) 2007-05-03
US7985854B2 (en) 2011-07-26
US8008474B2 (en) 2011-08-30
US7803933B2 (en) 2010-09-28
US20070141611A1 (en) 2007-06-21
US20120052487A9 (en) 2012-03-01
EP1560931A2 (en) 2005-08-10
US7579457B2 (en) 2009-08-25
US20080091001A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
US20050256525A1 (en) Dilation introducer for orthopedic surgery
US10293147B2 (en) Telescopic percutaneous tissue dilation systems and related methods
EP3205371B1 (en) Telescopic percutaneous tissue dilation systems and related methods of producing
US20080287981A1 (en) Dilation introducer and methods for orthopedic surgery
US12268423B2 (en) Stabilization system, implant, and methods for preventing relative motion between sections of tissue
US11191575B2 (en) Systems and methods for off-axis augmentation of a vertebral body
US7087058B2 (en) Method and apparatus for providing posterior or anterior trans-sacral access to spinal vertebrae
US9168033B2 (en) Interspinous implants and methods for implanting same
US8075593B2 (en) Interspinous implants and methods for implanting same
US7641657B2 (en) Method and apparatus for providing posterior or anterior trans-sacral access to spinal vertebrae
JP3573461B2 (en) Modular intramedullary nail inserted into cannula
US20040133201A1 (en) Methods and apparatuses for treating the spine through an access device
KR101469567B1 (en) Interspinous implants and methods for implanting same
US20130012955A1 (en) System and Method for Pedicle Screw Placement in Vertebral Alignment
JP6983204B2 (en) Systems and methods for intramedullary nail implantation
JP2021000440A (en) Systems and methods for intramedullary nail implantation
EP4601558A1 (en) Lateral mass drill guide system
WO2024081280A2 (en) Spinal decortication and grafting

Legal Events

Date Code Title Description
AS Assignment

Owner name: TRIAGE MEDICAL INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CULBERT, BRAD;OLMOS, FAUSTO;WARREN, CHRISTOPHER;REEL/FRAME:015719/0982

Effective date: 20050210

AS Assignment

Owner name: INTERVENTIONAL SPINE, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:TRIAGE MEDICAL, INC.;REEL/FRAME:020236/0722

Effective date: 20061128

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION